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Executive Summary
Eye health and vision have widespread and profound 
implications for many aspects of life, health, sustainable 
development, and the economy. Yet nowadays, many 
people, families, and populations continue to suffer the 
consequences of poor access to high-quality, affordable 
eye care, leading to vision impairment and blindness.
In 2020, an estimated 596 million people had distance 
vision impairment worldwide, of whom 43 million were 
blind. Another 510 million people had uncorrected near 
vision impairment, simply because of not having reading 
spectacles. A large proportion of those affected (90%), 
live in low-income and middle-income countries 
(LMICs). However, encouragingly, more than 90% of 
people with vision impairment have a preventable or 
treatable cause with existing highly cost-effective 
interventions. Eye conditions affect all stages of life, with 
young children and older people being particularly 
affected. Crucially, women, rural populations, and ethnic 
minority groups are more likely to have vision 
impairment, and this pervasive inequality needs to be 
addressed. By 2050, population ageing, growth, and 
urbanisation might lead to an estimated 895 million 
people with distance vision impairment, of whom 
61 million will be blind. Action to prioritise eye health is 
needed now.
This Commission defines eye health as maximised 
vision, ocular health, and functional ability, thereby 
contributing to overall health and wellbeing, social 
inclusion, and quality of life. Eye health is essential to 
achieve many of the Sustainable Development Goals 
(SDGs). Poor eye health and impaired vision have a 
negative effect on quality of life and restrict equitable 
access to and achievement in education and the workplace. 
Vision loss has substantial financial implications for 
affected individuals, families, and communities. Although 
high-quality data for global economic estimates are scarce, 
particularly for LMICs, conservative assessments based 
on the latest prevalence figures for 2020 suggest that 
annual global productivity loss from vision impairment is 
approximately US$410·7 billion purchasing power parity. 
Vision impairment reduces mobility, affects mental 
wellbeing, exacerbates risk of dementia, increases 
likelihood of falls and road traffic crashes, increases the 
need for social care, and ultimately leads to higher 
mortality rates.
By contrast, vision facilitates many daily life activities, 
enables better educational outcomes, and increases work 
productivity, reducing inequality. An increasing amount 
of evidence shows the potential for vision to advance the 
SDGs, by contributing towards poverty reduction, zero 
hunger, good health and wellbeing, quality education, 
gender equality, and decent work. Eye health is a global 
public priority, transforming lives in both poor and 
wealthy communities. Therefore, eye health needs to be 
reframed as a development as well as a health issue and 
given greater prominence within the global development 
and health agendas.
Vision loss has many causes that require promotional, 
preventive, treatment, and rehabilitative interventions. 
Cataract, uncorrected refractive error, glaucoma, age-
related macular degeneration, and diabetic retinopathy 
are responsible for most global vision impairment. 
Research has identified treatments to reduce or eliminate 
blindness from all these conditions; the priority is to 
deliver treatments where they are most needed. Proven 
eye care interventions, such as cataract surgery and 
spectacle provision, are among the most cost-effective in 
all of health care. Greater financial investment is needed 
so that millions of people living with unnecessary vision 
impairment and blindness can benefit from these 
interventions.
Lessons from the past three decades give hope that this 
challenge can be met. Between 1990 and 2020, the age-
standardised global prevalence of blindness fell by 28·5%. 
Since the 1990s, prevalence of major infectious causes of 
blindness—onchocerciasis and trachoma—have declined 
substantially. Hope remains that by 2030, the transmission 
of onchocerciasis will be interrupted, and trachoma will 
be eliminated as a public health problem in every country 
worldwide. However, the ageing population has led to a 
higher crude prevalence of age-related causes of 
blindness, and thus an increased total number of people 
with blindness in some regions.
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Key messages
Eye health is essential to achieve the Sustainable 
Development Goals; vision needs to be reframed as a 
development issue
There is extensive evidence showing that improving eye health 
contributes directly and indirectly to achieving many 
Sustainable Development Goals, including reducing poverty 
and improving work productivity, general and mental health, 
and education and equity. Improving eye health is a practical 
and cost-effective way of unlocking human potential. Eye 
health needs to be reframed as an enabling, cross-cutting issue 
within the sustainable development framework.
Almost everyone will experience impaired vision or an eye 
condition during their lifetime and require eye care services; 
urgent action is necessary to meet the rapidly growing eye 
health need
In 2020, 1·1 billion people had distance vision impairment or 
uncorrected presbyopia. By 2050, this figure is expected to rise 
to 1·8 billion. Most affected people live in low-income and 
middle-income countries (LMICs) with avoidable causes of 
vision impairment. During the life course, most people will 
experience vision impairment, even if just the need for reading 
glasses. Because of unmet needs and an ageing global 
population, eye health is a major public health and sustainable 
development concern which warrants urgent political action. 
Eye health is an essential component of universal health 
coverage; it must be included in planning, resourcing, and 
delivery of health care
Universal health coverage is not universal without affordable, 
high quality, equitable eye care. In line with the WHO World 
report on vision, we urge countries to consider eye care as an 
essential service within universal health coverage. To deliver 
comprehensive services including promotion, prevention, 
treatment, and rehabilitation, eye care needs to be included in 
national strategic health plans and development policies, 
health financing structures, and health workforce planning. 
Coordinated intersectoral action is needed to systematically 
improve population eye health, also within healthy ageing 
initiatives, schools, and the workplace. Integration of eye health 
services with multiple relevant components of health service 
delivery and at all levels of the health system is of central 
importance.
High quality eye health services are not universally 
delivered; concerted action is needed to improve quality 
and outcomes, providing effective, efficient, safe, timely, 
equitable, and people-centred care
Use of effective service coverage indicators for cataract and 
refractive error highlight the delivery gap between population 
eye health needs and the delivery of good outcomes. We urge 
eye health providers to take a holistic view to emphasise quality 
and design service delivery based on individual and population 
needs: a people-centred approach. Services need to be 
characterised by inclusiveness and equity in design and delivery, 
proactively addressing the needs of marginalised and 
vulnerable groups through targeted interventions. To 
encourage improved quality in cataract surgery, we support 
redefining a good vision outcome threshold as 6/12 or better. 
Highly cost-effective vision-restoring interventions offer 
enormous potential to improve the economic outlook of 
individuals and nations; a major scale up of financial 
investment in eye health is required
For 2020, we estimate that vision impairment resulted in 
$410·7 billion lost economic productivity; the full cost is most 
likely higher. Treatments for cataract and refractive error would 
meet more than 90% of unmet needs and are highly cost-
effective. The case for countries to invest in improving 
population eye health is compelling and more financial 
resources are urgently required. 
Financial barriers to accessing eye care leave many people 
behind; eye health needs to be included in national health 
financing to pool the risk
Health-care costs prevent many people from accessing essential 
eye health services. Eye care needs to be integrated into general 
health system financing to remove cost barriers. To improve 
access for the whole population and mitigate eye care 
expenditure, mechanisms that pool risk are highly desirable.
Technology and treatment developments offer new tools to 
improve eye health; thoughtful application is needed to 
maximise the potential to improve coverage, accessibility, 
quality, efficiency, and affordability
Technological developments such as telemedicine, mHealth, 
and artificial intelligence offer the potential to revolutionise eye 
health care in the next decade by delivering affordable, high-
quality services to remote areas. However, caution is needed to 
ensure all populations benefit from these developments.
The eye health workforce is unable to meet population 
needs in many countries; major expansion in service 
capacity is required through increased numbers, sharing 
tasks, strengthened training, enabling work environments, 
and effective leadership
Many areas have major shortages of personnel working in eye 
health. The available workforce needs to be distributed 
according to population need. Quality of training for the 
workforce needs to be updated, with renewed emphasis on 
competency. Enabling working environments need to be 
created, including appropriate support, supervision, and 
equipment. Long-standing issues of low productivity need to 
be systematically resolved. Mentoring and other programmes 
to cultivate an emerging generation of eye health leaders are 
needed. 
(Continued on next page)
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Despite this progress, business as usual will not keep 
pace with the demographic trends of an ageing global 
population or address the inequities that persist in each 
country. New threats to eye health are emerging, 
including the worldwide increase in diabetic retinopathy, 
high myopia, retinopathy of prematurity, and chronic eye 
diseases of ageing such as glaucoma and age-related 
macular degeneration. With the projected increase in 
such conditions and their associated vision loss over the 
coming decades, urgent action is needed to develop 
innovative treatments and deliver services at a greater 
scale than previously achieved.
Good eye health at the community and national level 
has been marginalised as a luxury available to only 
wealthy or urban areas. Eye health needs to be urgently 
brought into the mainstream of national health and 
development policy, planning, financing, and action.
The challenge is to develop and deliver comprehensive 
eye health services (promotion, prevention, treatment, 
rehabilitation) that address the full range of eye conditions 
within the context of universal health coverage. Accessing 
services should not bring the risk of falling into poverty 
and services should be of high quality, as envisaged by the 
WHO framework for health-care quality: effective, safe, 
people-centred, timely, equitable, integrated, and efficient. 
To this framework we add the need for services to be 
environmentally sustainable. Universal health coverage is 
not universal without eye care.
Multiple obstacles need to be overcome to achieve 
universal coverage for eye health. Important issues 
include complex barriers to availability and access to 
quality services, cost, major shortages and maldistribution 
of well-trained personnel, and lack of suitable, well 
maintained equipment and consumables. These issues 
are particularly widespread in LMICs, but also occur in 
underserved communities in high-income countries. 
Strong partnerships need to be formed with natural allies 
working in areas affected by eye health, such as non-
communicable diseases, neglected tropical diseases, 
healthy ageing, children’s services, education, disability, 
and rehabilitation. The eye health sector has traditionally 
focused on treatment and rehabilitation, and underused 
health promotion and prevention strategies to lessen the 
impact of eye disease and reduce inequality.
Solving these problems will depend on solutions 
established from high quality evidence that can guide 
more effective implementation at scale. Evidence-based 
approaches will need to address existing deficiencies in 
the supply and demand. Strategic investments in 
discovery research, harnessing new findings from 
diverse fields, and implementation research to guide 
effective scale up are needed globally. Encouragingly, 
developments in telemedicine, mobile health, artificial 
intelligence, and distance learning could potentially 
enable eye care professionals to deliver higher quality 
care that is more plentiful, equitable, and cost-effective.
This Commission did a Grand Challenges in Global 
Eye Health prioritisation exercise to highlight key areas 
for concerted research and action. This exercise has 
identified a broad set of challenges spanning the fields of 
epidemiology, health systems, diagnostics, therapeutics, 
and implementation. The most compelling of these 
issues, picked from among 3400 suggestions proposed 
by 336 people from 118 countries, can help to frame the 
future research agenda for global eye health.
In this Commission, we harness lessons learned from 
over two decades, present the growing evidence for the 
life-transforming impact of eye care, and provide a 
thorough understanding of rapid developments in the 
field. This report was created through a broad 
consultation involving experts within and outside the eye 
care sector to help inform governments and other 
stakeholders about the path forward for eye health 
beyond 2020, to further the SDGs (including universal 
health coverage), and work towards a world without 
avoidable vision loss.
The next few years are a crucial time for the global eye 
health community and its partners in health care, 
(Key messages continued from previous page)
Reliable survey and service data are key to progress in eye 
health; robust indicator data are needed to shape change 
and drive action 
To monitor progress in delivering improved eye health within 
universal health coverage, a balanced set of robust indicators 
are needed, which we outlined in this Commission. Service data 
should be available and used by implementers and policy 
makers to drive change. We highlight the scarcity of 
epidemiological data in several regions, which should be 
addressed as a priority.
Research has been crucial to advances in understanding and 
treating eye disease; solution-focused, contextually 
relevant research is urgently needed to deliver innovative 
prevention and treatment strategies and inform 
implementation of eye health within universal health 
coverage
Implementation research is needed, particularly in LMICs, to 
guide effective delivery of services within universal health 
coverage. Discovery research is needed for specific areas that 
remain without efficacious interventions. The economic impact 
of vision impairment, and the costs and benefits of 
interventions are only partly understood; a coordinated global 
effort to systematically collect data is needed. A step-change in 
the capacity of LMICs to do contextually relevant eye health 
research and a greater commitment are needed to improve 
diversity and inclusion in the research community.
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government, and other sectors to consider the successes 
and challenges encountered in the past two decades, and 
at the same time to chart a way forward for the upcoming 
decades. Moving forward requires building on the strong 
foundation laid by WHO and partners in VISION 2020 
with renewed impetus to ultimately deliver high quality 
universal eye health care for all.
Introduction
In 2020, an estimated 596 million people worldwide had 
distance vision impairment and a further 510 million had 
uncorrected near vision impairment.1 Most of these 
people live in low-income and middle-income countries 
(LMIC). Eye health is also affected by conditions that do 
not, at least initially, impair vision. Although these 
conditions are not currently included in global prevalence 
estimates, they contribute substantially to the unmet 
need for eye health services. Vision is important for 
many aspects of life, and vision impairment can 
profoundly affect individuals, families, and society. Eye 
health touches all lives, either directly or indirectly, 
through its impact on those close to us.
The year 2020 marks the culmination of the global 
initiative to eliminate avoidable blindness, VISION 2020: 
The Right to Sight (appendix 1 p 7). This initiative 
provided the framework for national programmes to 
address eye health over the past 20 years. In 2019, WHO 
published the World report on vision,2 which was endorsed 
by the 73rd World Health Assembly in 2020. The report 
and resolution call for the advancing of eye health as an 
integral part of universal health coverage, by 
implementation of integrated people-centred eye care, 
following the approach outlined in a broader health 
services framework.3
The Lancet Global Health Commission on Global Eye 
Health contends that eye health should be part of the 
mainstream agenda to achieve universal health coverage 
and sustainable development. We define eye health as 
the state in which vision, ocular health, and functional 
ability are maximised, thereby contributing to overall 
health and wellbeing, social inclusion, and quality of life. 
Eye health can be considered both a process and an 
outcome. We define eye care services as those that 
contribute to any of vision, ocular health, or functional 
ability being maximised.
This report broadly divides into two halves. First, we 
present evidence for the importance of eye health, 
supporting the case for urgent action. Second, looking 
beyond 2020, we examine approaches to enable delivery 
of eye health services within universal health coverage. In 
section 1 we summarise the visual system, vision 
impairment, and common conditions. In section 2, we 
synthesise several reviews done by the Commission on 
the relevance of eye health to the Sustainable Development 
Goals (SDGs), as well as its impact on quality of life, 
general health, and mortality. In section 3, we describe 
the magnitude and causes of vision impairment in 2020 
and projected global and regional trends. We explore 
service needs of people with non-vision impairing eye 
conditions. We propose a more standardised approach to 
reporting population-based eye health surveys and 
examine the disability weights applied to vision 
impairment. In section 4, we summarise findings from a 
systematic review of eye health economics, identifying 
important areas for future work. We present a new 
estimate of global lost productivity associated with vision 
impairment for 2020, and an analysis of the cost-
effectiveness ratios for cataract surgery and refractive 
error services. In section 5, we outline a bibliometric 
analysis of eye health research since 2000, and report a 
global Grand Challenges project, highlighting crucial 
issues for concerted research and action. Lastly, we 
address the question of how health systems can practically 
advance towards delivering high quality integrated 
Figure 1: The development of global eye health
Blue circles indicate major global developments. Red circles indicate major treatments and programmatic 
developments. WHA=World Health Assembly. IAPB=International Agency for the Prevention of Blindness. 
RAAB=Rapid Assessment of Avoidable Blindness. RACSS=Rapid Assessment of Cataract Surgical Services.
WHO founded - 1948
First WHO Trachoma Expert Committee - 1952
First implanted intraocular lens - 1949
First laser treatment for diabetic retinopathy - 1956
IAPB formed - 1973
WHA resolution on blindness - 1975
WHO Prevention of Blindness programme established - 1988
WHO recommends vitamin A supplementation - 1988
WHA resolution on trachoma - 1998
VISION 2020 launched by WHO and IAPB - 1999
WHA Elimination of avoidable blindness - 2003
WHA Action Plan for prevention of avoidable blindness 2009–13
WHA Universal Eye Health: Global Action Plan 2014–19
WHO publishes World report on vision - 2019
Onchocerciasis control programme launched - 1974
Eye drops for glaucoma - 1980
First national vision impairment survey - 1981
Ivermectin donated for onchocerciasis control - 1987
Manual small-incision cataract surgery - 1990
Affordable intraocular lens produced in 
India and Nepal - 1992
RACSS survey method developed - 1995
Azithromycin donated for trachoma control - 1998
RAAB survey method developed - 2004
First anti-VEGF treatment for 
age-related macular degeneration - 2005
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people-centred eye care within universal health coverage.2 
We argue that business as usual will be insufficient, as 
evidenced by new analysis of effective cataract surgical 
coverage data. We examine service delivery components: 
primary eye care and integration with general health 
services, workforce strengthening, financing, health 
information systems, indicators, advocacy, and 
approaches to increase quality and equity.
The development of global eye health
This Commission views global eye health through the 
global health framework articulated by Koplan and 
colleagues.4 Eye health started with an understanding of 
the anatomy, physiology, diseases of the eye, and the 
development of clinical ophthalmology, the medical and 
surgical discipline for diagnosis and treatment of eye 
diseases. From the mid-20th century onwards (figure 1), 
there have been major technological advances in micro-
surgical techniques for cataract and other conditions, and 
equipment for diagnosis and treatment of major non-
communicable eye diseases, resulting in more effective 
interventions. There has been an enormous demo-
graphic transition, with ageing popu lations and epidemio-
logical changes from infectious diseases and towards 
non-communicable diseases, requiring accessible and 
affordable eye services with long-term follow-up. The 
increase in demand, emphasis on better quality, and 
higher cost of more sophisticated diagnostic and 
treatment services is requiring an increase in resources, 
which presents enormous public health challenges.
There are many lessons from the past 70 years that are 
instructive for the future of global eye health (appendix 1 
p 8). First, the importance of advocacy in creating global 
platforms to address a public health issue. Second, the 
value of common definitions, high quality data and 
research to develop global, regional, and national health 
programmes. Third, the importance of identifying and 
addressing specific eye diseases of public health 
importance that can be eliminated through public–
private partnerships. Fourth, that the VISION 2020 
initiative created an easily understood message for 
advocacy and planning services, and a global partnership 
involving different stakeholders in public health, 
including the private sector and non-governmental 
organisations, which resulted in extra resources and a 
common goal and focus. Fifth, that in promoting a global 
programme, inadequate attention was given to the 
engagement and partnership with ministries of health to 
ensure national ownership. There remains a need to 
integrate eye care planning and resource allocation into 
national health systems and share the achievements 
and successes. Sixth, that the transition from elimination 
of focal eye diseases with regional programmes and 
international funding to the development of compre-
hensive services to achieve universal eye health requires 
engagement, commitment, and leadership by the 
ministries of health and the willingness of all stakeholders 
(including the private sector) to support eye care services 
integrated within national health-care plans.
Section 1: The eyes, vision impairment, and eye 
conditions
The visual system
Vision is the most dominant of human senses. The eye, 
its associated adnexal tissues, and visual pathways within 
the brain are very intricate (figure 2). All these elements 
need to function well together to achieve clear vision. 
The transparent optical elements at the front of the eye 
(cornea and lens) focus light onto retinal photoreceptors. 
These transduce light stimuli into neuronal impulses 
with which the brain creates a three-dimensional image. 
Vision requires structural and physiological integrity of 
the eyes, brain, and their connections. Disruption of any 
part of this pathway causes vision impairment.
Measuring visual function
Our eyesight has several distinct components that require 
specific types of testing, including visual acuity (distance 
and near), contrast sensitivity, colour vision, and visual 
fields (appendix 1 p 9). Tests of cerebral visual function 
include interpreting the meaning of a picture or 
recognising faces. Vision-driven activities of daily living 
can be captured using quality of life tools and vision 
function-related tasks. The most common measure of 
visual function is distance visual acuity, which tests the 
ability to discern letters or characters of high contrast at 
decreasing size using the central retina.
Figure 2: The human eye and common conditions
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Defining vision impairment
There have been progressive developments in WHO 
recommendations on how vision impairment is 
measured, defined, and categorised, particularly in 
population-based epidemiological surveys (appendix 1 
p 10). International Classification of Diseases 11th Revision 
(ICD-11) definitions of distance vision impairment were 
updated in 2019 with additional subdivisions (table 1).5 In 
the World report on vision,2 WHO has signalled an 
intention to change the way vision impairment is 
reported, moving away from only presenting visual acuity 
(with spectacles or contact lenses if available), to also 
reporting uncorrected visual acuity (without spectacles or 
contact lenses if worn). Including the measurement of 
uncorrected acuity allows for better estimation of the 
ongoing service need and effective coverage of refractive 
error correction. In prevalence surveys, vision impairment 
is generally reported as visual acuity in the better seeing 
eye. This Commission uses visual acuity categories 
defined on Snellen charts in metres when presenting 
data. Moderate and severe vision impairment (MSVI) is 
defined as visual acuity worse than 6/18, but equal to or 
better than 3/60, and blindness is defined as worse than 
3/60 (table 1).
Common eye conditions
Many conditions can affect eye health, and even those 
that do not cause vision impairment can produce 
pronounced morbidity. Common eye conditions covering 
key clinical features, epidemiology, and management are 
summarised in appendix 1 (pp 11–14). The most common 
causes of vision impairment in adults are uncorrected 
refractive error, cataract, glaucoma, age-related macular 
degeneration, diabetic retinopathy, corneal scarring, and 
trachoma (figure 2). Among children the leading causes 
of blindness and MSVI include uncorrected refractive 
error, cataract, retinopathy of prematurity, congenital 
ocular anomalies, corneal scarring, and cerebral visual 
impairment. There are also many conditions causing 
pronounced symptoms (eg, pain, itching, discharge) and 
affecting a large number of people without vision 
impairment. These include infectious and allergic 
conjunctivitis, blepharitis, and dry eyes. The resulting 
morbidity needs to be addressed, forming a substantial 
proportion of ophthalmic service work.6
Social determinants of eye health
Public health approaches can prevent or treat most 
common eye diseases. Vision loss and access to eye care is 
greatly affected by social determinants.7,8 These encompass 
many issues: social exclusion, gender inequity, racism, 
early childhood development, educational opportunities, 
employment conditions, design and implementation of 
health systems and public health programmes, urbani-
sation, globalisation, and commercial determinants.7,9 
Inequity in health, between and within countries, is 
mostly attributable to social determinants of health.9 We 
will explore questions on access, equity, and health 
financing in the wider context of universal health 
coverage in section 6.10
Eye health during the life course
Life course perspectives focus on health trajectories 
during key developmental periods and across the whole 
lifespan.11 At each stage of life, multiple biological, 
socioeconomic, and environmental factors interact to 




acuity equal to or 
better than
0 - no vision impairment
Snellen, metres NA 6/12
Snellen, feet NA 20/40
LogMAR NA 0·30
Decimal NA 0·5
1 - mild vision impairment
Snellen, metres 6/12 6/18
Snellen, feet 20/40 20/60
LogMAR 0·30 0·50
Decimal 5/10 (0·5) 0·3
2 - moderate vision impairment
Snellen, metres 6/18 6/60
Snellen, feet 20/60 20/200
LogMAR 0·50 1·00
Decimal 3/10 (0·3) 0·1
3 - severe vision impairment
Snellen, metres 6/60 3/60
Snellen, feet 20/200 20/400
LogMAR 1·00 1·30
Decimal 1/10 (0·1) 0·05
4 - blindness
Snellen, metres 3/60 1/60*
Snellen, feet 20/400 5/300
LogMAR 1·30 1·80
Decimal 1/20 (0·05) 0·02
5 - blindness
Snellen, metres 1/60* Light perception
Snellen, feet 5/300 Light perception 
LogMAR 1·80 Light perception 
Decimal 1/50 (0·02) Light perception 
6 - blindness
Test for light perception Light perception No light perception
Sourced from WHO, 2019.5 There are several visual acuity chart types, which differ 
in the number and type of characters (optotypes), spacing, and reporting formats. 
The participant is asked to read down the chart, which has multiple rows with 
progressively smaller characters, at a specific distance. The visual acuity is the line 
with the smallest characters correctly identified. Snellen is expressed as a fraction: 
the numerator is the test distance and the denominator is the smallest line size 
correctly read. For each vision impairment category, the equivalent visual acuity 
thresholds are presented. NA=not applicable. LogMAR=Logarithm of the 
Minimum Angle of Resolution. *Or counting fingers at 1 metre.
Table 1: WHO definitions for vision impairment 
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(figure 3).13 Lifelong accumulation of risk factors, 
particularly during crucial periods of visual 
development, influence visual function trajectories and 
underlie marked regional differences in vision 
impairment.12
The socioeconomic environment into which a child 
is born has profound effects on eye health over the 
individual’s life course. Maternal nutritional and 
vaccination status, and development of intrauterine 
infections (rubella, toxoplasmosis, syphilis, Zika) are 
important determinants.14,15 Preterm birth can lead 
to retinopathy of prematurity and cerebral visual 
impairment. Low birthweight, fetal growth restriction, 
antenatal maternal smoking and alcohol misuse, and 
social deprivation in childhood can also cause vision 
impairment.16,17 Congenital eye conditions frequently 
have strong genetic components. Over the life course, 
biological and social determinants interact to determine 
visual function. For example, retinoblastoma, a mostly 
genetically determined childhood eye cancer, is not 
expected to vary by socioeconomic status. However, 
socioeconomic and cultural factors that influence 
timely access and adherence to treatment are 
responsible for important differences in vision and 
survival outcomes.18
Visual acuity develops rapidly after birth and reaches 
full development at around age 8 years. Early childhood 
is a crucial period because visual cortex plasticity 
progressively diminishes after age 2 years. Since vision is 
important for early child development, early onset vision 
impairment can lead to psychomotor and cognitive 
developmental delay.19 Visual stimulus deprivation 
between birth and age 8 years can lead to permanent 
vision impairment (amblyopia) if not managed in a 
timely manner.11 As the eyes grow and change shape 
there is a further sensitive period from childhood to 
adolescence when a combination of genetic and 
environmental factors, such as light exposure and time 
spent outdoors, can lead to myopia.20 Several infectious 
diseases (trachoma, toxoplasmosis, onchocerciasis) 
begin in childhood and lead to vision impairment later in 
life from accumulated pathology.21,22
Many conditions are age-related. Presbyopia starts 
developing from age 35 years, as the lens ages. Some 
Figure 3: Life course perspective on eye health
Arrows indicate the period in the life course in which different conditions typically present. The yellow line indicates a hypothetical functional vision trajectory of someone with a condition leading to 
increased vision impairment. The black line represents the functional vision trajectory of someone who does not have a condition leading to vision impairment. This figure is partly based on the 
concept of functional trajectories illustrated in WHO, 2001.12 The disability threshold represents the level of functional vision below which there is functional vision impairment.
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conditions (eg, glaucoma and age-related macular 
degeneration) have a complex polygenetic background, 
which can interact with nutrition and other biological 
factors.23,24 Diabetes and diabetic retinopathy are influenced 
by multiple social and environmental determinants (diet, 
activity, obesity).25 Cataract arises from multiple factors 
across the life course that promote lens ageing: ultraviolet 
light exposure, smoking, poor nutrition, diabetes, and 
severe dehydration.26
The life course trajectory of visual function is not 
fixed. Many conditions and risk factors are amenable 
to interventions, including social determinants, along 
the spectrum of promotion, prevention, treatment, 
and rehabilitation. These are complex issues, requiring 
multisectoral approaches (nutrition, housing, social 
security, education), long-term policies, and health 
system investment for greater health equity.13,27
Section 2: The importance of eye health
Eye health and the SDGs
The UN SDGs are a group of broad target-driven goals for 
2030, designed as a “blueprint to achieve a better and 
more sustainable future for all”.28 We did a series of 
systematic and scoping reviews to examine the 
relationship between eye health and the SDGs. Together, 
these reviews provide compelling evidence that improving 
access to eye health services will contribute to achieving 
many SDGs, including the goals to reduce poverty and 
increased work productivity, health, education, and equity 
(figure 4). Furthermore, progress towards many SDGs 
will benefit vision and eye health. Therefore, we believe 
improving eye health should be viewed principally as a 
human development issue.
This Commission explored the relationship between 
eye health and general health and wellbeing (SDG3) in 
Figure 4: Improving eye health and Sustainable Development Goals
Green arrows indicate relationships with direct evidence of a beneficial effect from improving eye health on Sustainable Development Goals. Dashed green arrows 
represent hypothesised direct beneficial effects. Black arrows represent possible indirect beneficial effects.
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six separate reviews, as well as doing a further review on 
the relation between eye health and the 16 other SDGs 
(appendix 1 p 15; table 2).57 In terms of these 16 SDGs, we 
showed that the provision of eye care services is associated 
with improvements in workplace productivity,29 house-
hold consumption,30,31 household income,32–35 employment 
prospects,36 and economic productivity.37–40 Economic 
benefits, particularly in resource-limited communities, 
contribute to achieving SDGs such as poverty reduction 
(SDG1), food security (SDG2), and decent work (SDG8). 
An example of benefits resulting from provision of eye 
care services is shown by the Cataract Impact Study30,31 
done in Kenya, Bangladesh, and the Philippines 
(appendix 2 p 3).
Educational performance is linked to vision. Children 
with vision impairment have poorer educational outcomes 
and are more likely to be excluded from schools (less likely 
to attend). We found evidence that providing spectacles to 
children improves educational performance, supporting 
quality education (SDG4), with effect sizes at least as large 
as other health interventions.41–45 Improved education is 
crucial to development, reducing poverty and hunger, and 
enabling work (SDGs 1, 2, and 8).58
Improving eye health contributes to increased gender 
equity (SDG5) and reduced inequalities (SDG10).49 Cataract 
surgery can improve equity, measured by expenditure.31 
Women have poorer access to eye health services and 
more vision impairment; addressing gender inequality 
will help advance eye health.59 Specific interventions such 
as community outreach vision screening services increase 
equity for conditions such as cataract and glaucoma among 
women, marginalised communities, and older people.51,60
Improved eye care can contribute to improving the 
sustainability of cities and communities (SDG11). 
Studies52–56 show that improved vision enhances road 
safety, thereby contributing to safer cities. Although no 
studies met our inclusion criteria for the remaining 
SDGs, we contend that environmentally responsible eye 
health services would reduce carbon emissions and 
plastic waste, thereby contributing to progress towards 
the SDGs for affordable clean energy (SDG7), responsible 
consumption (SDG12), climate action (SDG13), life below 
Number and type of study Summary of study findings
Poverty-related (SDGs 1, 2, 8)
Relative productivity in the 
workplace




Two (prospective cohort studies) Increase in household per-capita expenditure in people with vision impairment who underwent cataract surgery—eg, in 
the Philippines, increase by 88% over 1 year (p<0·001)30,31
Household income Four (prospective cohort studies and 
one retrospective cohort study)
Household income increased after cataract surgery—eg, 1 year after provision of surgery for marginalised communities in 
rural India,32–34 the proportion of households with a monthly income (<1000 Rupees) decreased from 51% to 21% (p=0·05); 
in the USA,35 children who became blind by age of 6 years and attended vision impairment schools had a lower salary than 
those who attended public schools (possibly confounded by other determinants)
Employment rates One (retrospective cohort study) Vocational rehabilitation services for vision impairment in the USA were positively associated with paid employment—
eg, training and support services increased odds of obtaining paid employment (odds ratio 1·10, p=0·001)36
Economic productivity Four (cost-effectiveness and 
evaluation studies)
Benefits to economic productivity from cataract surgery37,38 and trichiasis surgery39,40—eg, there was a net 13-year 
US$123·4-billion return on investment from a 1-year cohort after cataract surgery, including an increase in US national 
productivity of US$25·4 billion37
Quality education (SDG 4)
Academic test scores Seven (randomised controlled trials and 
prospective cohort studies)
Providing children with spectacles improved academic test scores41–47—eg, in China, vision correction reduced the odds of 
failing a class by 44% (p<0·01)43
Reading or word identification Two (cohort studies) Improved reading and word identification with spectacle wear and attendance at specialised schools35,48
Inequalities (SDGs 5, 10)
Gender inequality Three (systematic review with meta-
analysis, and pair of cross-sectional 
surveys)
Reduced gender inequality in all-cause blindness, clinic attendance, cataract surgery coverage, and trachoma treatment 
coverage following interventions to promote eye services by trained rural community volunteers in low-income and 
middle-income countries;49 free cataract screening and low-cost quality cataract surgery in China reduced gender disparity 
in willingness to pay at 5-year follow-up (88% men, 91% women) compared with baseline (67% men, 50% women)50
Equity (per-capita 
expenditure)
One (cohort study) People who had cataract surgery in Kenya, the Philippines, and Bangladesh were poorer than non-visually impaired 
people before surgery (p≤0·02), but after surgery, there was no difference in household per-capita expenditure between 
the groups (p≥0·2), showing equity improvement33
Inequalities in use of eye care 
services
One (series of repeat cross-sectional 
studies)
Free eye examinations in Scotland increased use of eye care services at the aggregate level but widened inequalities by 
income (p<0·001) and education (p<0·001)
Sustainable cities and communities (SDG 11)
Driving-related difficulties One (meta-analysis) Reduced driving-related difficulties after cataract surgery (pooled odds ratio 0·12, 95% CI 0·10–0·16)51
Motor vehicle crashes Five (observational studies) Cataract surgery reduced motor vehicle crashes (all studies statistically significant)52–56
Changes in eye health following an intervention are directly linked to one or more Sustainable Development Goals.
Table 2: Eye health and Sustainable Development Goals
See Online for appendix 2
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water (SDG14), and life on land (SDG15).61,62 Unaddressed 
eye care needs in displaced populations underscore the 
potential for such interventions to contribute to the 
resilience of these disadvantaged communities (SDG16).63
Underlying all SDGs is SDG17, strengthening 
partnerships to achieve the goals. The global eye health 
community provides examples of effective health-care 
partnerships, including the GET2020 Alliance64 and the 
African Programme for Onchocerciasis Control,65 which 
have yielded major reductions in the disease burden.
Vision impairment and health and wellbeing
Vision impairment affects multiple functional domains 
(physical, cognitive, psychological, social), and overall 
quality of life and wellbeing.66,67 Here, we reflect on vision 
impairment and inclusive development before sum-
marising each review done by this Commission.
Vision impairment and inclusive development
The UN places great emphasis on “realization of the 
SDGs by, for and with persons with disabilities”, 
including people with vision loss.68 This emphasis 
recognises that people with vision-related disability play 
an important part in achieving the SDGs, and their 
exclusion from schooling and employment is a violation 
of their rights, as set out in the UN Convention on the 
Rights of Persons with Disabilities. For example, children 
with vision impairment in multiple LMICs are up to five 
times less likely to be in formal education than children 
without disabilities.69 In high-income countries, where 
school attendance is usually mandatory, children with 
vision impairment often achieve poorer outcomes 
(appendix 1 p 16)70 and might face social exclusion and 
violence in schools, impacting their edu cation.71,72 People 
with vision impairment also experience reduced 
employment prospects and are more likely to have low 
paid work rather than professional jobs.73,74 Beyond 
education and employ ment, vision impairment is linked 
to social exclusion including the experience of negative 
attitudes,75 violence and bullying,76 sexual assault,77 and 
loneliness.
The key to promoting the rights of people with vision 
impairment is to improve functional ability by increasing 
access to vision rehabilitation services and creating more 
inclusive environments through strengthening inclusive 
policies and laws, providing assistive technology, inclusive 
education and vocational training, advocacy, and creating 
accessible spaces. To ensure vision rehabilitation is 
considered as an integral component of eye care services 
in pursuit of universal health coverage, this Commission 
calls for adoption of a new definition of eye health, which 
involves maximised vision, ocular health, and functional 
ability, thereby contributing to overall health, wellbeing, 
social inclusion, and quality of life.
The International Classification of Functioning, 
Disability and Health model by WHO67 can help to 
contextualise the impact of vision impairment on a 
person’s life, including walking, eating, education, 
employment, and social participation (appendix 1 p 16). 
This model illustrates the importance of environmental 
factors to maximise participation of people with vision 
impairment in society, including the opportunity to 
access vision rehabilitation.
Studies have shown78–80 that vision screening and 
provision of glasses helps to improve educational 
outcomes for children with vision impairment, and the 
provision of other types of assistive devices and reading 
aids is also likely to be effective. However, spectacles are 
not universally available and the ability to read and write 
using assistive technology, such as screen reading 
software or an electronic braille display, requires skills; 
the means to procure, purchase, and power the 
technology; and access to information in a compatible 
format. Compensatory skills learned in vision 
rehabilitation, such as orientation and mobility using a 
white cane, presupposes the necessary infrastructure of 
predictable paths and spaces in which the person can 
confidently move. These skills might be useful in one 
context but are not transferable to another—eg, in an 
urban setting with requisite infrastructure versus a rural 
setting without appropriate infrastructure. Clearly, much 
needs to be done to maximise the function and societal 
participation for people living with vision impairment. 
This is explored further in section 6.
The Commission calls for a more holistic approach to 
the health of people with vision impairment, who might 
have great difficulties with other health conditions and 
some might be perceived to no longer require eye care 
services.81,82 We see integrated people-centred eye care as 
an opportunity to ensure that any reorientation of care 
promotes the rights of people to access eye care that they 
require during the life course, which is not limited to the 
condition causing their vision loss.
Vision impairment and quality of life
Assessment of quality of life describes an overall state 
of wellbeing from the individual’s perspective. Health-
related quality of life describes the degree to which 
health affects wellbeing, whereas vision-related quality 
of life reflects the degree to which vision affects 
wellbeing.83,84 Health-related quality of life and vision-
related quality of life are used to understand how vision 
impairment affects wellbeing from a person-centred 
perspective, and how this perspective is influenced by 
personal, social, and environmental contexts.
To summarise the extensive research on the impact of 
vision impairment, eye conditions, and ophthalmic 
interventions on the quality of life, we conducted an 
umbrella review of systematic reviews (appendix 1 
p 17).85 In total, 69 systematic reviews were identified. 
Nine of those reviews evaluated the relationship 
between quality of life and vision impairment or 
specific eye conditions, such as age-related macular 
degeneration, glaucoma, or diabetic retinopathy, and all 
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concluded that vision loss and eye disease were 
associated with poor quality of life outcomes. The 
remaining 60 reviews evaluated quality of life between 
groups receiving alternative ophthalmic interventions, 
active treatment (appendix 1 p 18), and controls who 
did not receive an ophthalmic intervention. 75% of 
ophthalmic interventions showed a positive impact on 
quality of life. Most notably, cataract surgery and anti-
vascular endothelial growth factor treatment for age-
related macular degeneration, diabetic macular oedema, 
and macular oedema secondary to other causes resulted 
in improved quality of life (appendix 1 p 18).
Our umbrella review reinforces the close relationship 
between good vision and enhanced quality of life and 
provides a strong argument for increased investment 
in eye health. The umbrella review also highlights 
that despite quality of life being commonly assessed 
in ophthalmic studies, definitions varied widely. This 
Commission calls for the development and the adoption 
of standardised and culturally sensitive measures of 
quality of life for eye health research, to better understand 
the effect of vision impairment and ophthalmic inter-
ventions from the patient’s perspective.
Vision impairment and other health conditions
People with self-reported vision impairment have 
increased risk of some health conditions such as 
depression, dementia, cardiovascular disease, and lung 
cancer.86–89 The causal relationship between vision 
impairment and other conditions is complex, but can be 
broadly summarised by three different pathways 
(figure 5); (1) vision impairment causes or exacerbates 
other conditions either directly, through injuries, or 
indirectly—eg, through reduced access to health care, 
limitations in physical activity, or increased social 
isolation; (2) vision impairment and other conditions 
share common risk factors—eg, smoking, poverty, 
reduced health-care access, ageing, or poor diet; and 
(3) systemic health problems can lead to vision 
impairment—eg, diabetes and diabetic retinopathy, 
cancer and ocular metastases, and dementia—limiting 
access to eye health services.
More than one pathway seems to underlie the 
association between vision impairment and other health 
conditions, making the pathways difficult to elucidate. 
Here, we summarise a rapid review led by one of the 
commissioners to investigate the relationship between 
Figure 5: Relationships between vision impairment and general health
These associations are derived from multiple literature reviews done by this Commission. *Hypothetical common degenerative pathways.
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vision impairment and mental health; and cardiovascular 
disease, respiratory disease, and cancer (appendix 1 p 19).
The rapid review found that vision impairment is likely 
to be linked to depressive illness. A meta-analysis of 
data from high-income and middle-income countries 
found that 25% of people with eye conditions also 
have pronounced depressive symptoms.87 Depressive 
symptoms have been shown to increase with more severe 
eye disease.90,91 Another meta-analysis found a significant 
reduction in depression after cataract surgery.92 A review 
done by members of this Commission, in addition to 
the rapid review, found an association between vision 
impairment and dementia, and suggested that inter-
ventions to improve vision could possibly slow down 
cognitive decline (panel 1).
Indirect pathways might also link vision impairment 
with systemic conditions—eg, as a barrier to accessing 
health care. A UK study93 found that women with vision 
impairment were less likely to participate in breast and 
bowel cancer screening than women with no disabilities, 
after adjusting for confounding factors. Reduced physical 
activity might be another important factor; older adults 
in the USA with vision impairment took 26% fewer steps 
each day and spent 48% less time in moderate or vigorous 
physical activity than those with healthy vision.94,95 
Reduced physical activity is a leading risk factor for non-
communicable eye diseases.
Ocular and general health conditions might share 
common risk factors. Smoking is associated with 
lung cancer, chronic obstructive pulmonary disease, 
stroke, coronary artery disease, dementia, and numerous 
eye conditions including cataract, age-related macular 
degenera tion, diabetic retinopathy, and possibly 
glaucoma.96–99 Sun exposure is associated with cataract and 
skin cancer.100 Poor diet, obesity, and low physical activity 
are common to systemic diseases and eye diseases. 
Consumption of vegetables, fruit, and micronutrients are 
protective for some cancers, cardiovascular disease, and 
depression. Similarly, a Mediterranean diet and some 
micronutrients might protect against cardio vascular 
disease and cataract, diabetic retinopathy, glaucoma, and 
age-related macular degeneration.97,101–103
Panel 1: Vision impairment and dementia
In 2016, 43·8 million adults aged 60 years and older had 
dementia, with numbers doubling every 20 years 
(GBD Dementia Collaborators, 2019; Prince et al, 2013). The 
estimated global economic cost of dementia in 2018 was 
US$1 trillion (Wimo et al, 2017). Although there are few 
effective treatments (Mukaden et al, 2019), in the past 
decade vision impairment has emerged as a potential 
modifiable risk factor (Ehrlich et al, 2019; Swenor et al, 2019; 
Zheng et al, 2018; Brenowitz et al, 2019; Fischer et al, 2016; 
Schubert et al, 2017; Rogers et al, 2010; Nael et al, 2019; 
Maharani et al, 2018).
Longitudinal studies indicate that vision impairment might be 
a risk factor for dementia and accelerated cognitive decline 
(Swenor et al, 2019; Zheng et al, 2018; Fischer et al, 2016; 
Rogers et al, 2010; Tran et al, 2020). In Singapore, adults with 
vision impairment had an accelerated cognitive decline 
(Lim et al, 2020). In the USA, vision impairment was 
associated with 55% increased hazard of incident cognitive 
impairment and the effect of declining vision on future 
declines in Mini-Mental State Exam scores was significantly 
stronger than the reverse association (Swenor et al, 2019). 
Among more than 1000 women in the USA, incident 
dementia increased with vision impairment severity (Tran 
et al, 2020). In France, near vision impairment was associated 
with increased dementia risk at 4 years, although this 
association waned with longer follow-up (Nael et al, 2019). 
Preliminary data suggest that cataract surgery might decrease 
risk of cognitive decline. In an English longitudinal study of 
ageing, cognitive decline slowed down significantly (by 50%) 
following cataract surgery (Maharani et al, 2018). Together, 
these data provide strong evidence of an association between 
vision impairment and dementia.
Most research on vision impairment with cognitive function 
and dementia has been done in high-income countries, with 
few ongoing studies from LMICs (Lee et al, 2019; Kowal et al, 
2012). However, there is a pressing need in all settings to test 
causal pathways that might underlie the association of vision 
impairment with cognitive decline and dementia. Although 
several hypotheses have been proposed to account for this 
relationship (Whitson et al, 2018), none have been rigorously 
tested. The postulated reason that dementia might be more 
prevalent in those with poor vision could be because of a single 
common underlying cause, such as neurodegenerative or 
microvascular disease. This reason is supported by the possible 
use of retinal imaging as a biomarker for dementia (Chan et al, 
2019). Several indirect pathways have also been proposed. Poor 
vision is known to increase cognitive load (Pigeon et al, 2019), 
a stressor that might increase dementia risk. Another possibility 
is that decreased visual input could result in direct alteration of 
brain structure. Finally, vision impairment might exert its effect 
on dementia risk by limiting social and physical activity, factors 
that have separately been shown to elevate dementia risk (Tan 
et al, 2017; Reas et al, 2019; Rafnsson et al, 2020).
Vision impairment is possibly a modifiable risk factor for 
dementia because most of vision loss is preventable or treatable. 
However, vision impairment has not been widely recognised as 
such outside of the vision research community (Livingstone et al, 
2020). Additional work is needed to ensure that various 
stakeholders invest in the importance of characterising cognitive 
trajectories of older adults with vision and multisensory 
impairments and in the testing of interventions to slow 
cognitive decline across diverse cultural and geographic contexts. 
References for this panel can be found in appendix 1 (p 105).
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For cases in which systemic diseases directly cause 
vision impairment, the pathophysiology is often better 
understood. However, causative effects of general illness 
on vision impairment can also be mediated indirectly 
through the reverse of some of the indirect pathways. For 
example, poor systemic health might limit physical activity, 
which might increase risk of diabetic retinopathy104 and 
glaucoma progression.105 Preventive initiatives that reduce 
smoking, improve diet, and promote physical activity are 
likely to have shared benefits for general and ocular health. 
The question of whether interventions to ameliorate vision 
impairment can also improve general health is an 
important area for future investigation.
Dual sensory impairment
In a similar way to vision impairment, hearing impairment 
is also associated with age. Therefore, dual sensory 
impairment—ie, when these two conditions occur 
concurrently—is an important consideration for healthy 
ageing.106 This Commission did a scoping review to 
summarise dual sensory impairment definitions, 
prevalence, and the effect on people’s lives (appendix 1 
p 21). We found striking heterogeneity in the definitions of 
dual sensory impairment (67 variations in 151 studies), the 
age groups included, and prevalence estimates. Despite 
this hetero geneity, dual sensory impairment appears 
prevalent in older adults (increasing prevalence with age), 
and many studies reported that people with dual sensory 
impairment had worse physical and psychosocial health 
outcomes and reduced social participation compared with 
those who had only vision impairment or hearing 
impairment. In the context of an ageing population, this 
Commission calls for greater emphasis on dual sensory 
impairment, including a consensus on definitions and 
reporting, and collaborative efforts to advance the research, 
clinical care, and social inclusion for this population.
Vision and driving
Driving is a complex vision-dependent task with a risk of 
road traffic injury. SDG3 (good health and wellbeing) and 
SDG11 (improving the sustainability of cities and 
communities) include targets to reduce road traffic 
injury, which is the leading cause of death for children 
and young adults.107 This Commission did a systematic 
review of the relationship between vision impairment 
and driving, outlined in appendix 1 (pp 22–23). Findings 
from 115 studies showed that some causes of vision 
impairment, such as glaucoma and cataract, are 
associated with motor vehicle collisions and unsafe 
driving practices.108,109 Interventions such as cataract 
surgery can reduce the risk of motor vehicle collisions,56,110 
whereas anti-vascular endothelial growth factor (for 
age-related macular degeneration or diabetic macular 
oedema) can enable continued participation in 
driving.111,112 Most of these data were from high-income 
countries (88%). With the increasing reliance on motor 
vehicle transport, maintaining vision is essential for 
drivers to prevent road traffic injuries and promote 
independent mobility. This Commission calls for ready 
access to eye care services for drivers and evidence-based 
legislation to mitigate the risks associated with vision 
impairment and driving, particularly in LMICs.
Vision impairment and falls
Globally, a third of people aged over 65 years fall each year 
and falls are the leading cause of injury-related death 
among adults over 70 years.113,114 This Commission did a 
systematic review to assess the relationship between 
vision impairment, ophthalmic interventions, and falls 
(appendix 1 pp 23–24). The main findings from 
129 studies showed that vision impairment is an 
independent risk factor for falls among older adults and 
that timely access to ophthalmic interventions such as 
cataract surgery can reduce the risk of falls.115–117 On the 
basis of these findings, we call for vision to be included 
in risk assessment tools for falls and for eye care services 
to be better integrated with fall prevention efforts.
Vision impairment and mortality
Vision impairment seems to be associated with an 
increased risk of all-cause mortality.118–121 Several 
explanations are possible for this association in relation 
to non-communicable eye diseases, mental health, and 
injuries (figure 5). This Commission did a systematic 
review and meta-analysis to contribute an updated 
appraisal of the literature, assessment of bias, and overall 
grading of the quality of evidence (appendix 1 p 24).122 
We included studies that measured visual acuity and 
contained at least 1-year follow-up to assess all-cause 
mortality. A total of 28 studies representing 30 cohorts 
were included. Studies came from 12 countries in Africa, 
Asia, Australia, Europe, and North America and included 
451 001 participants.
The primary meta-analysis included studies comparing 
mortality among participants with vision better or worse 
than the prespecified thresholds of 6/12, 6/18, and 6/60. 
Since age is a common risk factor for vision impair-
ment and mortality, all measures of association in this 
meta-analysis were age-adjusted. Where available, we 
also selected estimates adjusted for other possible 
confounders such as smoking, diabetes, access to health 
care, and socioeconomic status. Figure 6 presents the 
results of this analysis. We found that the hazard of 
mortality was higher among those with visual 
acuity <6/12 (hazard ratio [HR] 1·29, 95% CI 1·20–1·39) 
and <6/18 (1·43, 1·22–1·68) compared to those with 
better vision. At the 6/60 threshold, the hazard of 
mortality was higher than for those with visual acuity 
of ≥6/18 (1·89, 1·45–2·47). However, no significant 
association was detected when comparing those 
with visual acuity better and worse than 6/60 (1·02, 
0·79–1·32), probably because the reference group 
contained participants with a substantial degree of 
vision impairment (≥6/60). We evaluated the certainty 
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of evidence using the Grades of Recommendation, 
Assessment, Development, and Evaluation (GRADE) 
framework and judged it to be of moderate certainty.123 
Additional research is needed to better understand 
factors that modulate mortality risk among adults with 
vision impairment, and to more fully characterise risk in 
LMICs, where data remain scarce. Given the prevailing 
finding of an association between vision impairment 
and mortality, future calculations of disability-adjusted 
life-years might include years of life lost due to vision 
impairment, which could provide a more complete 
estimate of the overall global burden of vision 
impairment. The impact of vision impairment on 
mortality should drive action to address avoidable sight 
loss and reinforces the relevance of eye health to SDG3 
(good health and wellbeing) and the SDGs in general.
Section 3: Magnitude of eye disease
Burden of global vision impairment in 2020
World Health Assembly Resolution 66/11 Universal eye 
health: a global action plan 2014–19, opened up a new 
opportunity for WHO member states to progress with 
their efforts to prevent vision impairment and strengthen 
vision loss rehabilitation in their countries.124 Central to 
this process is an understanding of the prevalence, 
magnitude, and causes of vision loss.
The Vision Loss Expert Group (VLEG) has worked with 
the Global Burden of Disease (GBD) collaborators since 
2007 to produce global vision loss metrics. The VLEG 
published global estimates for vision loss and modelled 
temporal change for the first time in 2010,125,126 and 
subsequently in 2015.127,128 The results from 2015 were also 
published in the World report on vision by WHO.2 These 
Figure 6: Vision impairment and mortality
Random-effects meta-analysis results showing the maximally adjusted pooled hazard of mortality in adults with (A) mild vision impairment or worse 
(<6/12 compared with ≥6/12); (B) moderate vision impairment or worse (<6/18 compared with ≥6/18); (C) severe vision impairment or worse (<6/60 compared 
with ≥6/18); and (D) severe vision impairment or worse (<6/60 compared with ≥6/60). Events are defined as the number of participants in the study who died, 
and N is the total number of participants in the study. 12 cohorts that were included in the systematic review are not depicted in this figure for the following reasons: 
they used other vision impairment thresholds that could not be aggregated with these studies; they reported results per unit difference in visual acuity; they reported 
odds ratios or risk ratios that could not be pooled with HRs; or they compared a reference category of participants with good vision to participants with various vision 
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analyses use definitions from the ICD-11 for distance and 
near vision impairment. The VLEG–GBD group 
collaborators have jointly published estimates for 2020, 
which we summarised here.1
Globally, of 7·79 billion people living in 2020, it is 
estimated that 43·28 million (95% uncertainty interval 
[UI] 37·57–48·36) are blind with presenting visual acuity 
of worse than 3/60 in the better eye and a crude all-age 
prevalence of 0·55% (0·48–0·61; table 3). Of these, 55% 
or 23·88 million (20·83–26·82) are women. The 
prevalence of blindness increases with age; most (77·7% 
or 33·61 million, 28·58–38·54) people with blindness are 
aged 50 years or older.
Moderate or severe vision impairment (MSVI) is 
defined as presenting visual acuity of worse than 6/18 to 
3/60 in the better eye. MSVI is estimated to affect 
295·09 million (95% UI 267·32–324·60) people, which is 
3·74% (3·39–4·12) of the global population (table 3). 
A further 257·83 million (232·66–285·34) or 3·27% 
(2·95–3·62) have mild vision impairment, defined as 
presenting visual acuity of worse than 6/12 to 6/18 in the 
better eye. Globally, an estimated 509·69 million 
(371·11–666·66) people globally have near vision 
impairment from uncorrected presbyopia, representing 
22·06% (15·52–29·62) of people aged 50 years and older. 
Similar to the gender imbalance in blindness, 55% or 
162·97 million (147·43–179·21) of individuals who have 
MSVI and 55% or 142·29 million (128·45–157·36) of 
people with mild vision impairment are women.
Globally, 91·75% of people who are blind (39·62 million, 
95% UI 34·64–44·79) and 87·68% of those with MSVI 
(257·90 million, 231·87–285·81) live in LMICs. There are 
large inter regional differences in crude and age-
standardised prevalence of blindness and MSVI for 2020 
(figure 7; appendix 1 p 26). Western sub-Saharan Africa 
has the highest age-standardised prevalence of blindness 
(1·11%, 0·95–1·26) and high-income North America has 
the lowest prevalence (0·12%, 0·11–0·14). South Asia has 
the highest age-standardised overall prevalence of MSVI 
(6·44%, 5·79–7·13). The largest number of blind people 
live in South Asia (11·9 million, 10·4–13·4), followed by 
east Asia (9·1 million, 7·9–10·3), and southeast Asia 
(5·9 million, 5·2–6·7), because of the large regional 
populations (figure 7; appendix 1 p 26). MSVI follows a 
similar pattern.
The World report on vision2 by WHO used estimates of 
people with distance vision impairment for 2015, provided 
by the VLEG, and combined these with an estimated 
1·8 billion people with addressed (974 million) and 
unaddressed (826 million) near vision impairment due to 
presbyopia, derived from a different model, to reach an 
overall figure of 2·2 billion people with vision 
impairment.127–129 These 2015 estimates have now been 
superseded by 2020 estimates from the VLEG–GBD 
group.
In summary, for 2020, there are an estimated 596 million 
people with distance vision impairment and a further 
510 million with uncorrected presbyopia. These estimates 
do not include people who have already received spectacles 
or contact lenses to correct distance refractive error or 
presbyopia, because reliable population-based data are 
scarce. However, this group probably represents a very 
large number of people who require ongoing services to 
meet their eye health needs.129,130
Causes of global vision impairment in 2020
The leading causes of blindness globally are cataract 
(17·01 million, 95% UI 14·40–19·93), uncorrected 
 Blindness Moderate and severe vision impairment Mild vision impairment




Number, millions Crude prevalence Age-standardised 
prevalence



















































































































Data are n (95% uncertainty interval) or % (95% uncertainty interval). Data taken from VLEG–GBD, 2020.1
Table 3: Global number, crude prevalence, and age-adjusted prevalence of vision impairment in 2020
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refractive error (3·70 million, 3·10–4·29), glaucoma 
(3·61 million, 2·81–4·42), age-related macular 
degenera tion (1·85 million, 1·35–2·43), and diabetic 
retinopathy (1·07 million, 0·76–1·51; appendix 1 
p 27).131 Notably, 37% (16·04 million, 14·00–18·06) 
of all blindness is attributable to a variety of other 
conditions. This group cannot be overlooked when 
focusing on the five leading causes of blindness. 
A person can have more than one cause of vision 
impairment; however, epidemiological studies tend to 
report only the primary cause.
In 2020, the leading causes of MSVI globally 
are uncorrected refractive error (157·49 million, 
140·30–175·54), followed by cataract (83·48 million, 
71·76–95·98), age-related macular degeneration 
(6·23 million, 5·04–7·59), glaucoma (4·14 million, 
3·24–5·18), and diabetic retinopathy (3·28 million, 
2·41–4·34; appendix 1 p 28).1
Regions with particularly high prevalence of cataract 
blindness (as a proportion of all-cause blindness) include 
south Asia, Oceania, and southeast Asia, where cataract 
is responsible for around half of all blindness in 2020 
(figure 8).131 In high-income regions, glaucoma and 
age-related macular degeneration account for a greater 
proportion of blindness than other regions. In all regions, 
uncorrected refractive error is responsible for most 
MSVI. In 2020, 77·3% of people with blindness and 
MSVI have an avoidable cause, defined as cataract or 
uncorrected refractive error; increasing to 90·9% if near 
vision impairment is included.
Vision impairment in children
Data on vision impairment in children and adults 
younger than 40 years are scarce. Surveys need to be 
larger because blindness prevalence is lower in this age 
group (3 per 10 000 children in high-income countries, 
10 per 10 000 in low-income countries) and some 
conditions appear as clusters. Measuring visual acuity of 
young children is challenging. As a result, population-
based data are rare and mostly consist of school surveys. 
Mindful of these data limitations, the VLEG–GBD group 
has estimated that for 2020, 1·44 million children aged 
0–14 years are blind (including uncorrected refractive 
error), 22·16 million have MSVI, and 46·60 million have 
mild vision impairment.
In 1990, WHO estimated that 1·5 million children 
(aged 0–15 years) worldwide were blind, excluding those 
with refractive errors.132 In 1999, WHO updated this 
estimate using an alternative method based on under-5 
mortality rate as a proxy indicator for prevalence of 
blindness in children aged 0–15 years; reporting 
1·4 million children.133 The rationale was that many 
causes of blindness in children also cause mortality, 
such as measles infection, vitamin A deficiency, 
meningitis, malaria, birth hypoxia, and prematurity. 
This prevalence was re-estimated at 1·14 million 
for 2015.134 Using the same method, this Commission 
re-estimated prevalence of blindness to be 1·02 million 
for 2020; representing a global prevalence of 4·8 per 
10 000 children (appendix 1 pp 29–31). Further decline 
reflects a fall in under-5 mortality rate and stabilisation 
of the global population of children at 2·1 billion. South 
Asia and Western sub-Saharan Africa account for almost 
half (45·6%) of all children who are blind (appendix 1 
p 30).
Overall, these two different estimation approaches have 
produced similar values. However, there is a pressing 
need for new methods to obtain more extensive survey 
data that would be representative of the population and 
would improve the estimates of vision impairment in 
children.
Figure 7: Vision impairment by Global Burden of Disease region
(A) Age-standardised prevalence of vision impairment and (B) number of people with vision impairment. Data 
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Trends in vision impairment
To model temporal trends, the VLEG–GBD group1 
generated forecasts of vision impairment prevalence for 
1990–2019 (in 5-year increments), using age-specific 
prevalence as input into a regression model with year, 
region, and age as predictors. In the past 30 years, age-
standardised prevalence of blindness has reduced by 
approximately 28·5%. By 2050, the number of people who 
are blind is predicted to increase to 61·05 million globally 
(95% UI 52·85–69·27). For MSVI, the number affected is 
expected to rise to 474·12 million (428·43–518·23), followed 
by 360·35 million (321·96–399·96) for mild vision impair-
ment, and 865·67 million (628·79–1154·14) for vision 
impairment from uncorrected presbyopia (figure 9).
These trends are continuing—largely driven by 
population ageing and changes in disease patterns. 
UN projections135 indicate a substantial increase in the 
number of people aged 65 years and older over the next 
30 years, from 700 million to 1·5 billion, with the largest 
increase in LMICs. Many conditions causing vision 
impairment become more prevalent with age.
Projections suggest that the proportion of people with 
vision loss who are women will increase (figure 9).1 When 
actual numbers are assessed, there are more women than 
men living with blindness and MSVI in all regions of the 
world (figure 10). This gender imbalance can be attributed 
to demographic factors (women living longer than men) 
and social factors (women having reduced access to care). 
To adjust for demographic differences, age-standardised 
prevalence can be compared to provide a better estimate 
of gender inequity. Even after this adjustment, MSVI 
prevalence is higher in women in all regions of the world 
(except in two regions: central and southern sub-Saharan 
Africa; appendix 1 p 32). Men have lower age-standardised 
prevalence of blindness in less than half of world regions. 
Globally, for every 100 men with blindness or MSVI there 
are 108 women with blindness and 112 women with 
MSVI. The persistent gender differences after age-
standardisation suggest that, in some settings, greater 
vision loss in women is socially determined. Some groups 
of women have difficulty accessing eye care, particularly 
in southeast Asia. These demographic and social factors 
have major implications for the pursuit of gender equity 
within universal health coverage.
There are several important risk factor and disease-
specific trends that are changing the epidemiology of 
eye disease in many populations (panel 2). In the 
past three decades there has been substantial success 
in controlling trachoma and onchocerciasis. Environ-
mental factors and educational practices, particularly 
in Asian populations, are believed to explain the 
pronounced increase in myopia in schoolchildren and 
young adults. Increasing urbanisation, less active 
lifestyles, and altered diets are contributing to a marked 
increase in diabetes, resulting in more people affected 
by diabetic retinopathy (appendix 1 p 33). Myopia and 
diabetic retinopathy require specific prevention and 
Figure 8: Causes of vision impairment by Global Burden of Disease region
(A) Blindness and (B) moderate and severe vision impairment attributable to the five leading causes of vision 
impairment and other conditions (combined), all ages. Data are presented for the 21 Global Burden of Disease 
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management strategies. New treatments for wet 
age-related macular degeneration have reduced the 
progression to blindness from this cause.
Non-visually impairing ocular conditions
Population-based eye health surveys typically quantify 
vision impairment at an individual level. Surveys usually 
do not report conditions that have the potential to cause 
vision loss later in life, such as early glaucoma or diabetic 
retinopathy, or conditions that typically do not cause 
vision impairment. Surveys report data for the better 
seeing eye, overlooking individuals with monocular 
problems, which greatly underestimates the magnitude 
of eye conditions and service needs.
Broadly there are three groups of people that need eye 
care services: the first group are people with manifest or 
corrected vision impairment who need ongoing care, 
including rehabilitative services; the second group are 
people with early stage disease or at high risk of eye 
conditions that might cause vision impairment in later 
life, who need ongoing care to prevent the disease or its 
progression; and the third group are people with 
symptomatic conditions that typically do not cause vision 
impairment but require services.
The first group is partly quantified in population-based 
surveys measuring vision loss and summarised by the 
2020 VLEG–GBD data.1 There is also a large but poorly 
quantified group of people, mostly with corrected 
refractive error or presbyopia, who need ongoing 
intermittent eye checks. Recording uncorrected visual 
acuity, in addition to visual acuity, in future population-
based surveys will help to quantify this group.2 Data on 
the younger age groups are particularly scarce.
For the second group, vision-impairment-based surveys 
and analyses underestimate common diseases because 
they do not report conditions in people without impaired 
vision.136–138 Using population-based comprehensive survey 
data, it has been estimated that 76 million people are 
living with glaucoma worldwide in 2020.136 However, the 
latest 2020 global estimates for blindness (3·61 million) 
and MSVI (4·13 million) attributed to glaucoma are 
substantially lower (appendix 1 pp 27–28). Although these 
estimates are derived using different approaches, clearly, 
most people with glaucoma are not included in GBD 
estimates because their central visual acuity is preserved. 
Glaucoma constricts the visual field and even mild forms 
cause problems with reading, walking, and increase the 
risk of falling. Most people living with glaucoma have not 
been diagnosed and are not receiving treatment.139
In 2020, 4·4 million people were estimated to be blind 
or have MSVI from diabetic retinopathy (appendix 1 
pp 27–28). However, this number is small compared 
with the 160 million people who have any diabetic 
retinopathy, or the estimated 463 million people living 
with diabetes in 2019, all of whom require regular access 
to eye care services to reduce long-term risk of vision 
loss (appendix 1 p 33).138,140 People with vision impairment 
represent only a small proportion of all people who need 
these services. The second group also includes high-risk 
populations that require screening services for early 
disease detection. For example, premature infants at risk 
of retinopathy or older (≥40 years) African Americans, at 
risk of glaucoma.
The third group includes conditions that rarely affect 
vision, such as conjunctivitis and dry eyes. Existing data 
Figure 9: Forecast to 2050 of global cases of blindness and vision impairment by sex
Reproduced from VLEG–GBD, 2020.1
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Figure 10: Women with blindness and MSVI
Excess number of women over men, in adults (≥50 years). Data are plotted for the 21 Global Burden of Disease 
regions using a log scale. Size of the circle represents the total number of adults with blindness and MSVI in that 
region. Oceania has less than 1000 excess women with MSVI and was not plotted on this figure. Data available in 
appendix 1 (p 33), from VLEG–GBD.1 MSVI=moderate and severe vision impairment.
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Panel 2: The changing epidemiology of eye disease
Changing epidemiology of eye disease
References for this panel can be found in appendix 1 
(pp 106–08).
Global increase of myopia
Myopia is a major growing public health challenge. More than 
2 billion people worldwide have a degree of myopia 
(≥–0·5 dioptres), 15% of whom have high myopia (≥–5 dioptres; 
Holden et al, 2016; WHO, 2015). In 2020, an estimated 161 
million people worldwide were blind or had moderate to severe 
vision impairment from uncorrected refractive error, the leading 
cause of vision impairment (Bourne et al, 2020). By 2050, 
myopia is expected to affect 5 billion people, more than half of 
the projected global population (Holden et al, 2016), which will 
place an enormous burden on health services to provide 
spectacles and detect and manage serious eye diseases caused 
by high myopia (appendix 1 p 34). Uncorrected myopia and 
myopic macular degeneration, a major complication of high 
myopia, were responsible for approximately US$250 billion lost 
global productivity in 2015 (Naidoo et al, 2019).
Myopia is rapidly increasing worldwide (Holden et al, 2016; 
Naidoo et al, 2019; Koh et al, 2014; Vitale et al, 2008; Morgan 
et al, 2019). Myopia is considered a genetic condition with 
more than 200 associated genes, individually and in 
combination these genes contribute to only a small proportion 
of myopia (Tedja et al, 2019). Furthermore, the rapid global 
increase in school myopia cannot be explained by genetics 
alone, given the prevalence rise in a short timeframe (Morgan 
et al, 2019). Environmental factors and gene–environment 
interactions are thought to play a large role.
The large increase in myopia prevalence in east and southeast 
Asia since 1960 have mirrored rapid economic development 
and the associated educational and lifestyle changes in societies 
such as Hong Kong, Taiwan, Singapore, and South Korea 
(Siddiqi et al, 2001). The prevalence of myopia in people aged 
20 years has risen from 20–30% in the mid-20th century to 
more than 80% nowadays (Morgan et al, 2019). China has also 
shown a rapid increase in myopia in the past few decades 
(Morgan et al, 2019; Sun et al, 2015). High myopia is becoming 
more prevalent and developing at a younger age (WHO, 2015), 
resulting in increased vision impairment and blindness from its 
complications (myopic macular degeneration, retinal 
detachment, and glaucoma; Liu et al, 2020; Fricke et al, 2018).
Educational pressures are substantially higher in east and 
southeast Asia than in other world regions (Morgan et al, 2019), 
which creates two interrelated environmental risk factors for 
myopia: a combination of increased near work activity (including 
screen time with increasing use of smart devices) and reduced 
outdoor activity (Dirani et al, 2019). With long periods of near 
work (Huang et al, 2015), children from east and southeast Asia 
spend less time outdoors than their peers in countries such as 
Australia (Rose et al, 2016; Wen et al, 2020). Clinical trials of 
increased time outdoors report a 25–50% reduction in incident 
myopia, although the precise mechanisms for these effects are 
not yet understood (Wu et al, 2018).
Finally, optical interventions such as spectacles and contact 
lenses reduce retinal defocus and slow myopia progression 
(Wildsoet et al, 2019). Pharmacological therapies such as low-
dose atropine, have also been shown to slow myopia 
progression, although the underlying mechanism is unclear 
(Wildsoet et al, 2019; Walline et al, 2020). There are no good 
treatment options for myopic macular degeneration, although 
the treatment of one of its major complications, myopic 
choroidal neovascularisation, has improved with anti-vascular 
endothelial growth factor therapy (Cheung et al, 2017).
Reducing the growing societal burdens of uncorrected myopia 
will require complex strategies—ie, combining prevention 
methods with enhanced capacity to deliver high quality, 
affordable, and equitable refractive services (Ang et al, 2020). 
Investments will be substantial but are likely to be outweighed by 
the cost of inaction. 
Diabetic retinopathy
Diabetic retinopathy is the most common microvascular 
complication of diabetes (Wong et al, 2016). The global 
prevalence of diabetes has tripled in the past 20 years. In 2019, 
diabetes prevalence was estimated at 9·3% (95% CI 7·4–12·1) of 
the global population aged 20–79 years, which is 463 million 
people, and is projected to reach 700 million by 2045 (Saeedi 
et al, 2019). The increase, mainly in type 2 diabetes, is 
attributed to dietary and lifestyle changes related to 
urbanisation, population growth, and increasing life 
expectancy (Saeedi et al, 2019; WHO, 2016). There are large 
regional differences in age-standardised prevalence of diabetes, 
with the highest in north Africa and the Middle East (12·2%, 
8·3–16·1) and the lowest in sub-Saharan Africa (4·7%, 3·2–8·1). 
The greatest number of people with diabetes are in China, 
India, and the USA (Saeedi et al, 2019). In the next 25 years, 
sub-Saharan Africa is projected to have the largest percentage 
increase in diabetes (appendix 1 p 33). People with diabetes in 
LMICs are predominantly younger than 65 years and face a 
large unmet need for diabetes treatment, leading to inadequate 
glycaemic control and subsequent complications of diabetes 
(Manne-Goehler et al, 2019).
As the global prevalence of diabetes increases, the prevalence of 
vision loss from diabetic retinopathy will also increase. Although 
the crude prevalence of other causes of blindness decreased 
between 1990 and 2020, diabetic retinopathy-related blindness 
increased by 68%, mainly in LMICs (Flaxman et al, 2017; Leasher 
et al, 2016). A meta-analysis of population-based studies 
estimated that globally 34·6% (34·5–34·8) of people with 
diabetes have some degree of diabetic retinopathy and 10·2% 
(10·1–10·3) have vision-threatening diabetic retinopathy
(Continues on next page)
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(Yau et al, 2012). Some findings show that the risk of developing 
diabetic retinopathy varies between populations although these 
data are scarce (Yau et al, 2012). Multiplying the estimated 
number of people with diabetes (Saeedi et al, 2019) by the global 
diabetic retinopathy prevalence provides an estimate of the 
magnitude of these conditions (Yau et al, 2012). In 2019, 
an estimated 160 million people had some form of diabetic 
retinopathy, of whom 47 million had vision-threatening diabetic 
retinopathy; by 2045 this number is projected to increase to 
242 million (for diabetic retinopathy) and 71 million (for vision-
threatening diabetic retinopathy; appendix 1 p 33).
In northern USA with good access to care, cumulative lifetime 
incidence of diabetic retinopathy for a person with type 1 
diabetes was estimated at 90% in 1984 and for type 2 diabetes, 
approximately 50% (Klein et al, 1984 and 1984). The risk seems 
to be decreasing over time, particularly in high-income 
countries, probably because of improved risk factor control and 
advances in diagnostics over the past 30 years (Sabanayagam 
et al, 2019 and 2016).
Several factors influence the risk of developing diabetic 
retinopathy. Glycaemic control is a key factor, particularly in 
type 1 diabetes, and improved glycaemic control reduces the 
incident risk of diabetic retinopathy, progression, and sight loss 
(Diabetes Control and Complications Trial Research Group, 
1993; UK Prospective Diabetes Study [UKPDS] Group, 1998). 
Increasing duration of diabetes is another major determinant 
for diabetic retinopathy, with incident risk rising to more than 
75% in those living with diabetes for more than 15 years (Klein 
et al, 1984 and 1984). Hypertension is the third risk factor and 
might be more important in people with type 2 diabetes. Tight 
blood pressure control is thought to prevent the development 
of diabetic retinopathy, although its effect on diabetic 
retinopathy progression is less clear (UKPDS, 1998; Do et al, 
2015). There appears to be genetic variation in diabetic 
retinopathy susceptibility, particularly among people with type 
1 diabetes (Arar et al, 2008; Huang et al, 2011). Epigenetic 
factors might also be important in the pathophysiology 
(Kowluru et al, 2015).
Early detection and timely treatment of vision-threatening 
diabetic retinopathy can prevent 95% of blindness from this 
cause (Vujosevic et al, 2020). Strong links between general 
medical services and eye care are needed to ensure effective well-
coordinated care. Treatment of vision-threatening diabetic 
retinopathy includes laser photocoagulation for retinopathy and 
maculopathy and careful consideration of an intravitreal injection 
with anti-vascular endothelial growth factor (Wong et al, 2018). 
Diabetic retinopathy screening and treatment programmes are 
considered by WHO as other recommended effective 
interventions in health care for non-communicable diseases 
(WHO, 2017). Low resources in many low-income and middle-
income countries, to implement screening programmes and 
current cost-effectiveness ratios (outside the <$100 per disability-
adjusted life-year range), means that reducing costs and 
increasing efficiency (through targeted screening, decreasing cost 
of treatment, and increasing completion rates) should be a high 
priority (Poore et al, 2015; Burgess et al, 2013). Additionally, a 
high proportion of people with diabetes are undiagnosed, with 
marked inequity seen within populations. In high-income 
countries, populations from disadvantaged groups (eg, highly 
deprived, ethnic minorities, and Indigenous people) are unable to 
equitably access services, leading to differential outcomes 
(Denniston et al, 2019; Foreman et al, 2017). New technologies, 
including teleophthalmology and artificial intelligence, offer 
potential new solutions (Vujosevic et al, 2020).
Successful disease control programmes
Onchocerciasis control efforts
Onchocerciasis, also known as river blindness, is a neglected 
tropical disease resulting in parasitic filarial infection caused by 
Onchocerca volvulus, which is transmitted by the Simulium 
blackfly. After an infected blackfly bite, adult worms 
(macrofilariae) develop in nodules under the skin. These worms 
release large numbers of microfilariae, which disperse around 
the body. The Global Burden of Disease study (Disease and 
Injury Incidence and Prevalence Collaborators, 2018) estimated 
that onchocerciasis infected 20·9 million people worldwide and 
caused vision loss in 1·15 million people from inflammatory 
damage to the cornea, retina, and optic nerve. The Simulium 
blackfly requires fast-flowing well-oxygenated water for its 
lifecycle, so larvicide treatment of fly breeding sites can 
interrupt transmission. Ivermectin can reduce symptoms and 
break transmission by killing microfilariae and stopping their 
release from adult female worms.
During the past five decades, four regionally focused control 
programmes have been developed. The Onchocerciasis Control 
Programme between 1974 and 2002, was launched by the World 
Bank, WHO, UNDP, and the Food and Agriculture Organization to 
control onchocerciasis transmission by larvicide spraying of rivers 
in seven (later expanded to 11) west African countries. The African 
Programme for Onchocerciasis Control between 1994 and 2015 
was launched by the World Bank and WHO in 19 (other) African 
endemic countries and to assist the original 11 countries, using 
community directed treatment with ivermectin to control (and 
later eliminate) the disease. The Onchocerciasis Elimination 
Programme for the Americas was launched by WHO in 1992 to 
eliminate transmission of onchocerciasis in six endemic countries 
in central and south America using twice a year distribution of 
ivermectin. The Expanded Special Project for the Elimination of 
Neglected Tropical Diseases was established in 2016 by WHO 
Regional Office for Africa, member states, and neglected tropical 
disease partners to mobilise political, technical, and financial 
resources to accelerate the elimination of the five most prevalent 
neglected tropical diseases.
(Continues on next page)
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These programmes led to several key achievements. Infection 
has been prevented or treated and vision loss was prevented in 
more than 80 million people in 27 African countries and 
six countries of the Americas. Transmission of O volvulus has 
been eliminated in four of six endemic countries in the Americas 
and some areas in Africa. Programmes have supported health 
system capacity building for control of neglected tropical 
diseases. Arable land in Africa has been reclaimed for agriculture 
and economic development (WHO, 2008).
A key component of success of the African programme was 
implementation research, which identified that community-
directed drug administration was an effective delivery strategy 
for ivermectin. A further benefit was the provision of extensive 
capacity building opportunities for African researchers, who are 
now global leaders in their field.
Lessons from onchocerciasis control
Economic impact research and advocacy led to the donation of 
ivermectin by Merck in 1988—“as much as is needed for as long 
as it is needed”. This donation was crucial in creating an 
international public–private partnership to improve the health 
of affected communities.
Regional programmes enabled efficient use of technical 
resources and cross-border treatment of endemic communities.
The community-directed distribution of ivermectin increased 
coverage, while keeping the cost of distribution low and 
improving coverage and sustainability.
The partnership between endemic communities, ministries of 
health, UN agencies, international and local non-governmental 
organisations, agricultural agencies, and the pharmaceutical 
industry has become a model for control of onchocerciasis and 
other neglected tropical diseases.
Implementation research built into these programmes to 
address issues of disease transmission, resistance, coverage, 
cost-effectiveness, adverse effects, and disability, has been 
crucial to their successful implementation (WHO, 2008).
Eliminating trachoma as a public health problem
Trachoma is the leading infectious cause of blindness, recognised 
as a clinical entity for many years, and responsible for vision 
impairment or blindness in 1·9 million people (Bourne et al, 
2013). The pathogen, Chlamydia trachomatis, was first isolated in 
China in 1955 (Tang et al, 1957). The discovery that one oral dose 
of the antibiotic azithromycin was effective against C trachomatis 
reinvigorated efforts to control and eliminate the disease (Bailey 
et al, 1993). The WHO Alliance for the Global Elimination of 
Trachoma by 2020 was established in 1996 (WHO, 1997). 
Elimination of blindness from trachoma was included in VISION 
2020 (WHO, 2000 and 2003). Since then, as a result of a well-
coordinated effort between health ministries, donors, and 
implementing partners, the number of people at risk of blindness 
from trachoma has decreased by 91% from an estimated 
1·5 billion in 2002 to under 137 million in 2020, and the number 
of people requiring surgery for trichiasis has decreased by 74% 
from 7·6 million in 2002 to 2 million in 2020 (WHO, 2020). Nine 
countries have been validated by WHO as having eliminated 
trachoma as a public health problem (WHO, 2020). Many other 
disease communities have monitored the trachoma community.
Four crucial factors might underlie success
First, normative guidance from WHO translated into preferred 
practices by the International Coalition for Trachoma Control, 
based on the SAFE strategy (surgery for trichiasis, antibiotic 
treatment, facial cleanliness, and environmental improvement).
The SAFE strategy was formally adopted by WHO member states 
in 1998 in the World Health Assembly Resolution 51.11 (WHO, 
1998). Conclusions and recommendations from the annual 
meeting of the Alliance for the Global Elimination of Trachoma 
are translated into complementary action plans by health 
ministries, academics, donors, and implementing partners.
Second, partnerships fostered within the Alliance for the Global 
Elimination of Trachoma and International Coalition for 
Trachoma Control, supporting government-led 
implementation of the SAFE strategy in endemic countries. 
Partners come together to strengthen national capacity; to 
coordinate the efforts of governments with those of funders, 
implementing partners, and researchers; and to mobilise 
resources from various donors to fill gaps in the global 
programme (Courtright et al, 2018).
Third, committed donors and a data-driven medicine donation 
programme with a strong country-led accountability 
framework. Pfizer’s commitment to supply azithromycin for 
trachoma elimination is coupled with robust stewardship of the 
donation by the International Trachoma Initiative. Many other 
committed and motivated donors also support these 
programmes.
Fourth, credible national plans to achieve elimination. Through 
trachoma action plans and neglected tropical disease plans, 
health ministries have crafted ambitious but attainable targets, 
facilitating the political decision making that underlies progress 
in public health. Crucial decisions include commitments to scale 
up interventions, standardise approaches, allocate domestic 
resources, and recruit new stakeholders.
Now, in the last mile of trachoma elimination, the trachoma 
community has built on its strong foundations and 
strengthened global collaboration with four key enabling factors.
(1) A shared passion and ambition to target gaps and achieve a 
world free of trachoma.
(2) Use of high-quality prevalence data generated by the Global 
Trachoma Mapping Project and Tropical Data, coupled with 
rigorous research overseen by the WHO Network of 
Collaborating Centres for Trachoma to underpin evidence for 
interventions and facilitate refinement in programme delivery 
(Solomon et al, 2015 and 2018; WHO, 2017).
(Continues on next page)
For more on the International 
Coalition for Trachoma Control 
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For the International Trachoma 
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trachoma.org/
For the Tropical Data see 
https://www.tropicaldata.org/
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suggest that the number of people affected are 
considerable. For example, a large UK database141 of 
3 million people showed that ocular problems without 
vision impairment account for 88·1% of all general 
practitioner consultations related to eye health and 68·9% 
of referrals. Data from secondary eye units, which are 
part of the Aravind Eye Care System in India, show a 
similar pattern; only 41% had visual acuity of worse than 
6/12 in the worse eye and 28% in the better eye (appendix 1 
p 35). Similarly, data from a secondary eye unit in Kenya 
found that less than half of presentations were for 
conditions associated with vision impairment.6
The implications of these findings are important and 
require action. There is a need for standard terminology 
and robust definitions to measure the magnitude of 
eye disease that does not impair vision; data need to 
be collected and analysed to assess this magnitude; 
the impact of non-visually impairing eye disease on the 
quality of life and its economic consequences need to be 
assessed; and the full magnitude and impact of all eye 
disease needs to inform health-care planning to serve the 
population and improve eye health.
Quantifying the magnitude of eye disease
Population-based surveys provide estimates of disease 
prevalence, service coverage, and outcomes. These 
data are needed to support service planning, resourcing, 
and monitoring, and can be aggregated to provide 
regional or global estimates.1,127,128,131,142 Broadly, there are 
two approaches to eye health surveys, comprehensive 
and rapid (appendix 1 pp 36–37). Comprehensive eye 
health surveys typically include an in-depth ophthalmic 
examination with imaging for independent retinal 
grading and data on risk factors. Several rapid assessment 
methods are available.143 The most used method is the 
Rapid Assessment of Avoidable Blindness (RAAB), for 
people aged 50 years and older. The most applicable 
approach balances the required epidemiological detail 
and the available resources.
Developing reliable estimates of eye disease depends on 
good quality survey data. This Commission has analysed 
the distribution of surveys since 2000 (appendix 1 
pp 38–42). Most were RAAB surveys. Some regions have 
scarce or old data (eg, western and central sub-Saharan 
Africa, central Asia, central Europe, North America; 
figure 11). Where there are few data for a region, modelling 
approaches are sometimes used to fill in the gaps.
Rapid and comprehensive techniques have predomin-
antly reported presenting distance visual acuity (ie, with 
available correction). However, following the WHO World 
report on vision, future eye health surveys are strongly 
encouraged to measure uncorrected visual acuity as well, 
and acknowledge met and unmet need for refractive 
services in addition to presenting vision impairment 
prevalence.2 With new focus on effective refractive error 
coverage as a core indicator, accurate diagnosis of refractive 
error needs to be ensured. The accuracy of pinhole 
correction to identify uncorrected refractive error (a 
common survey approach), might be variable as opposed to 
subjective refraction, on account of the quality, the type of 
pinhole occluder used, or other pathology.144 Standardisation 
of procedures and equipment is required.
Reporting eye health surveys
The World report on vision by WHO2 highlighted the 
need for greater methodological and reporting 
standardisation of eye health surveys. Although generic 
tools such as the Strengthening The Reporting of 
Observational Studies in Epidemiology (STROBE) 
checklist and the risk of bias assessment exist, none are 
specific to eye health surveys,145 which is a missed 
opportunity to promote robust study design, reduce 
risk of bias, and emphasise complete reporting. In 
response, we did a two-round Delphi survey to identify 
(Panel 2 continued from previous page)
(3) Innovation for continuous improvement and accelerating 
the global programme, including new tools for active 
trachoma diagnosis and trichiasis surgeon training and 
practice (Solomon et al, 2018; Gower et al, 2014; Merbs et al, 
2012); open online courses for programme managers 
(London School of Hygiene & Tropical Medicine, 2020); 
streamlining of reporting for endemic countries through the 
Trachoma Elimination Monitoring Form jointly managed by 
WHO and the International Trachoma Initiative; and 
transparent updates about the progress of antibiotic 
shipments through the International Trachoma Initiative 
azithromycin tracker.
(4) Integration by pursuing mutually advantageous 
opportunities to engage with interdependent sectors (water, 
sanitation, and hygiene, education, vision, and neglected 
tropical diseases).
WHO noted in an analysis of progress towards trachoma 
elimination, the 2021–30 Neglected Tropical Disease Roadmap, 
that key components (technical progress, strategy, service 
delivery) were in place, with enabling factors producing 
amplification of collective efforts (WHO, 2020). The essential 
actions required to achieve global elimination of trachoma as a 
public health problem are: continued investment in 
implementation, additional research to better understand 
transmission and how to limit transmission in different settings, 
improvements in surgical quality, strengthening surveillance 
capacity to monitor possible recrudescence, and ongoing 
advocacy for domestic financing (Habtamu et al, 2016; Last et al, 
2020). These actions for trachoma overlap substantially with 
recommendations for the vision sector in the WHO World report 
on vision, reminding communities that integrated people-
centred eye care is a cornerstone to end trachoma.
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key methodological issues and develop a checklist 
to improve the design, conduct, and reporting of 
vision impairment surveys, including minimising bias 
(appendix 1 p 43). Generic STROBE checklist items 
were endorsed as essential for high quality reporting in 
comprehensive and rapid surveys. We identified several 
STROBE items that were frequently poorly reported, 
several vision-specific extensions, and a need for better 
guidance to enhance the standardisation and quality of 
future eye health surveys (panel 3).
Disability weights for vision impairment
How important are blindness and vision loss to an 
individual, compared with other health morbidities? 
Disability weights (where 0 equals a state of full health 
and 1 equals death) and disability-adjusted life-years 
(DALYs) provide an answer. Nine studies (appendix 1 
p 44), published between 1994 and 2015, used various 
approaches to estimate the disability weight associated 
with blindness, which ranged widely from 0·600 (in 
1994) to 0·173 (in 2015).
There are multiple explanations for this variation.146 First, 
the construct being measured shifted over time from loss 
of wellbeing (disability) to loss of health. Second, studies 
described the impact on health states differently.147 Third, 
studies framed their questions differently. Fourth, some 
studies used expert panels exclusively from high-income 
countries, while others sought responses from large 
samples of the general public internationally. There are 
likely to be considerable regional differences in the impact 
of vision loss on quality of life. Finally, studies used 
different valuation methods, which included person trade-
off, paired comparison, population health equivalence, 
and the visual analogue scale.
The GBD 2010 study disability weights sparked a lively 
debate.148,149 By reporting a blindness disability weight 
reduction from 0·600 to 0·195, the apparent global 
importance of cataracts fell substantially.150,151 WHO 
subsequently incorporated health state data to calculate 
another blindness disability weight of 0·338.152 In view of 
the wide range and major implications that this figure has 
on how vision loss is valued, further empirical research 
is urgently needed to understand societal valuations of 
vision impairment and reach a broad, evidence-based 
consensus of weights that should be applied, possibly 
allowing for the use of different weights in different 
settings.146
Section 4: The economics of vision
As a society, what value do we place on vision? How 
much are we willing to invest, relative to the other 
demands on finite health resources, to ensure that people 
can access services? These questions are especially 
complex in 2021 as the world continues to battle the 
COVID-19 pandemic. In response, this Commission did 
a systematic literature review of the economic costs of 
vision impairment and its major causes to identify and 
summarise what is currently known. Using studies 
identified in this review, we then determined a new 
estimate for global and regional productivity losses from 
vision impairment, and summarised studies reporting 
cost-effectiveness ratios of cataract surgery and refractive 
error correction.
Systematic review of eye health economics
We searched the literature from Jan 1, 2000, to 
Dec 31, 2019, for partial economic studies (eg, cost of 
illness and economic burden of disease) and full 
economic studies (eg, cost-effectiveness and cost-benefit) 
reporting the economic cost of vision impairment or the 
cost of evaluating interventions for seven leading causes: 
cataract, refractive error, glaucoma, diabetic retinopathy, 
Figure 11: Most recent population-based eye health surveys globally
All surveys (rapid and comprehensive, national or subnational) done since 2000. Not applicable indicates that no surveys were done. Data from VLEG–GBD,1 and the 
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age-related macular degeneration, corneal opacity, and 
trachoma (appendix 1 pp 45–49).153 We excluded studies 
reporting only incremental costs, benefits, or cost-
effectiveness ratios.
In total, 138 publications met these criteria, with scarce 
information about many regions and conditions. The 
geographical distribution and focus of each publication 
are shown in appendix 1 (p 48). We identified fourteen 
studies that reported global estimates related to eye health 
economics. Most (72%) regional estimates were from 
high-income countries. Study types were heterogeneous 
(appendix 1 p 49). The main economic study perspectives 
of vision impairment were societal (35%), health system 
(18%), or third-party payer (17%). Most studies (90%) 
used a prevalence-based approach for estimation.
Economic literature on eye health has multiple 
limitations and great uncertainty. First, many studies 
were not comprehensive in approach; most (70%) 
considered only one cost category (direct health-care 
costs, direct non-health-care costs, productivity loss, 
informal care, or intangible costs). Heterogeneity limits 
comparability and the few cost items included in many 
studies probably underestimate the full cost of treatment 
and rehabilitation. Second, vision impairment severity or 
disease stage are not standardised. Third, studies tended 
to be small and unrepresentative. Fourth, productivity 
loss estimates were limited in scope and generally made 
major, largely unsupported assumptions about the 
productivity and proportion of people with vision 
impairment who work. Finally, few studies did sensitivity 
analysis or addressed uncertainty. These limitations 
mean that previous estimates might have substantially 
underestimated or overestimated the economic impact 
of vision impairment, which limits the usefulness of 
Panel 3: Key recommendations for improving population-based vision impairment surveys
Improving survey design and conduct
• Standardise equipment, participant recruitment strategy, 
and team training 
• Measure vision at a constant distance using a vision chart 
with high contrast, crowded, standardised optotypes
• Assess quality assurance (survey staff accuracy of measuring 
vision) using Bland-Altman Limits of Agreement to test 
visual acuity or kappa, allowing to compare vision 
impairment categories
• Address declining response rates globally by updating 
sample size calculations, sampling, and analytical approaches 
(eg, weighting by cluster non-response)
• Incorporate standard socioeconomic position indices (eg, 
Equity Tool) and other known associated demographic or 
equity factors (eg, disability, distance from services)
Improving completeness of reporting
Improve application of Strengthening The Reporting of 
Observational Studies in Epidemiology (STROBE) items
• Item 6 (participant recruitment): report participant 
recruitment strategy in full
• Item 12 and 16 (statistical methods): analyse and report 
crude and adjusted prevalence estimates with measures of 
uncertainty (eg, 95% CI), to account for the sampling 
design
• Item 13 (results): report the number of units (eg, villages, 
households, people) sampled at each stage (assessed for 
eligibility, recruited, examined) with numbers of not 
contactable participants and reasons for non-participation
• Item 14 (results): report missing data for each variable of 
interest
Extensions of STROBE items for vision impairment surveys
• Items 7 and 11 (variables): define and report vision categories 
and unit of analysis (eg, best eye or binocular), eye disease 
case definitions, avoidable vision loss, and any risk exposures 
of interest
• Item 8 (details of measurement): for vision testing, report 
chart type (scale, optotype), approach to maintaining 
constant test distance, location of testing, and whether the 
examination protocol differed for different subgroups 
(eg, children or adults with cognitive impairment); 
if collecting clinical images, report details of reading centre 
personnel, training and grading or agreement criteria
Major risks of bias to minimise and report 
• Wrong sample size bias—sample too small to yield precise 
prevalence estimates or too large and resource inefficient—
eg, if expected prevalence of blindness is lower than sample 
prevalence
• Selection bias—the sampled population not accurately 
representing the target population, resulting in erroneous 
inferences about the population’s magnitude of vision 
impairment—eg, if the random sampling and enumeration 
procedures are not rigorously observed, a convenience 
sample might be recruited, yielding an apparently good 
response rate, who differ in important but unmeasurable 
ways from the true target population
• Non-responder bias—non-responders might differ 
substantially from responders—eg, older people (in whom 
vision impairment is more prevalent) or people not working 
on account of vision impairment, are more likely to be 
available for examination than younger employed people
• Diagnostic purity bias—narrow case definitions—eg, 
exclusion of ocular comorbidities might lead to misleading 
cause attribution, a tendency to over-report causes most 
easily identified from simple examination protocols and to 
underreport posterior segment disease
• Missing clinical data bias—missing data might differentially 
impact reliability of results in different subgroups—eg, 
likelihood of agreeing to pupil dilation might vary between 
different clinical subgroups, affecting the ability to collect 
data
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cost-of-illness estimates and possibly led to flawed policy 
prioritisation decisions.
Global productivity losses from vision impairment
We have already explored the limitations that vision 
impairment can place on an individual’s ability to engage 
in the workplace, ensuing loss of productivity and 
income. Addressing avoidable vision impairment and 
enabling people with permanent impairment to access 
and function well in the workplace, increases productivity. 
For example, a trial29 in India found that provision of 
near vision spectacles resulted in significantly increased 
productivity of people with presbyopia in harvesting tea 
(appendix 2 p 4).29
Our systematic review identified 37 articles on 
productivity loss (appendix 1 p 49). Studies reported 
different combinations of components (absenteeism, 
presenteeism, wage reduction, reduction in employment, 
and premature mortality), although reduction in 
employment was the most frequently reported component. 
Assumptions around reduced employment attributable to 
vision impairment were variable, predominantly based on 
scarce data and diverse methods. Most studies focused on 
a single condition or a few regions. There are only three 
previous global productivity loss estimates for vision 
impairment and blindness, and they are compared in 
appendix 1 (p 50).154–156
This Commission has established a new estimate for 
global and regional productivity losses from unaddressed 
vision impairment (appendix 1 pp 51–53). We syste-
matically searched for employment gap data for people 
with vision impairment, identifying 11 reports, with 
limited geographical distribution (appendix 1 p 52). 
Productivity loss calculations included the number 
of people with blindness or MSVI of working-age 
(15–64 years) in 2020, national employment rates for 
2018, per-capita gross domestic product for 2018, and 
employment gap data published between 2004 and 2018. 
Values are presented for 2018 in US$, adjusted for 
purchasing power parity.
In 2020, it was estimated that globally, 18·1 million 
(95% UI 14·4–22·6) people are blind and 142·6 million 
(112·5–179·6) are living with MSVI in the working-age 
group. The overall relative reduction in employment 
of people with blindness or MSVI was estimated to 
be 30·2%. We estimated that the global annual 
productivity loss was $410·7 billion (95% uncertainty 
interval $322·1–518·7 billion), which represents 0·3% 
of the gross domestic product of the 21 GBD regions in 
2018. Potential productivity losses were estimated 
at $43·6 billion, ($34·4–54·5 billion) attributable to 
blindness, and $367·1 billion ($287·7–464·2 billion) 
attributable to MSVI. Figure 12 shows the productivity 
losses for each GBD region. Productivity losses were 
highest in east Asia ($90·4 billion, $70·5–115·3 billion). 
Productivity losses as a proportion of gross domestic 
product was highest in south Asia (0·6%).
Our new analysis provides a robust estimate of the 
global annual productivity loss attributable to vision 
impairment. For the first time to our knowledge, regional 
VLEG–GBD estimates were used to estimate the number 
of people with vision impairment in the working-age 
group and regional employment reduction variables 
derived from a literature review. However, additional 
productivity loss components were not included in our 
analysis because reliable data at country and regional 
level remain scarce. The components that were not 
included are absenteeism and presenteeism (reduced 
productivity in the working place), premature mortality, 
people older than 64 years, productivity losses of 
caregivers, and value of time lost from unpaid or informal 
labour activities. Data do not sufficiently differentiate 
Figure 12: Productivity losses resulting from vision impairment
Estimates made for 2020 using the number of people who were blind or had moderate and severe vision 
impairment, an employment gap of 30·2%, 2018 employment rates, and gross domestic product for (A) productivity 
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between reduction in employment for blindness and 
MSVI. Therefore, we only included components for 
which sufficient evidence was available, and consequently 
the magnitude of productivity loss could have been 
underestimated.
Overall, this analysis indicates that blindness and 
MSVI have substantial economic impact worldwide and 
highlights the opportunity to unlock human potential by 
addressing avoidable vision impairment and providing 
rehabilitation services to enable people to work.
Cost-effectiveness of eye health interventions
As an adjunct to the systematic review, we examined 
cost-effectiveness ratios of eye health services and 
interventions (appendix 1 pp 54–57). We identified 
182 reports for 16 ophthalmic conditions. The most 
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Figure 13: Cost-effectiveness ratios for cataract surgery
Studies reporting either DALYs averted or QALYs gained. Costs have been inflated to 2018 levels and converted to US$ purchasing power parity. Studies which 
provide only a single estimate are plotted as a diamond. For studies reporting more than one estimation the highest and lowest values are plotted as a range 
(appendix 1 pp 56–57). Letters shown next to some regions are related to the WHO regional coding labels. References for this figure can be found in appendix 1 
(p 101). DALYs=disability-adjusted life-years. ECCE=extracapsular cataract surgery. QALYs=quality-adjusted life-years. SICS=small-incision cataract surgery.
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frequently studied interventions addressed age-related 
macular degeneration,53 glaucoma,32 cataract,29 and 
diabetic retinopathy.27 We focused on cataract and 
uncorrected refractive error interventions and only 
included studies reporting health benefits using DALYs 
or quality-adjusted life-years (QALYs). Costs were 
adjusted to 2018 values expressed in US$ purchasing 
power parity.
For cataract, we identified 11 publications providing 
58 separate national or regional cost-effectiveness ratio 
estimates.37,157–165 The average cost-effectiveness ratios 
are shown in figure 13. The studies are heterogeneous 
in perspective, costs included, surgical procedure, and 
assumed duration of the health benefit, which limited our 
comparison. The cost-effectiveness ratio ranged from 
$5 per QALY gained in India to $24 783 per QALY gained 
in the UK. However, most ratios were less than $1000 per 
DALY averted or QALY gained, and in 19 (33%) countries 
the cost-effectiveness ratio was less than $100 per DALY 
averted or QALY gained. In general, LMICs reported 
more favourable cost-effectiveness ratios for cataract 
surgery than did high-income countries. Two studies 
from India158 and Nepal160 showed that the cost-
effectiveness ratio of a manual small-incision cataract 
surgery ranged from $5 to $95 per QALY gained and 
phacoemulsification surgery ranged from $47 to $142 per 
QALY gained. The highest estimate, from the UK, used a 
wider perspective, including personal social-care costs.163 
The higher cost-effectiveness ratios in some studies, 
mostly from high-income countries, might be partly 
because of a higher proportion of mild vision impair-
ment in those receiving surgery and possibly higher 
remuneration to eye care professionals in high-income 
countries than in LMICs.
There were two studies on screening and treatment of 
uncorrected refractive error in schoolchildren, providing 
16 separate national or regional cost-effectiveness ratio 
estimates (WHO subregions), and an additional cost-
effectiveness ratio analysis for a facility-based refractive 
error service in Zambia.165–167 The average cost-effectiveness 
ratios, shown in figure 14, ranged from $95–184 per DALY 
averted in southeast Asia D, to $987–2127 per DALY 
averted in Western Pacific A. The most cost-effective 
strategy ($95 per DALY averted) in all 14 regions involved 
screening children in the age group 11–15 years.166 The 
cost-effectiveness ratio exceeded $1000 in only three 
regions: Europe A, West Pacific A, and rural India. 
Reports in India showed that cost-effectiveness ratios for 
screening and treating schoolchildren were lower in 
urban areas ($264) than rural areas ($1448).167 Both studies 
concluded that screening and treating schoolchildren for 
uncorrected refractive error seems to be economically 
attractive in many settings and world regions.
The wide range of cost-effectiveness ratios suggest 
regional variations in resource use, costs, and patient 
characteristics, and heterogeneous study methods such 
as the cost component, measurement of health benefits, 
duration of health benefits, and use of different discount 
rates. This heterogeneity is common in health economics, 
but limits comparability. The low costs per QALY gained 
or DALY averted indicate that cataract surgery and 
refractive services are cost-effective in many settings, 
encouraging countries to prioritise eye care services. 
Cataract surgery seems favourable compared with other 
essential surgical procedures and non-surgical public 
health interventions in LMICs.168,169 However, cost-
effectiveness ratios are only one consideration when 
making resource allocation decisions; others include the 
locally relevant cost-effectiveness ratio threshold, budget, 
feasibility, and other specific context factors.170
Strengthening research on eye health economics
Our systematic review and analyses highlighted marked 
methodological heterogeneity, limitations, and data gaps 
in eye health economics literature. To address these 
several actions are needed.
First, standardised methodological approaches and 
reporting need to be adopted, following international 
guidelines for health economic evaluations.171–173 This 
improvement would increase reliability and enable the 
comparison of findings between settings and over time. 
This Commission calls for an international consensus on 
the process to develop guidance for eye health economic 
studies and standardise approaches for core components 
and analyses, particularly for the cost of illness.
Second, more standardised data need to be collected 
from diverse settings and repeated over time. Our review 
revealed that data are particularly scarce from LMICs, a 
gap that needs to be urgently addressed to better inform 
Figure 14: Cost-effectiveness ratios for refractive error services
Cost-effectiveness of screening and treating refractive error in schoolchildren166,167 and for facility-based refractive 
error services for all ages.165 Studies reported either DALYs averted or QALYs gained. Costs have been inflated to 
2018 levels and converted to US$ purchasing power parity. For studies reporting more than one estimation, the 
highest and lowest values are plotted as a range (appendix 1 p 57). References for this figure can be found in 
appendix 1 (p 101). 
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policy and planning decisions. This step will require 
financial investment and development of capacity for local 
data collection and analysis. Opportunities to integrate 
data collection into routine health system data processes 
should be investigated. Few long-term studies have 
revisited estimates over time; these would be invaluable to 
monitor trends and the impact of interventions.
Third, robust, comprehensive economic impact analyses 
should be developed to better understand the true impact 
of vision impairment. Our productivity loss analysis 
provides only a partial perspective and is limited by the 
availability of data. A systematic approach in a representative 
set of countries is needed to collect data to inform more 
comprehensive models. For example, to improve the 
estimation of productivity losses, more data are needed in 
relation to vision impairment and its impact on 
employment status, wages, absenteeism, and presenteeism.
Fourth, better analyses are needed on cost-effectiveness, 
budgetary impact, and feasibility in a broader range of 
settings to better inform national decision making. Cost 
and cost-effectiveness analyses evaluating alternative 
service delivery approaches should be done—eg, moving 
to greater primary-care-based and community-based 
delivery platforms, integration with other services, and 
task sharing. Extended cost-effectiveness analyses that 
would include health system objectives, such as improved 
financial protection and equity to inform policy and 
planning decisions, are needed.
Section 5: Global eye health research
Research is crucial to advancing global eye health; 
specifically, to understand population eye health needs, 
identify effective interventions, optimise delivery, and 
support effective advocacy. This Commission analysed 
vision and eye health research done in the past 20 years. 
We investigated the diversity of the research community 
and explored issues around equitable partnerships and 
growing capacity. Finally, we did a study (unpublished) to 
collectively identify the grand challenges in global eye 
health, highlighting key issues that would benefit from 
focused research. We outline crucial actions necessary to 
advance research and to improve eye care delivery within 
universal health coverage.
20 years of eye health research
To investigate how research relates to the distribution 
and causes of vision impairment, we examined all 
primary peer-reviewed research on eye health published 
between 2000 and 2019 using a systematic search of 
online databases and a semi-automated bibliometric 
analysis (appendix 1 p 58). After excluding editorials, 
comments, reviews, and case reports, 156 954 articles 
were analysed. There was a 50% increase in research 
output across two decades (62 868 publications for 
2000–09 vs 94 086 for 2010–19). Only 4% of publications 
were trials. One notable finding was the three-times 
increase in the number of publications from China 
(3602 vs 10 594). Almost half (42%) of publications were 
on one of the five leading conditions, glaucoma being the 
most frequent (11·0%), followed by cataract (9·3%), and 
refractive error (8·8%; appendix 1 p 59). Overall, these 
findings appear in line with the need for research to 
focus on leading causes of vision impairment.
However, there is substantial maldistribution in the 
geographic focus of eye health research (figure 15). Almost 
three-quarters of published reports are from high-income 
countries. Several regions such as southeast Asia, Latin 
America and the Caribbean, and sub-Saharan Africa, had 
particularly low research output per person. We anticipate 
high-income countries will continue to produce a large 
proportion of basic science, therapeutic, and translational 
research, although this distribution is changing with the 
Figure 15: Global distribution of research
Number of primary research studies on vision and eye health, by country, done between 2000 and 2019 (studies identified by “explode eye disease” on MEDLINE, 
July 10, 2020; n=156 954; appendix 1 pp 58–59).
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emergence of India and China as major pharmaceutical 
centres. It is important that all regions have a solid local 
evidence base on the epidemiology of eye disease and an 
equally strong understanding of which treatments and 
service delivery approaches are most effective in their 
settings. A major gap is the lack of research that explores 
solutions to eye health problems, particularly in LMICs, 
where decision makers do not have sufficient and 
contextually relevant evidence. This gap was highlighted 
in two systematic reviews.174,175 For the first review, of 
interventions that aimed to increase attendance at diabetic 
retinopathy screening, 66 randomised controlled trials 
were identified, none of which were done in LMICs.174 The 
second review of interventions to improve access to 
cataract services in LMICs identified only two studies.175
Given the magnitude of vision impairment in sub-
Saharan Africa, we did an in-depth review of randomised 
controlled trials done in this region since 2000 (appendix 1 
pp 60–61). There were four key findings. First, geographic 
spread of the 86 trials was limited; 16 countries had at 
least one trial and more than half were done in Nigeria, 
South Africa, Ghana, or Ethiopia (appendix 1 p 61). 
Second, trachoma (28 trials) and onchocerciasis (17 trials) 
were most the commonly assessed. High-quality trials 
have been crucial for shaping disease control and 
programme success. Third, trachoma and onchocerciasis 
research communities are well coordinated in identifying 
key questions and minimising unnecessary duplication; 
they engage in extensive collaboration with government-
led programmes on neglected tropical disease and their 
funders recognise that research is needed to develop 
elimination strategies. Finally, 16 trials were about 
glaucoma. Given that glaucoma has a high prevalence in 
many African populations and the uncertainty around 
how to address this issue, we believe that concerted 
research action is urgently needed to develop contextually 
relevant management strategies for glaucoma.
Equity, diversity, and inclusion in eye health research
Inequality is pervasive in medical science; eye health 
research is no exception.176 Equity and diversity in 
research teams produces higher quality science that 
better meets the needs of society. This Commission 
explored equity, diversity, and inclusion in eye health 
research in three ways.
First, we assessed female authorship in eye health 
research since the beginning of 2000 to the end of 2019 
(appendix 1 p 58). There were almost 880 000 authorships; 
gender could be assigned to 780 000. Around 33% were 
female across the whole timespan. Since 2000, female 
authorship increased from 28% to 37%. Women held 
36% of first authorships and 24% of last authorships.
Second, we assessed diversity of 112 ophthalmology 
journal editorial boards listed in Scopus (appendix 1 p 62). 
Gender and country of affiliation were available for 5061 
editorships. Women held 23% of editorships and 11% 
editor-in-chief positions. 72 countries had at least one 
editor; 1643 (32%) of 5061 editorships were held by 
researchers in the USA (25% women), compared with only 
15 (0·2%) across all of sub-Saharan Africa (20% women). 
Among 47 countries with at least five editorships, the 
proportion of editorships held by women within each 
country ranged from 0% to 60% (median 22%).
Third, we assessed authorship of 89 reports from 
86 randomised controlled trials in sub-Saharan Africa to 
evaluate the extent to which researchers from the 
continent itself and female researchers were involved. All 
but one of the 89 reports included authors who originated 
from the country of the study. Researchers from the 
country of the study held 51% of all authorships, 74% of 
first authorships, and 43% of last authorships. However, 
female researchers from the country of the study held 
only 8% of all authorships, 12% of first authorships, and 
8% of last authorships.
Change is required to improve equity, diversity, and 
inclusion for women, and other under-represented 
groups. Strategies for organisational change have been 
outlined and the need for measurable targets has been 
reinforced.177 The Lancet has shown how editors and 
publishers can address gender gaps and set diversity 
targets, leading to increased inclusion of women and 
people from LMICs among its authors and reviewers.178 
We commend this pledge, and in preparing this 
Commission we aimed for balance in gender and LMIC 
representation. Despite our efforts, the proportion of 
commissioners who are women (44%) or originate from 
LMIC (38%) falls short of parity. Among our subsidiary 
papers, more than 50% of authors were female (more 
than two-thirds held first authorship).
Increasing capacity for eye health research
Delivery of eye health within universal health coverage 
requires substantial expansion in capacity to deliver 
high-quality research in LMICs. We call for investment 
in institutions in LMICs so that eye health research is 
primarily executed by researchers living and working in 
the region. The analysis of randomised controlled trials 
in sub-Saharan Africa highlights that most research 
in this region appears to have substantial academic 
involvement from high-income countries. A structural 
shift is required so that LMIC institutions increasingly 
take the lead and are supported by equitable partnerships 
that address priorities identified within the region. Such 
partnerships need to maximise meaningful capacity 
building for local researchers. Previously, some externally 
driven research projects have failed to sufficiently 
consider this issue, with local eye health personnel 
limited to data collection roles as opposed to scientific 
design and leadership. Subsequently, personnel might 
be included as authors without being empowered 
to engage in a meaningful way that develops their 
research skills. Some lessons can be drawn from the 
Commonwealth Eye Health Consortium, which built 
eye health research capacity in LMICs (particularly in 
For the Commonwealth Eye 
Health Consortium see 
https://cehc.lshtm.ac.uk/
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sub-Saharan Africa) by providing Masters degrees, 
doctoral scholarships, and post doctoral fellowships, with 
a focus on mentoring and empowering independent 
researchers. More regionally focused peer-reviewed 
journals are needed. Some regions might need capacity 
development support for longer. Increasingly this 
involves South-South collaboration, with the development 
of research community networks. This improvement is 
important considering that there are few, widely 
dispersed eye health researchers. Funding arrangements 
are very important for equitable partnerships, with a 
need for LMIC institutions to take the lead role in 
obtaining and managing funding.
Grand challenges in global eye health
Global eye health research needs to focus resources on 
key questions to maximise benefit. Previous research 
prioritisation processes were done in the UK, the USA, 
and for LMICs; these included expert panels with or 
without open calls for contributions from clinicians and 
the public, including people who live with vision 
loss.179,180 To collectively identify and focus on key areas 
that need attention in the upcoming decade, this 
Commission did a global prioritisation exercise. We 
drew on the Grand Challenges method, which involves 
a three-round modified Delphi process (appendix 1 
p 63).181 We recruited 336 people from 118 countries, 
working in clinical practice, eye health system 
management, research and policymaking, and people 
who live with vision and eye health problems. In round 
one, participants were asked the question “What are the 
grand challenges in global eye health?” and could 
nominate up to five challenges and five corresponding 
solutions. All 3400 responses were thematically analysed 
Panel 4: Prioritised Grand Challenges in global eye health
Improve treatment (condition-specific)
• Develop models to encourage population demand and 
ensure access to accurate refraction and affordable, good 
quality spectacles.
• Identify and implement strategies to improve the quality, 
productivity, equity, and access of cataract services.
• Improve child eye health by integrating evidenced-based 
primary eye care services for children into general health 
services and ensure strong connections to secondary eye care 
services. Develop and implement sustainable school eye 
health programmes, including screening and management 
for refractive error or amblyopia, which are well integrated 
within education services.
• Develop and implement effective, accessible, and 
inexpensive pathway approaches for screening, diagnosing, 
monitoring, and managing glaucoma.
• Develop and implement one-stop services for people with 
diabetes by integrating diabetic retinopathy screening 
services with general diabetes care and develop robust 
systems to ensure ongoing follow-up and referral for 
assessment and treatment.
• Develop and implement evidenced-based, effective, 
sustainable, and context-relevant screening and early 
detection strategies for eye conditions.
Health system
• Encourage governments to prioritise integrated people-
centred eye care services for universal health coverage.
• Develop and implement evidence-based strategies for the 
effective integration of eye health services between the 
primary, secondary, and tertiary level to improve referral 
pathways, ensuring recognition of those who need 
secondary care and a timely, reliable, accessible, and 
affordable care mechanism.
• Develop and implement evidence-based strategies for the 
effective integration of eye care at the primary care level and 
with other medical services (eg, child health, diabetes or 
other NCD services), ensuring that services are widely 
accessible, affordable, of high quality, and meet the primary 
eye care needs of the population.
• Strengthen the information system for eye health within 
health facilities, integrating them into national systems.
• Ensure financing for eye health exists within national 
budgets and financing structures and increase the 
investment.
Access and equity
• Develop and implement services that prioritise, and by 
design, reach marginalised or vulnerable groups (women, 
poor communities, Indigenous people, ethnic minorities, 
people with disabilities, people in residential care, prisoners, 
and refugee camps) and people living in rural communities 
with quality affordable eye services.
• Develop and implement strategies that reduce out-of-pocket 
costs for those requiring eye care who are unable to afford 
full-cost services—eg, subsidy, tiered pricing, or insurance.
• Develop and implement responsive programmes to increase 
the access to and use of eye health services and treatment—
eg, reduce barriers to accessing services and increase demand 
through greater awareness of need and confidence in health-
care provision.
Build resource capacity
• Increase support from international bodies, professional 
bodies, colleges, and non-governmental organisations, for 
geographical regions with severe eye health resource 
shortages.
• Strengthen leadership and public health expertise across all 
levels of eye care and ensure that national leadership can 
influence policy and resource allocation. Additionally, 
strengthen regional and national professional bodies for eye 
health practitioners.
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and consolidated into 85 unique challenges. Ranking 
was done across two rounds to arrive at 16 priority 
challenges (panel 4).
Six of the 16 challenges focused on improving specific 
services and treatment for cataract, refractive error, 
glaucoma, diabetic retinopathy, and children’s eye 
diseases. The available evidence for each condition 
warrant different research approaches. For example, 
cataract and refractive error can be treated by 
well-established and efficacious interventions, but these 
do not reach all who could benefit with sufficient quality 
to be effective. Implementation research is needed to fill 
this gap; there are few examples, perhaps the most well 
known is onchocerciasis, for which implementation 
research was done to determine the best way to distribute 
ivermectin. Optimal treatment and implementation 
approaches also need to be determined, in different 
populations, for glaucoma and diabetic retinopathy to 
improve acceptance and sustained uptake of lifelong 
care (panel 5).
Five of the 16 challenges related to health system 
factors including: advocating for and establishing the 
policy framework to implement people-centred eye 
care for universal health coverage; strengthening 
integration between primary and secondary levels of 
care, and between eye care and other health services; 
and strengthening the health information system 
and ensuring better budget allocation for eye care. 
Two challenges reflected the need to address shortages 
in human resources for eye health in parts of the 
world—eg, sub-Saharan Africa, and to increase capacity 
of eye health personnel in public health and leadership. 
Panel 5: The challenge of glaucoma
Glaucoma is the second leading cause of blindness (age-
standardised prevalence), which results in substantial disability 
before blindness, yet remains undertreated globally (Bourne 
et al, 2020). In most prevalence surveys from high-income 
countries, less than half of all detected glaucoma was previously 
diagnosed, and in low-income and middle-income countries 
(LMICs) over 90% of people with glaucoma are not in care 
(Tham et al, 2014; Vijaya et al, 2008; Kyari et al, 2015). This high 
percentage is because glaucoma is mostly asymptomatic until 
relatively late in the disease. As many as 35% of people are blind 
at diagnosis in LMICs, precluding effective interventions that 
would have prevented vision loss (Ramakrishnan et al, 2003; 
Buhrmann et al, 2000; Kyari et al, 2013; Abdull et al, 2015). 
Glaucoma lacks a one-stop solution such as cataract surgery, 
because of its chronic nature and complexity of management. 
In the absence of simple and affordable diagnostic and treatment 
solutions, the global eye health community has not prioritised 
glaucoma—eg, when VISION 2020 was being developed (WHO, 
2000). There are several crucial issues. 
First, there is a need to provide effective treatments that 
prevent glaucoma progression, and maybe someday, restore 
function to those with glaucoma damage. Several high-quality 
clinical trials have shown that lowering intraocular pressure 
slows, and in some cases stops, glaucoma progression 
(Garway-Heath et al, 2015; Collaborative Normal-Tension 
Glaucoma Study Group, 1998; Heijl et al, 2002). To do this 
intervention safely and effectively remains a challenge in all 
resource settings. The current treatment is long-term topical 
ocular hypotensive drops, but poor compliance and ongoing 
costs are major challenges in LMICs (Newman-Casey et al, 
2020). Laser trabeculoplasty, which can be administered in a 
single session, is one effective strategy that has shown 
effectiveness in locations with scarce resources (Gazzard et al, 
2019). Unfortunately, trabeculoplasty rarely provides lifetime 
control of intraocular pressure. Future hope is that more 
effective surgical or laser approaches will provide safe and 
sustained pressure lowering. Many novel approaches have been 
developed in the past decade, but none are able to overcome 
these challenges (Poitras et al, 2019).
Second, individuals need to be monitored to determine 
whether their glaucoma is progressing so that treatment can be 
changed or escalated when needed. Such monitoring presents 
challenges for more remote and resource-limited populations. 
However, glaucoma monitoring is undergoing a rapid evolution 
and home-based monitoring using off-the-shelf technology 
might become available in the near future (Che Hamzah et al, 
2020). The growth of vision centres in India and elsewhere, 
staffed by mid-level ophthalmic personnel and supported 
remotely by ophthalmologists, is an example of how to provide 
ongoing monitoring and shared care for people living in 
remote settings.
Third, affordable and effective screening approaches are needed 
to enable identification of individuals at risk of sight loss. Major 
advances in automated grading of optic disc photographs has 
led to highly accurate glaucoma diagnosis on the basis of a single 
photo (Li et al, 2018). Widespread use of screening using fundus 
imaging with artificial intelligence-assisted grading could allow 
glaucoma to be diagnosed alongside the other major causes of 
blindness at low cost. Implementation studies are needed to 
determine how and where to apply these new tools. 
Innovation in glaucoma detection and management, which will 
probably occur soon given the rapidly improving technology, 
could catalyse a new care model in which earlier detection and 
effective long-term intraocular pressure lowering combined 
with remote monitoring can prevent unnecessary blindness 
globally. To reach this goal, the global eye care community 
needs to include glaucoma in eye care planning, recognising the 
centrality of the patient as a partner in management. Many 
important research questions remain unresolved and require 
substantial investment and a concerted global effort to answer. 
References for this panel can be found in appendix 1 (p 109).
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These challenges could benefit from the application of 
health systems and policy research to answer questions 
such as to what extent improving integration between 
primary and secondary eye care services improve 
coverage, quality, and equity, and reduce out-of-pocket 
costs.
Equity is a crucial issue for universal health coverage 
and is of relevance to any service delivery-related 
research. We identified three challenges concerned with 
improving access and promoting equity, reaching 
vulnerable and marginalised groups, and developing 
and testing strategies to reduce out-of-pocket costs. 
Disadvantaged groups might have worse outcomes that 
are obscured by aggregate data. A simple step is to 
disaggregate data by the minimum set of social variables 
that are relevant in each context. In addition, equity-
relevant reporting guidelines and frameworks are 
available and can be used in eye health research to 
consider equity in the design, analysis, and reporting of 
research.182,183 These challenges highlight the need for 
researchers to include people with vision impairment 
and communities that the research is targeting in all 
aspects of the process, from identifying the research 
question to co-designing and implementing the study, 
data collection, analysis, and dissemination.
We believe this list of challenges serves as a starting 
point for immediate action that needs to be taken by 
researchers and funders. We call for funders to use the 
grand challenges to guide their research investments. 
Further, the list provides an opportunity for consortia 
and networks, advocacy organisations, universities, 
and governments to organise their activities around 
these challenges. In 2021, the authors of this Commission 
will seek to cohost a workshop to generate a research 
agenda and establish collaboration opportunities. The 
outputs of this workshop will include a strategy for 
periodic monitoring of eye health progress.
Delivering research for universal eye health
We have identified six crucial actions to generate and 
use evidence to promote eye health within universal 
health coverage. First, to develop a research agenda 
based on the grand challenges. Second, to increase 
solution-focused research including more contextually 
relevant implementation and health systems research, 
in partnership with patients, communities, service 
implementers, and policy makers, with an emphasis on 
ensuring that services address the leading causes of 
vision impairment in terms of coverage, quality, equity, 
and financial protection. Third, to ensure more emphasis 
is put on translating research findings into policy and 
practice, including better partnership with policy makers 
and integrating eye health research into general research 
priorities. Fourth, to avoid research waste by ensuring 
relevant questions are answered by adequately powered, 
robustly designed studies that are informed by 
systematic reviews of all the available evidence. Fifth, to 
support capacity building through equitable North-
South and South-South partnerships between 
researchers and research institutions. Sixth, to ensure 
inclusion by monitoring diversity of research teams with 
structural change toward better inclusion, and by 
including communities and patients throughout the 
research development process.
Section 6: Beyond 2020—delivering high-quality 
universal eye care
The case for action
The UN has set ambitious SDG targets for 2030.28 This 
Commission argues that eye health is integral to 
advancing sustainable development. Extensive evidence 
shows that improving eye health contributes directly 
and indirectly to several SDGs. Vision impairment 
profoundly impacts education and work, with substantial 
implications for poverty and the economy. Improving 
eye health benefits quality of life, general health, and 
wellbeing.
Universal health coverage is central to delivering SDG3 
(good health and wellbeing). We reason that universal 
health coverage is not universal without affordable, 
accessible, high quality comprehensive eye care. One of 
the leading recommendations in the WHO World report on 
vision2 is “making eye care an integral part of universal 
health coverage” through implementation of integrated 
people-centred eye care. However, this ambition is far 
from being realised. In many regions, the scale and 
approach of existing service delivery are insufficient to 
meet current population needs, let alone projected 
increases in the magnitude of chronic eye conditions and 
vision impairment by 2050. In view of likely benefits to 
sustainable development, increasing need, and availability 
of cost-effective scalable interventions for many common 
eye conditions, the case for urgent action on eye health is 
compelling. Global eye health needs to take its rightful 
place within global development and the health agenda.
Conceptualising eye health within universal health 
coverage
WHO defines universal health coverage as follows: 
“Universal health coverage means that all people and 
communities can use the promotive, preventive, curative, 
rehabilitative and palliative health services they need, of 
sufficient quality to be effective, while also ensuring that the use 
of these services does not expose the user to financial hardship”.184
The core components of universal health coverage are 
often illustrated using a cube (appendix 1 p 64) and are 
intrinsically linked to health financing; the inner cube 
reflects budget constraints.185 To conceptualise eye health 
within universal health coverage, we have adapted the 
cube (figure 16). Universal health coverage is not a fixed 
final goal; population health needs change constantly 
and new treatment options are regularly developed, 
which presents challenges for defining interventions and 
measuring impact.
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Here, we explore what the delivery of high-quality eye 
care involves within universal health coverage, and the 
actions needed to move towards this goal by 2030. We 
propose a framework for how eye health services could 
be integrated within the broader health system and in 
non-health sectors. We highlight promising integration 
strategies across levels of care and examine key enabling 
factors: workforce, financing, and technology. We 
illustrate important issues by focusing on cataract 
surgery and refractive error services, drawing together 
the available data to understand how these services are 
currently doing in relation to universal health coverage 
(coverage, quality, equity, and financial protection). 
Finally, we discuss cross-cutting issues integral to 
delivering eye care within universal health coverage 
(monitoring progress, quality, access, equity, and political 
prioritisation).
Selecting eye services for universal health coverage
National policy makers face complex, context-specific 
decisions in prioritising services that maximise public 
health benefit with finite resources.186 Cost-effectiveness 
is often an influential consideration, alongside need, 
sustainability, affordability, and feasibility. Additionally, 
countries might also consider equity—giving higher 
priority to services that benefit the poorest communities 
or those offering greater protection from financial 
risk.186 Ideally, coverage of high-priority services is 
extended to all before adding medium-priority or low-
priority services.
Our eye health economic literature review (section 4) 
highlighted the scarcity of cost-effectiveness data, 
particularly for LMICs, covering few interventions. 
Substantially more economic data are needed to inform 
countries that are deciding which eye health services to 
offer within universal health coverage. Considering 
current data limitations, how should eye care 
prioritisation choices be made? The epidemiology of eye 
disease is key, with an emphasis on the leading causes 
of vision impairment. However, many people presenting 
for eye health services have non-vision-impairing 
conditions and an eye health need that requires these 
services.
WHO is currently developing a package of eye care 
interventions for multiple eye conditions, informed by 
epidemiology and field experts.187 The inclusion of 
interventions is guided by high quality clinical practice 
guidelines and systematic reviews. Countries will be able 
to use these tools to inform service inclusion decisions, 
method of delivery, and resource implications. However, 
the need for more cost-effectiveness data to inform 
decisions relative to other health priorities remains.
Although countries vary widely in terms of population 
needs and health system capacity, core components 
necessary to meet general population eye health needs are 
similar in different settings. Ideally, a minimum package 
of eye care within universal health coverage would include 
primary eye care (promotion, prevention, and refractive 
services), eye care integrated within other services (neonatal 
care, school eye health, non-communicable eye disease 
services, care of older people), specialist ophthalmic 
services (to restore—eg, cataract surgery and preserve 
vision—eg, glaucoma, diabetic retinopathy and age-
related macular degeneration management), and vision 
rehabilitation services.
Delivering integrated people-centred eye care
Delivering eye health services within universal health 
coverage requires multidimensional integration, 
throughout and beyond the health system. Eye health 
needs to be included within national health plans, 
policies, and financing mechanisms. It also needs to be 
considered in policies and planning by other government 
ministries such as education, labour, and finance.
Although we recognise that health systems vary 
substantially between and within regions in terms of 
capacity and the stage of development, there are some 
broad organisational similarities. Here, we present how 
eye care can be integrated into different aspects of society 
and health systems including community, primary, 
secondary, and tertiary levels (figure 17). Appendix 1 
(pp 65–67) summarises services that could be provided in 
different settings in low-resource, middle-resource, and 
high-resource settings.
The World report on vision2 by WHO has placed renewed 
and welcome emphasis on a people-centred approach to 
eye care delivery. Individuals and communities need 
to be empowered through increased health literacy to 
actively engage in shaping and using services to drive 
demand. Effective, timely services need to be easily 
Figure 16: Considerations for universal eye health coverage
Adapted from WHO 2015,185 to contextualise to eye health services and include the quality component. The inner 
cube has a colour gradation representing a range in the quality of delivered services; green represents effective 
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accessible to the population in convenient locations, with 
easy navigation through the system in cases for which 
more specialised services are required. Effective health 
systems are characterised by strong connections within 
and between levels.
A crucial component of delivering eye health within 
universal health coverage is effective primary eye care, 
needed in all resource settings, which connects with the 
wider primary health system and secondary eye health 
services. This Commission takes a broad view of primary 
eye care, encompassing activities and interventions within 
community settings and primary health facilities (general 
care and eye care). Primary eye care can include promotive, 
preventive, diagnostic, treatment, and rehabilitative 
services.
Eye care in community settings
Delivering services within or close to where people live 
and work results in increased access and use.188,189 There 
are many effective eye health interventions that can be 
delivered at community level.
Eye health education and promotion within com-
munities can lead to improved knowledge and service 
uptake.190–192 Promoting community-based facial cleanli-
ness is integral to trachoma elimination programmes.21 
Health promotion messages about meticulous contact 
lens hygiene are important in reducing corneal 
infections.193 To deliver education and promotion within 
integrated eye care, providers need to use more people-
centred or community-centred design approaches, 
recognising that people are co-producers of health, not 
just users, beneficiaries, or choosers.194 More behaviour 
change and co-design research is needed. Previously, 
many interventions intended to improve facial cleanli-
ness for trachoma ignored accepted theories and 
findings about behaviour change.195 A co-design process 
is underway in Ethiopia that seeks an in-depth 
understanding of social and cultural determinants of 
behaviour, working with community groups to propose 
and test contextually relevant strategies to promote facial 
cleanliness.196 Digital communication offers new routes 
to share and amplify such messages.192
Several community-level interventions have shown 
effectiveness. Vitamin A supplementation and measles 
vaccination markedly reduced childhood cornea 
scarring.197 Rubella vaccination has rendered ophthalmic 
complications of congenital rubella rare.198 Mass drug 
administration for trachoma and onchocerciasis are 
delivered in community settings and frequently involve 
community members in distribution (community-
directed).21 Community volunteers distributing azithro-
mycin were integral to trachoma elimination in Ghana.199
Some countries train community health workers in 
primary eye care, including health promotion, vision 
testing, and referrals. Clinical trials are few; however, 
they indicate promise in identification of people with eye 
health needs. In Nepal, community health workers were 
trained to recognise corneal abrasions and infections 
using a torch, and to provide early treatment and referral, 
which led to improved outcomes.200 In Kenya, community 
health workers have been trained to use a smartphone-
guided vision test and algorithm to identify and refer 
people with vision impairment and other eye problems.201 
This approach has been tested in a cluster randomised 
controlled trial in Kenya,202 and preliminary findings 
(unpublished) have shown that an increased number of 
people with vision impairment and eye problems are 
attending eye clinics.
However, sustaining programmes that engage general 
community health workers is hard.203 Although studies 
show efficacy of community health worker programmes 
under controlled research conditions, long term program-
matic implemen tation is less certain.204 Implemen tation 
research is needed to establish approaches to sustainably 
embed basic eye health in training and activities of 
community health workers.
Traditional eye remedies are widely used in south Asia 
and sub-Saharan Africa to treat many eye conditions.205–208 
These remedies, frequently plant-based, are either home-
made or sourced from traditional healers.205 They can 
worsen clinical outcomes through direct toxic effects, 
secondary infection, or delay in seeking appropriate 
treatment.206 Several studies have found that careful 
engagement and training programmes for traditional 
healers can improve practice, reduce the use of traditional 
eye remedies, and promote more rapid referral.208,209 Such 
programmes are not widespread, but have potential for 
impact.
Pharmacies and informal drug sellers (eg, patent 
medicine vendors in Nigeria), can be the first source of 
health care accessed by people with eye conditions.207 
They can be an important source of health advice and 
simple treatments. However, in some countries drug 
stores are poorly regulated, which leads to inappropriate 
advice or treatments such as sale of steroid eye drops to 
people with corneal infections.210 There is an opportunity 
in many settings to engage with pharmacists and drug 
stores to promote eye health messages, safe prescribing, 
and appropriate referral.
Eye care in schools
Many countries have developed school eye health 
programmes (appendix 2 p 5).44,45,211 Screening approaches 
to identify children with vision impairment—eg, 
training teachers to test vision, appear effective.78,212,213 
Most vision impairment in school-aged children is due 
to uncorrected refractive error.214 Providing services in 
schools (refraction and dispensing spectacles) increases 
access and uptake; low cost, high quality, ready-made 
spectacles can meet the needs of more than 80% of 
children with uncorrected refractive error.215 However, 
subsequent spectacle wear can be low; contextual 
interventions are required to increase spectacle use.216 
An important consideration is how to reach children 
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who are not in school.217 Comprehensive school eye 
health programmes also include health education and 
promotion, and support inclusive education for children 
with irreversible vision impairment.
Well-coordinated action is crucial in Asia to address 
myopia, with strong collaboration between departments 
of health and education. This issue requires major 
changes in education delivery and preventive approaches 
to slow down the onset of myopia.218 For example, China 
is currently developing a national myopia strategy, with 
strong links between health and education (appendix 2 
p 6).
Preventing eye injuries
Workplace injuries are an important cause of serious 
ocular morbidity.219 Minor abrasive corneal trauma 
during agricultural work is a frequent risk factor for 
corneal infection in south Asia.200 Using safety goggles 
while performing some tasks can prevent such injuries.220 
The introduction of seat belts and firework regulations 
reduced ocular trauma; these should be promoted in 
areas where eye-related injuries remain common.221,222
Eye care delivery in general primary health care
WHO calls for strengthening eye care delivery within 
primary health care to complement work in secondary 
and tertiary eye care.2 In many countries, general primary 
health-care workers assess, treat, and refer people with 
eye problems. Primary health-care staff might also 
support community-based activities. Services vary 
substantially between contexts; here we outline some 
similarities and integration opportunities.
Longstanding work has enabled primary health-care 
workers to deliver primary eye care and several training 
manuals have been developed.223 However, experience is 
mixed; establishing primary eye care within primary 
health care is not simple and requires substantial 
training investment and enabling environments. General 
health-care workers usually receive little primary eye care 
training, leading to important knowledge and skill 
gaps.210,224–228 For example, training primary health-care 
nurses to test visual acuity did not increase referral rates 
in Malawi.229 Short supply of basic equipment and 
insufficient ongoing support to deliver primary eye care 
are frequent issues.203,210,224,230,231 Programme sustainability 
is challenging in areas that depend on external non-
governmental funding.232
There are some promising strategies such as the Lady 
Health Worker programme233 in Pakistan, which includes 
primary eye care, increasing detection, and referral from 
the community; however, connecting to secondary care 
still remains challenging (appendix 2 p 7). In China, 
village doctors are trained by secondary eye care teams to 
identify and refer people with vision impairment.234 
There is strong policy backing, whereby all people 
younger than 6 years and older than 65 years are offered 
a vision check in primary health-care facilities. This 
policy increases the number of people attending 
secondary units, which are more invested in supporting 
primary eye care services. An intensive programme in 
Rwanda, training health-care nurses in primary eye care, 
is now embedded in the general nursing curriculum 
which substantially improves access to eye care services 
throughout the country.235
Integration of primary eye care into primary health 
care services for younger children is a major opportunity. 
WHO identified ten key activities to promote healthy 
eyes in children.236 These activities were tested in 
Africa.237 A modification was included in the curriculum 
of WHO’s Integrated Management of Newborn and 
Childhood Illness (IMNCI)238 in Tanzania (appendix 2 
p 8). IMNCI is used in more than 100 countries to guide 
facility-based management of illnesses in children 
younger than 5 years, in the primary care setting, and is 
possibly a scalable and sustainable way to deliver 
interventions that address primary eye care needs of 
young children.
Screening for diabetic retinopathy depends on close 
partnerships with general medical services. The delivery 
of screening is being transformed by the increasing 
availability of low cost retinal cameras operated by non-
specialists, acquiring images for remote grading. In 
high-income countries, established diabetic retinopathy 
screening and treatment programmes deploy technicians 
to community settings to collect images for remote 
grading and decide on the referral. In the UK, the 
proportion of blindness in the working-age population, 
caused by diabetic retinopathy, has declined because of 
improved diabetes control and the national screening 
programme (appendix 2 p 9).239 Programmes are also 
being developed in LMIC settings. For example, in India, 
multiple public pilot programmes have been developed 
by the Ministry of Health, showing a substantial increase 
in the number of people screened at clinics for non-
communicable diseases and community health centres.240 
In sub-Saharan Africa and the Caribbean, multiple 
countries have developed regional or national diabetic 
retinopathy screening programmes that also embed 
diabetic retinopathy services within general non-
communicable disease services.241
The delivery of primary eye care by general health 
workers is an area that requires systematic high-quality 
implementation research that analyses policies and 
systems to assess strategies, which would fully embed 
primary eye care within primary health care. Realistic 
expectations are needed in terms of the tasks that general 
primary health-care workers can do alongside other 
duties. In this context, technological developments hold 
promise in enabling task sharing.
Specialist eye health services within primary care settings
Some LMICs have permanently based mid-level 
ophthalmic personnel (non-physician specialised prac-
titioners) in larger primary health-care facilities such 
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as community ophthalmic nurses stationed in large 
district health centres in The Gambia.242 These nurses 
serve approximately 30 000 people and provide a bridge 
between primary health care and secondary services, 
supervising community-based primary eye care activities. 
Similar examples are seen in Ethiopia (integrated eye 
care workers) or in Tanzania (assistant medical officers 
in ophthalmology).
Outreach services are delivered in more remote regions 
by eye care teams visiting periodically, and providing 
outpatient clinics and surgery.204 In some countries these 
services are widely used to increase access to surgery (eg, 
cataract).243,244 Outreach services provide an opportunity 
for refresher training and supervision of primary health-
care staff involved in primary eye care. However, 
communities can be left without access to services for 
extended periods, and this method might discourage the 
development of local eye care services.
Primary eye care facilities or vision centres, pioneered 
by several large non-governmental eye health 
organisations in south Asia, are satellite units operated by 
mid-level ophthalmic technicians (appendix 2 p 10).245 
These units are separate from the public health system 
and are well integrated into the networks of secondary 
and tertiary hospitals, with teleophthalmology support 
and integrated electronic record systems.246 Approximately 
80–90% of people presenting to vision centres can be 
managed at that level, and the remainder are referred on. 
However, the degree of integration with general public 
health structures is suboptimal.
In high-resource and middle-resource settings, primary 
eye care is mainly delivered by specialised personnel. In 
many high-income countries within community settings, 
primary eye care and refraction services are usually 
provided by eye health specialists, optometrists, or 
ophthalmologists in the private sector, with access to 
sophisticated diagnostic equipment, particularly in 
urban areas.
Overall, populations are well served by easy access to a 
dedicated eye health workforce, closely connected to the 
general primary health-care system. This Commission 
recommends that, where possible, countries should 
move towards developing a dedicated eye health 
workforce to strengthen primary eye care in the public 
and private sectors. Cadres vary between countries. How 
these personnel are managed and integrated is an 
important area for implementation research.
Refractive error services and public–private collaboration
There is an increasing need for refractive error services for 
adults and children worldwide. Access to refractive error 
and optical services in primary care settings is crucial. 
Services vary between countries and include optometrists, 
refraction technicians, and ophthalmologists. A competent 
workforce is important, in addition to good governance 
and equitable delivery, to ensure appropriate and quality 
spectacles for all.
In many regions, refractive error and optical services are 
provided by the private sector and therefore, are largely 
market-driven to an extent that other eye care services 
might not be. Market forces have been a major incentive 
for service development at scale in some settings, providing 
well for population needs. However, if the distribution of 
refractive error services is influenced by what providers 
consider a viable return on investment, populations in 
areas of high deprivation could remain without access to 
services.247 The cost of spectacles can vary greatly between 
settings, and can involve large out-of-pocket expenditure 
and be unaffordable to many people. In some countries 
there is a large unregulated market of optical shops that 
might provide poor quality services.248 The private sector 
usually does not share data on the number of refractions 
done and spectacles dispensed—an information gap that 
needs to be addressed for countries to be able to monitor 
refractive error services.
However, the private sector represents a huge 
opportunity to bring refractive error services (and 
primary eye care more broadly) closer to communities. 
Indeed, given the magnitude of uncorrected refractive 
error globally, eye health cannot be addressed as part of 
universal health coverage without a major contribution 
from the private sector. To contribute to delivering 
eye health within universal health coverage, more 
consideration needs to be given to developing the right 
regulatory and market conditions to promote high 
quality, affordable, and equitable services.
A strong regulatory framework for prescribing and 
dispensing refractive error corrections allows for 
coherent health promotion messages. Users’ trust in the 
clinical competency and decision making of eye health 
workers is important for generating and sustaining 
service demand. By contrast, the sale of unregulated, 
variable quality optical devices (including via the 
expanding online market) might increase access, but at 
the possible expense of quality and sustainability.
Public–private partnerships are promising ways of 
increasing spectacle coverage while ensuring a safety net 
for those who are unable to afford private sector services. 
Examples include the national Jaminan Kesehatan 
Nasional (JKN) scheme in Indonesia, in which the vision 
test is provided by the public sector and a voucher is 
given to obtain spectacles from accredited private entities. 
The national school eye health programme in Trinidad 
and Tobago provides a government voucher for spectacles 
to reimburse the private sector provider. In Rwanda, the 
national insurance programme includes a sight test and 
a standard pair of spectacles, and more expensive 
spectacles will also be subsidised. In the UK, the Scottish 
Government made primary eye care free for all, at the 
point of use, and increased the fees paid to providers for 
their services. This change increased the viability of 
service providers in deprived areas, despite a lower 
demand for spectacles that generate more profit. Given 
the large and growing problem of uncorrected refractive 
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error, other strategies and better evidence, with a focus 
on equity, are needed to improve effective coverage.
Connecting people to secondary eye care
A study249 from Uganda illustrates several challenges in 
integrating eye health services into primary health care 
and connecting people to secondary services (appendix 2 
p 11). This study documented the journey of people with 
severe corneal infections seeking health care. Severe 
corneal infection is an acute painful condition requiring 
urgent specialist treatment within a few days of onset to 
prevent permanent sight loss. Although many people 
presented to a primary health-care facility within 2 days 
of symptom onset, the seriousness of their condition was 
frequently not recognised, appropriate treatment was not 
initiated, urgent referral to the hospital eye clinic was not 
given or followed, and the opportunity to prevent 
irreversible vision loss was missed. Many people visited 
multiple health facilities before reaching the eye unit 
for assessment and definitive management. Other 
studies250,251 have also reported that attending additional 
intermediate health facilities for emergency and non-
emergency conditions increases delays in accessing 
treatment and the direct and indirect costs for patients. 
Effective referral decisions and clearly defined pathways, 
ongoing supervision, and refresher training, would 
strengthen primary eye care. Referrals made using an 
electronic system have shown notable success in 
increasing the reliability and timeliness of attendance at 
secondary care facilities.212
Eye care within secondary and tertiary health care
Secondary eye health services are important for diagnosing 
and managing the leading causes of vision impairment, 
beyond uncorrected refractive error. These services 
include surgery (for cataract and glaucoma), and laser and 
injection therapies (for diabetic retinopathy and age-related 
macular degeneration). Access to rehabilitation services 
remains inadequate in many regions and requires 
concerted action. In many countries, secondary units 
support the development and supervision of primary eye 
care. Tertiary facilities usually have a larger number of 
specialists, offering a range of subspecialty services with 
more sophisticated equipment than in secondary units to 
manage complex problems. Typically, ophthalmology and 
ophthalmic nurse training programmes are based in 
tertiary facilities. In many LMICs, secondary and tertiary 
eye health services have had long-term underinvestment 
in eye health staff, equipment, and infrastructure. These 
issues are high priority and need to be addressed to deliver 
efficient and effective services.
At secondary and tertiary levels, good communication 
and integration within the health service is needed—eg, 
prevention, screening, and treatment of retinopathy of 
prematurity requires close collaboration with neonatal 
unit teams. With the increasing availability of low cost 
retinal cameras, task sharing is becoming a reality in 
some locations, including a remote assessment by an 
ophthalmologist (appendix 2 p 12).252 Similarly, diabetic 
retinopathy needs to be well integrated into primary 
health care, from screening to clinical assessment, and 
treatment in secondary and tertiary units.
Vision rehabilitation services
Vision rehabilitation is a set of services that assists 
individuals who experience disability to achieve and 
maintain optimal functioning. Services assist people with 
activities of daily living, accident prevention, and general 
physical and psychological wellbeing. People seeking 
vision rehabilitation face a range of challenges including, 
but not limited to, scarce services, physical barriers, 
inadequate skills and knowledge of the health workforce, 
and prohibitive costs. These barriers contribute to the 
global estimate of only 15% of people who could likely 
benefit from these services currently accessing them.253 
Insufficient systematic data remains a persistent issue in 
raising the profile of vision rehabilitation and 
understanding the extent of the problem.
A nuanced tension exists between identity and 
recognising disability being part of natural human 
diversity, the interaction of impairment with the physical 
and social environment causing disability and a perception 
of medical care narrowly construed as being to treat and 
cure disease. This tension becomes acute in determining 
who ought to have responsibility for driving progress in 
vision related rehabilitative services.
Concerned by the general challenges in rehabilitation, 
WHO convened a meeting in 2017, Rehabilitation 2030: 
A call for action.254 Participants agreed to improve the 
integration of rehabilitation within health systems and 
strengthen intersectoral links. This shift recognised the 
gap produced by different government departments who 
have responsibility for rehabilitation and placed an 
emphasis on health to drive change as part of a 
continuum of care. The WHO World report on vision calls 
for vision rehabilitation services to be included within 
eye care interventions. Intersectoral partnerships with 
education, social services, and labour, are essential to 
provide person-centred support with complimentary and 
additional support for social, economic, and cultural 
participation.
Although improvements in the external environment 
are important for inclusion and development, vision-
related rehabilitative services are intrinsic to person-
centred health care for people living with blindness or 
vision impairment. Because the availability and access 
to services is poor, this Commission urges a greater 
endeavour on the part of eye health policy makers, 
practitioners, administrators, providers, and donors to 
advance vision rehabilitation as an essential part of 
integrated people-centred eye care. This shift will require 
action by WHO, governments, and eye health leadership 
bodies such as the International Agency for the Prevention 
of Blindness to raise awareness and build policies in 
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collaboration with organisations for people with dis-
abilities, rehabili tation professionals, and other sectors.
Human resources for eye health
Aligning the health workforce and eye health needs
Delivering eye care within universal health coverage 
relies on an appropriately trained, connected, and 
enabled workforce who are available, acceptable, and 
accessible.2 Workforce compe ten cies and configuration 
need to be matched to population eye health needs. 
Services vary substantially in the complexity, type 
of equipment, facilities, and competencies required. 
Workforce plans for eye health need to be included in the 
overall national health workforce planning. Tools, such 
as the WHO Workload Indicators of Staffing Need, can 
be used to systematically analyse workforce requirements 
and personnel deployment to meet population needs.
An integrated eye care team within the public 
and private sector is needed and would encompass 
community-based volunteers, delivering health messages 
and preventive interventions, through to subspecialists in 
secondary and tertiary ophthalmology centres, providing 
complex medical and surgical treatment. Workforce 
structures and responsibilities differ between health 
systems; contributory roles include ophthalmologists, 
optometrists, allied ophthalmic personnel, general health 
workers, counsellors, equipment technicians, vision 
rehabilitation workers, managers, administrators (IT, 
finance, procure ment, maintenance), and community 
volunteers (appendix 1 p 68). Team composition varies 
with population characteristics, disease patterns, and 
health system maturity. The workforce needs to be well 
connected horizontally, within the local health system, 
ensuring appropriate access points and localised care and 
vertically for effective referral of more complex problems 
(figure 17).
WHO is calling for a change in eye health care delivery 
towards a more person-centred approach, with increased 
emphasis on service delivery initiated in primary care.2 
This WHO vision needs a broader workforce view, 
involving populations and civil society alongside the 
formal health sector, in contextually specific community-
based activities. To expand access to primary eye care in 
areas with few community-based allied ophthalmic 
personnel, sharing tasks with non-eye-care health 
workers is necessary. This expansion requires rigorous, 
competency-based training, reliable provision of essential 
equipment and consumables, supportive supervision 
from specialist services, quality assurance, and ongoing 
learning opportunities. The widespread introduction of 
core competency-based skills training for eye health into 
general medical and nursing training is a good starting 
point.
Primary eye care is preferably delivered by appropriately 
trained allied ophthalmic personnel, working closely 
with primary health care teams, located in easily 
accessible settings. Populations benefit from their 
expanded competencies and focus on eye health 
activities. For example, community-based vision centres 
in India. In high-resource and middle-resource settings, 
optometrists and ophthalmologists frequently provide 
the first point of contact for those with symptomatic eye 
conditions and can potentially provide opportunistic 
screening to detect asymptomatic conditions. Many 
LMICs need to develop training capacity for allied 
ophthalmic personnel and optometrists, and strengthen 
regulatory frameworks and ensure good governance.
For strong secondary and tertiary eye care services, 
planned investment in training and providing equipment 
for ophthalmologists and the associated team, is needed. 
The secondary and tertiary teams also support primary 
eye care, providing training and supportive supervision. 
Shaping the eye health workforce requires responsive 
planning and training for context specific needs.
Enabling environments to increase efficiency
Optimising productivity or efficiency of services 
requires personnel with the relevant competencies and 
resources to be present at each level. Workforce 
productivity can be a major challenge, with underuse of 
specialist eye health capacity, evidenced by wide 
variation in the number of cataract operations done 
each year by ophthalmologists.255,256 Simply increasing 
the workforce size is insufficient. An enabling 
environment is crucial for workforce productivity, as the 
shortage of eye health workers is compounded by 
limited access to equipment and consumables.230,257 
Maximising the effectiveness of each team member is 
key to increasing overall productivity, and needs to be 
addressed within a local and health system context.
There are good examples from different resource 
settings showing that service efficiency can be increased 
using careful process analysis and well-coordinated 
teamwork. With outreach teams supporting primary eye 
care and ensuring a steady flow of patients for cataract 
surgery and hospital support teams ensuring sufficient 
surgical supplies, sterile instruments, and regular 
equipment maintenance, the surgeon can be more 
productive and average around 1500 cataract surgeries 
a year, which is routinely achieved in settings such as 
Nepal and India.258 These principles can be applied in 
other LMICs.259
Efficiency also varies considerably between the public 
and private settings, with variation in output attributed 
to training, personnel oversight, enabling workplace, 
incentives, and good management.230,260 More research is 
needed on enabling and motivation factors that influence 
service volume and quality.261 Motivation and retention are 
driven by many factors such as the work, responsi bility, 
achievement, organisational purpose, recognition and 
growth, compensation, security, status, work conditions, 
and the relationship with the supervisor. Understanding 
these factors in local contexts will help in building 
empowered, self-led teams. Retention, motivation, and 
For the WHO Workload 
Indicators of Staffing Need tool 
see https://www.who.int/hrh/
resources/wisn_user_manual/en/
The Lancet Global Health Commission
40 www.thelancet.com/lancetgh   Published online February 16, 2021   https://doi.org/10.1016/S2214-109X(20)30488-5
performance depend to a large extent on how well this 
improvement is done.
Strengthening training to build quality
In many regions, education is based on outdated curricula 
taught in a traditional, professional, siloed approach 
focused on knowledge of diseases rather than compe-
tencies. The patient-centred approach outlined in the 
WHO World report on vision2 has not always been adopted 
by the health education system.124 There has been 
considerable development; updated and educationally 
sound competency-based training curricula for ophthal-
mology are now available, with several international 
collaborations leading to extensive exchange of 
knowledge.262 There needs to be a further shift, with 
increasing emphasis on competency focused learning 
tuned to meet population eye health needs.
Surgical training of ophthalmologists is an area of focus 
worldwide, with concern about insufficient training 
opportunities.263 To address these shortcomings, several 
initiatives are ongoing to strengthen surgical competency 
training programmes. The quality of these programmes 
and subsequent service provision depend on the training 
faculty, equipment, and opportunities to practise under 
supervision. There is increased emphasis on training the 
trainers to empower their approach. Programmes that are 
being cascaded in east Africa have transformed training 
practices.264 To improve the safety and efficiency of surgical 
skill acquisition, training has moved away from the 
apprentice model towards the use of simulation surgery. 
Simulation-based surgical education uses eye models and 
has been shown to rapidly and effectively increase surgical 
competence.265 This method increases confidence of the 
trainee surgeon and improves patient safety by reducing 
complications and surgical errors. Relying on the outdated 
apprentice model of surgical training is no longer 
appropriate. When underpinned by the principles of adult 
learning and encompassing key facets of educational 
theory, surgical simulation training is an important 
approach to bring novice eye surgeons to a competent 
level before operating on patients under supervision.
Lifelong learning is essential for the workforce to 
maintain skills in the context of rapid growth in medical 
knowledge and ever-changing health systems. In high-
resource settings, formal and informal opportunities 
build professionalism and competencies in areas such as 
research skills, leadership, policy, and management. 
Equitable transferability of these learning opportunities 
to a global scale is becoming increasingly recognised 
through platforms such as the Orbis Cybersight 
programme and the International Centre for Eye Health 
open education courses. Shared learning has grown with 
the increase of a global online audience, particularly 
during the first months of the COVID-19 pandemic. 
These resources enable self-directed learning and lifelong 
educational opportunities for eye health professionals, 
particularly beyond ophthalmologists.
Workforce size and distribution
Universal access to eye health can only be achieved if an 
appropriately skilled and equipped eye health workforce is 
available and accessible to all those in need. National and 
subnational analyses of workforce needs in relation to 
population eye health are crucial, but currently not readily 
available. The International Council of Ophthalmology 
(ICO) periodically assesses the global ophthalmology 
workforce. For 2015, they estimated 233 000 ophthal-
mologists in 194 countries (appendix 1 p 69).266 Similarly, 
the World Council of Optometry assessed the number and 
distribution of human resources for refractive services 
(2017–20), and reported 478 000 personnel in 126 countries. 
Recognition of optometry has developed in many countries 
and is either fully regulated, partly regulated, or legal 
recognition is underway. In some countries, the scope of 
optometry has expanded from primarily refractive services 
to some diagnostic and treatment services.267 These data 
are challenging to collect, but data on allied ophthalmic 
personnel have proven particularly difficult to collect 
because of the wide variability in nomenclature.268
The overall regional prevalence of blindness appears 
inversely correlated with the density of ophthalmologists 
per million population (figure 18). We recognise that these 
data are confounded by socioeconomic factors and not all 
causes of blindness are amenable to interventions by 
ophthalmologists. Several regions have clear shortages of 
ophthalmologists who are able to do surgery for cataract 
and other conditions, particularly in sub-Saharan Africa, 
which ranges between 1·1 and 4·4 ophthal mologists per 
million population compared with a mean of 76·2 ophthal-
mologists per million in high-income countries (appendix 1 
p 70). Similarly, the overall prevalence of all vision 
impairment appears inversely correlated to the combined 
density of ophthalmologists and optometrists (figure 18). 
Several regions have shortages of optometrists; inter-
regional variation is stark, with a median of 1 per million 
population in low-income countries compared with 
221 per million population in high-income countries.
National data on human resource density alone do not 
indicate access to eye care. There are several challenges 
that need to be addressed to reach universal access to eye 
health. First is the maldistribution of the workforce 
within countries. A study268 mapping eye health workforce, 
in 21 sub-Saharan African countries, reported the mean 
density of practitioners inside versus outside capital cities 
(ophthalmic surgeons 12·9 per million vs 1·7 per million, 
ophthalmic nurses 20·5 per million vs 7·7 per million, 
refractionists [including optometrists] 16·7 per million vs 
2·5 per million, respectively). Similarly, in Latin America 
there is strong evidence of inequality in the distribution 
of ophthalmologists, with higher density in more socially 
advantaged urban geographic areas.261 Small island states, 
such as those in Oceania and the Caribbean, face extreme 
challenges in developing and retaining an eye health 
workforce (appendix 2 p 13). Second, by only monitoring 
numbers, we have no information on workforce 
For Orbis Cybersight see 
https://cybersight.org/
For more on the ICEH see 
http://cehc.lshtm.ac.uk/oers/
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competency or scope of service. The ICO survey266 
explored whether ophthalmologists were surgically active, 
finding 0·9 surgically active ophthalmologists per million 
in low-income countries and 32 per million in high-
income countries.
Unmet needs, particularly in sub-Saharan Africa and 
parts of Asia, and future projections indicate that the eye 
care workforce needs to be urgently expanded, especially 
because training an ophthalmologist can take more than 
a decade. In the ICO survey, most countries (60·3%) 
reported growing workforces; however, the annual global 
growth rate (2·6%) lags behind the annual growth in the 
global population aged 65 years and older (2·9%), which 
is set to double by 2050. How the workforce is trained, 
deployed, and empowered to deliver services is equally as 
important as the numbers. Maximising health workforce 
capacity by developing enabling environments, practices, 
and increasing motivation is crucial for ophthalmic 
public health.
Innovating delivery: technology to support eye health
Advancing eye health services within universal health 
coverage, particularly in LMICs, will require substantial 
expansion of service capacity. Many conditions already 
have effective interventions. However, systems are failing 
to deliver and there needs to be innovation in delivery. In 
primary health care settings, appropriate tools are needed 
to enable non-specialist health workers to identify and 
refer people that need services. Technological advances 
offer promise in enabling the larger health workforce to 
support eye care delivery through task sharing.
Teleophthalmology
Teleophthalmology has been used for more than 
20 years—eg, to enable consultations for remote 
communities in Australia.269 Eye health technicians in 
vision centres in India have been linked to ophthalmology 
hub hospitals.246 Teleophthalmology can be broadly 
classified as asynchronous—ie, when images are 
collected by technicians for later review—or synchronous 
in live consultations. Asynchronous teleophthalmology 
screening for retinopathy (diabetic and of prematurity) 
substantially increases service coverage in a population, 
and reduces travel and opportunity costs with a high 
degree of acceptance and satisfaction.270 Synchronous 
teleophthal mology aids highly trained personnel in 
diagnosis and decision making and immediate initiation 
of appropriate treatment, while reducing the burden of 
patients travelling.
Mobile health
Rapid evolution of mobile telecommunications is 
profoundly impacting life, even in remote locations. 
Many mobile health (mHealth) applications for eye care 
have been developed, although few have achieved 
widespread uptake.271 Further, insufficient regulation is a 
concern, with most publicly available eye care applications 
being untested or unvalidated.272,273 Several visual function 
testing applications have been validated and show good 
performance compared with the conventional charts used 
in rural settings in Kenya and Ethiopia.274,275
By linking smartphone applications to a wider system, 
the effectiveness, efficiency, and knowledge gains can 
be considerable. For example, a cluster randomised 
controlled trial of an mHealth system for school vision 
screening in Kenya found that teachers can reliably 
identify pupils with vision impairment using a 
smartphone-based visual acuity application, which then 
initiates an electronic referral for full assessment.212 This 
method more than doubled the uptake of secondary eye 
Figure 18: Vision impairment and eye health workforce
Shown for the Global Burden of Disease regions. (A) Age-standardised prevalence of blindness (all ages) by the number of ophthalmologists per million population. 
The circle area is proportional to the number of people who are blind. (B) Age-standardised prevalence of vision impairment (mild, moderate, severe, and blind; all 
ages) by the number of ophthalmologists and optometrists per million population. The circle area is proportional to the number of people who have vision 
impairment. Data from Resnikoff et al,266 VLEG–GBD,1 and World Council of Optometry.257
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care services among those referred, with active tracing of 
referred individuals, and SMS messaging to nudge 
attendance. This system is being scaled up by the Kenyan 
Ministry of Health in several regions. An integrated 
mHealth system is also being scaled up in Pakistan, 
enabling community health workers to identify and 
refer people with eye health needs and increase vision 
testing and decision support in the community 
(appendix 2 p 14).
Artificial intelligence
There is considerable interest in the potential of artificial 
intelligence and particularly deep learning in 
ophthalmology.276 This interest is driven in high-income 
countries by challenges in managing high volume 
chronic conditions (age-related macular degeneration, 
diabetic retinopathy, and glaucoma). Deep learning is 
particularly suited to these conditions because their 
diagnosis and management is largely dependent on 
retinal photography (appendix 2 p 15) and optical 
coherence tomography (appendix 2 p 16). Artificial 
intelligence has many potential applications in eye health 
that could enhance delivery, optimise health system 
functioning, and lead to improved patient outcomes. 
Examples of potential uses that are in development 
include supporting point-of-care diagnostics,277,278 surgical 
decision making (risk stratification),279 or patient 
management and treatment.278 The most likely early 
application in public health programmes will be in 
screening for diabetic retinopathy and retinopathy of 
prematurity.280,281 Artificial intelligence solutions can 
possibly be integrated with electronic medical records to 
support administrative tasks such as identifying patients 
with a specific eye condition or at-risk patients.282 Artificial 
intelligence can be used in clinical, epidemiological, and 
health system research to incorporate data on social 
determinants of health, identify at-risk patient popu-
lations, and help to prioritise scarce clinical resources.283 
This area presents an opportunity to address the link 
between poverty and blindness, and the need to promote 
equity in eye health.10 Finally, artificial intelligence 
coupled with telemedicine and mHealth could help to 
reach populations with poor health system access, either 
because of geographical isolation or scarcity of human 
resources for eye health.280,284
There is little information on implementing artificial 
intelligence in eye health delivery and even less on 
whether it could improve care or outcomes. Before 
deployment into routine clinical practice, artificial 
intelligence applications require external validation on 
data that were not previously used in algorithm 
development and should undergo rigorous safety and 
efficacy testing in prospective clinical studies. In 2018, 
IDx-DR was the first artificial intelligence screening 
product for diabetic retinopathy to obtain approval from 
the FDA, after demonstrating good diagnostic accuracy 
in a prospective trial281 done in a real-world setting.
To assess the extent of translation-ready artificial 
intelligence (in use or soon to be in use), this Commission 
did a scoping review for publications related to artificial 
intelligence in eye health since 2015 to 2020 (appendix 1 
p 71). We identified 1256 primary data reports, most (60%) 
focused on retinal imaging (20% diabetic retinopathy, 
16% glaucoma, and 6% age-related macular degeneration). 
Only 12% of reports addressed conditions that affect 
the anterior segment and 1·5% were on childhood eye 
conditions. Most (90%), reported on artificial intelligence 
model development and internal validation. Of 113 reports 
on external validation or successful deployment in 
clinical settings, most were for retinal conditions (58%), 
facilitated by greater availability of images. Arguably, the 
greatest potential for artificial intelligence to contribute 
to advancing eye health would be to assist in case 
identification and health system efficiency, helping people 
with uncorrected refractive error and cataract access 
services, neither of which are currently well represented 
in artificial intelligence development platforms.
A substantial obstacle to artificial intelligence use in 
global eye health is the availability of large well curated 
datasets from multiple distinct populations for the 
development and validation of algorithms. Performance 
characteristics depend on the data on which algorithms 
are trained. This Commission did a global review to 
identify publicly available datasets of ophthalmic 
images.285 We identified 94 (including six with data from 
two world regions) open access datasets with more than 
500 000 images from 23 countries; there were 13 datasets 
for which the country was not specified. 34 datasets 
originated from populations in Europe, 21 from 
southeast or east Asia, 16 from North America, nine 
from north Africa and the Middle East, four from south 
Asia, two from Latin America, and one from sub-
Saharan Africa. The most common conditions were 
diabetic eye disease (35 datasets), glaucoma (19 datasets), 
and age-related macular degeneration (15 datasets). This 
under-representation of populations in LMICs is a new 
manifestation of the digital divide occurring in health, 
which we term health data poverty. The scarcity of 
representative datasets (public and other) limits the 
extent to which populations can benefit from digital 
health solutions and artificial intelligence systems. This 
limitation might lead to pronounced bias and failure of 
generalisability, with a risk of underperformance or 
even failure when transferred between settings 
and populations. We recommend that the visibility, 
accessibility, and use of existing public datasets is 
improved and that investment is made in developing 
new public datasets to support research, innovation, and 
validation in regions with insufficient health data.
Sustainable financing for eye health
Better health financing is crucial to make progress 
towards universal health coverage. To expand effective 
coverage for all, countries need to raise sufficient funds 
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for capital investment and ongoing service delivery costs; 
pool funds to spread the financial risks and protect the 
most vulnerable; allocate and use funds efficiently and 
equitably; and define the benefit package and rationing 
mechanisms.286 Mobilising financial resources is key for 
eye health in LMICs, and determines the scale, scope, 
and depth of coverage, quality, sustainability, and equity 
of eye health programmes.287
In many LMICs, eye health appears very underfunded. 
Data on eye health financing at a global and national 
scale are scarce. However, the national eye health system 
assessments done in the past decade indicate that in 
LMICs national health plans and budgets tend not to 
include eye care; national eye health plans, if developed, 
are often insufficiently funded, with eye health rarely 
considered in the allocation of resources; there is often 
little or no social insurance coverage for many eye health 
interventions; in many countries eye health programmes 
receive significant financial support from international 
non-governmental organisations and other development 
partners; and out-of-pocket payments for eye health are 
widespread.
Public spending
Public spending to increase coverage and financial 
protection is an important source of eye health funding, 
particularly for the poorest people. However, analysis of 
government expenditure on eye health is difficult as 
only a few countries make the data publicly available 
(appendix 2 p 17), partly because national budgets and 
health accounts tend not to delineate eye health 
explicitly and rather spread it across several categories.288 
Increased and better allocated public funding is central 
to making progress towards universal health coverage 
by promoting coverage, equity, financial protection, and 
sustainability.
Prepaid financing schemes
The inclusion of eye health services in compulsory prepaid 
financing (such as social health insurance) could be an 
effective means to promote scale up and reach those most 
in need. In countries where eye care services are included 
in benefit packages under social health insurance, 
providers respond strongly to payment incentives, with 
positive and negative consequences. For example, in 
Thailand, higher payment for cataract surgery increased 
surgical rates.289 However, in other settings such as the 
Philippines and Indonesia, payment structures can 
contribute to cost escalation for schemes that have 
resulted in efforts to limit surgical volumes, sometimes 
with potential negative consequences for equity. When 
considering eye health services within social health 
insurance, who is covered and from where services can be 
purchased are crucial to access, efficiency, coverage, and 
financial protection. Specific measures might be required 
to ensure the most disadvantaged are reached, as 
illustrated in Rwanda (appendix 2 p 18).
Out-of-pocket payments and private care
Regardless of the financing in place, out-of-pocket 
exemptions need to exist for the poorest and most 
vulnerable communities and health insurance schemes 
need to provide for poor individuals. In many LMICs, 
user fees are applied across the eye health sector by all 
health-care providers (public, private, faith-based, non-
governmental organisations) to partly or fully cover the 
costs. Such out-of-pocket payments can be a barrier to 
health care use, often for those needing it the most, and 
can push people into poverty.290,291 Studies in sub-Saharan 
Africa and east Asia have found that patient costs for 
cataract surgery can be as high as half of the average 
annual household income.292–294 Even when cataract 
services are included in insurance schemes, out-of-
pocket costs can remain high because of complex and 
often opaque arrangements on whether or how particular 
items are covered.295,296 Understanding how these costs 
reduce access and contribute to financial hardship is 
important for eye health in universal health coverage. 
Private financing (out-of-pocket, employer schemes, and 
private health insurance) will continue to be a substantial 
source of eye health funding in many contexts in the 
foreseeable future; therefore, more evidence is needed 
on financing arrangements and interventions that can 
make eye care affordable to all.
External sources
Eye health is an important component of universal health 
coverage, largely neglected by bilateral and multilateral 
donors. This Commission reviewed data on official 
development assistance from bilateral, multilateral, and 
private philanthropy organisations (appendix 1 p 72). 
Between 2014 and 2018, the annual average external 
assistance for all eye health was estimated to be 
approximately US$102 million, amounting to less than 
0·06% of the total global official development assistance. 
Around 66% of the US$102 million was spent on 
supporting the elimination of neglected tropical diseases 
that cause blindness, which reflects the great 
commitment by the US Agency for International 
Development, UK Aid, and several philanthropic 
organisations to tackle neglected tropical diseases. In 
view of the benefits to sustainable development, health, 
and wellbeing, we believe that the case for increased 
investment in eye health is strong, taking into 
consideration the crucial issues highlighted in our Grand 
Challenges exercise.
Several international non-governmental organisations 
provide substantial technical and financial support to 
LMICs. There is no comprehensive database that 
records all non-governmental organisation funding for 
eye health; therefore, estimating the total international 
funding is difficult. However, an analysis297 of annual 
reports suggested that 12 major non-governmental eye 
health organisations provided almost US$430 million 
in 2013, which included grants from bilateral and 
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multilateral donors, and philanthropic organisations. 
Increased international support for eye health, in 
partnership with public and private actors, and vision-
related international non-governmental organisations, 
would accelerate country-led efforts to move towards 
universal health coverage and fulfil the promise to leave 
no one behind. However, external funding needs to be 
considered as a supplement and not a replacement for 
government and other domestic expenditures on eye 
health.
Innovative financing
Although alternative financing mechanisms and private 
finance are unlikely to address all the unmet resource 
needs in eye health, they could provide substantial 
additional funding to progress eye health services rapidly 
within universal health coverage. The development of 
new alternative financing arrangements such as public–
private partnerships (eg, Onesight), development impact 
bonds and loans, social enterprises, and results-based 
financing could help to fund the growing demand for eye 
care services (appendix 2 p 19). These initiatives will need 
to be evaluated on their ability to access new financial 
resources, their costs compared with other funding 
schemes, the predictability and sustainability of the 
financing, the effectiveness in delivering quality eye 
health outcomes, the financial protection they provide, 
and their ability to address inequities in access and use of 
eye health services.
More eye health for the money
More resources need to be raised to maximise impact, 
but optimising funding allocation on eye health services 
is also crucial. Evidence on how to allocate funding is 
scarce, so a data revolution is required to ensure “more 
eye health for the money”.298 This revolution would 
include more and better research and programme data to 
inform priority-setting and strategic purchasing. Topics 
for future research include costs and cost-effectiveness of 
interventions, relative efficiency of various delivery 
models, affordability (for governments and individuals), 
and financial barriers to accessing services (including 
direct and indirect costs). We also need to better 
understand how much funding is required and how 
much is being provided from different sources, which 
interventions are being supported, who is benefitting 
from them and who is being excluded.
Delivering financing for eye health
To improve eye health: (1) more resources from all 
sources are urgently required, particularly in LMICs; 
(2) eye care needs to be integrated into general health 
financing for universal health coverage; (3) financial 
resources must be used wisely and a commitment is 
needed from all partners to ensure more eye health 
for the money; (4) countries need to improve social 
health insurance schemes as eye health needs change; 
(5) strategic purchasing arrangements need to be made 
to provide an incentive for efficiency, quality, equity, and 
financial protection; (6) step-change in data and evidence 
is needed on the financing of eye care, the value for 
money of interventions, and financial barriers to access 
and use of services; and (7) alternative financing 
arrangements need to be investigated.
Measuring progress in eye health
Strengthening eye health within universal health 
coverage requires clearly defined, scientifically robust 
indicators that capture key health system inputs, outputs, 
outcomes, and impacts. Indicators should provide 
insights to shape change and stimulate action. In this 
way, the indicator framework can be intrinsically linked 
to priorities, design, and continual improvement of 
services.
There are many potential indicators that could be used 
to monitor eye health services. For example, WHO has 
published several lists of eye health indicators in the past 
two decades: the 2002 framework for VISION 2020 
included 35 indicators,299 the 2006–11 action plan had 
29 core indicators and multiple additional indicators,300 
the 2014–19 action plan included 19 indicators,124 and in 
2017 WHO produced a list of 32 eye health indicators for 
the African region.301 The uptake and use of these 
indicators has been variable, probably because collecting 
such data is challenging and expensive.
To contribute to thinking on indicators, this 
Commission convened an international panel of 72 eye 
health system experts to participate in an indicator 
prioritisation exercise (appendix 1 p 73). We developed a 
menu of 22 indicators covering each stage of the results 
chain: inputs, outputs, outcomes, and impact (appendix 1 
p 74–75). From these, seven core indicators were selected 
(table 4). These indicators were considered suitable to 
monitor universal access to quality affordable eye care 
services, including proxy measures for accessibility and 
affordability, and two effective service coverage indicators. 
We anticipate countries might wish to prioritise data 
collection for core indicators, facilitating regional and 
global comparisons of eye health progress within 
universal health coverage. Additional work is required to 
develop detailed indicator metadata, address gaps around 
specific conditions (eg, glaucoma), and consider how to 
measure the integration of eye health into the broader 
health system.
Ideal indicators to track outcome progress within 
universal health coverage capture coverage and quality of 
an intervention, with disaggregation to assess equity. 
These are referred to as effective service coverage 
indicators. WHO and the World Bank have selected a 
panel of 16 tracer indicators to monitor progress towards 
universal health coverage, including several effective 
coverage indicators.302
A useful framework for conceptualising effective 
coverage and indicators in general is the health-service 
For more on Onesight see 
https://onesight.org/
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coverage cascade model, first proposed by Tanahashi, 
and later revised by the Effective Coverage Think Tank 
Group and others.303,304 This framework illustrates key 
dependencies and health system bottlenecks that prevent 
effective delivery of services (appendix 1 p 76). With each 
step down the cascade, additional members of the 
population in need do not progress towards the desired 
health outcome. Ideally, effective coverage measures are 
outcome-adjusted, reflecting the desired health impact. 
However, measuring the health outcome of interest is 
not always possible, particularly in chronic diseases, for 
logistical or cost reasons, or because of the delay between 
the intervention and realisation of the full health benefit. 
Therefore, earlier steps in the cascade are sometimes 
necessary to consider.
Intervention or service coverage indicators measure the 
proportion of the population that needs a service and 
receives it. This measure depends on those in need 
attending a service provider that has all the necessary 
inputs available (staff, equipment, consumables) to deliver 
Definition Rationale Data sources Responsible 
entity
Comments





Total numbers (public and private) of 
primary, secondary, tertiary, and low vision 
services per million population, by place of 
residence (urban or rural); additional 
subnational administrative or geographic 
divisions as relevant to setting
Place of residence should not be a 
barrier to accessing eye health services
Facility records, 
population data
Health ministry Informs policy and planning about 
location of eye health services in relation 
to population density; outreach 
programmes might be planned according 






Total numbers of ophthalmologist, 
optometrist, ophthalmic nurses, and other 
ophthalmic personnel per million 
population, by place of residence (urban or 
rural); additional subnational administrative 
or geographic divisions as relevant to setting
Availability and accessibility of eye 
health workers dictates access to care
Facility records, data 
from professional or 
regulatory bodies, 
population data
Health ministry Informs policy and planning on 
recruitment and distribution of resources 
for eye health; known disparities exist in 
the number and distribution of trained eye 
care personnel between countries and by 
urban and rural settings within countries









Proportion of population covered with 
health finance pooling mechanisms that 
include eye care services (considered 
individually): out-patient care, cataract, 
refractive error services, glaucoma 
treatment, and diabetic retinopathy 
treatment
Cost should not be a barrier to 
accessing eye care; proxy for WHO, 
World Bank, UHC financial risk 
protection indicators; catastrophic and 
impoverishing out-of-pocket payments 
unlikely to be discriminatory for 
monitoring affordability of elective eye 
care services
Health finance 
scheme reports and 
questionnaires
Health ministry Informs policy about eye health financing 
and affordability; coverage within the 
lowest wealth quintile should be reported 
alongside the total population to 






Median (and range) of out-of-pocket 
payments made for cataract surgery as a 
proportion of median monthly household 
(or individual) income
Cost should not be a barrier to accessing 
eye care. Proxy for WHO, World Bank, 
UHC financial risk protection indicators; 
catastrophic and impoverishing out-of-
pocket payments unlikely to be 
discriminatory for monitoring 








Informs policy about eye health financing 
and affordability; additional services 
could be monitored in the same way





Among the population aged 50 years and 
older, people with operated cataract and 
good postoperative presenting visual acuity 
as a proportion of all people with operated 
cataract or operable cataract (disaggregated 
by sex or gender)
Sex-disaggregated or 
gender-disaggregated effective 
coverage measures UHC dimensions of 
access, quality, and equity for the 









Informs policy and planning about the 
met and unmet need for cataract surgical 





Adults with refractive error corrected to a 
predefined visual acuity threshold with 
habitual correction as a proportion of all 
people with corrected and uncorrected 




coverage measures UHC dimensions of 
access, quality, and equity for the 









Informs policy and planning about the 
met and unmet need for refractive error 
services; candidate WHO UHC tracer 
indicator




The prevalence of all cause distance and near 
vision impairment (WHO definitions); 
disaggregation by key equity measures and 
by avoidable versus non-avoidable vision 
impairment
Proxy measure of eye health; a measure 
of programmatic success. Journey 








Disaggregated vision impairment 
prevalence estimates inform policy 
makers about the impact of eye health 
systems on eye health among population 
subgroups
Seven core indicators identified through the indicator prioritisation exercise, done by this Commission. UHC=universal health coverage.
Table 4: Core indicators to monitor universal access to quality, affordable eye care services
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the service. Considering service quality, how closely the 
delivery follows guidelines indicates how likely the service 
is to result in the desired health outcome. These are 
quality-adjusted coverage indicators. For interventions 
that require ongoing acceptance and use, adherence-
adjusted or acceptance-adjusted coverage indicators can 
be applied. Proxy indicators are sometimes used, if service 
coverage indicators are not available, and these provide a 
measure of health service provision.302,305 Measuring equity 
in service provision by disaggregating data and comparing 
subpopulations—eg, by wealth quintiles, education, sex or 
gender, age, ethnicity, and geographical location—is very 
important.302
Eye health outcomes are currently not reflected by the 
16 tracer indicators outlined by WHO.302 However, two 
indicators, effective cataract surgical coverage and 
effective refractive error coverage, have been proposed 
for inclusion in the Thirteenth General Programme Of 
Work 2019–23 framework306 by WHO and endorsed in the 
World report on vision.2 Both conditions are common and 
account for around 77% of vision impairment and these 
two indicators also have a broader relevance to the health 
system. Cataract surgery, one of the most frequent 
operations in many settings, is a marker for the provision 
of surgical services and spectacle correction by refractive 
error services is a marker for the provision of assistive 
devices.
Several indicators have been developed for cataract 
surgical services, which are defined in appendix 1 (p 76).307 
Cataract surgical rate (the number of cataract operations 
per million population per year) has been widely used for 
many years as a measure of service output. Cataract 
surgical rate is used to set and track a desirable target to 
address the backlog and ongoing incidence of cataract. 
Cataract surgical outcome is a measure of visual acuity 
outcome and reflects the quality of surgery. It can be 
reported by the individual surgeon, health facility, or by a 
programme. Cataract surgical coverage is measured in 
cross-sectional population-based surveys, such as the 
RAAB survey. Effective cataract surgical coverage 
combines the proportion of population covered and the 
visual acuity outcome (figure 19).308 The term operable 
cataract defines the threshold of vision impairment 
required for an individual to be included in the population 
denominator of people with cataract, which is used for 
estimating cataract surgical coverage or effective cataract 
surgical coverage. RAAB surveys estimate these 
coverages using an operable cataract threshold of worse 
than 3/60, 6/60, or 6/18. Each country determines which 
threshold is most relevant to their context.
Effective refractive error coverage was proposed and 
described as a method in 2019.2,309 Effective refractive 
error coverage assesses the proportion of people with 
refractive error who have received and use refractive error 
correction who achieve a specified visual acuity threshold 
(eg, 6/12); it takes into consideration the met, under-met, 
and unmet refractive error needs in a population 
(appendix 1 p 77). This method represents a major shift in 
the way refractive error is reported. Surveys previously 
focused only on counting unmet need (uncorrected 
refractive error) and excluded those who already had 
access to refractive error correction. An important 
consideration is whether spectacles are routinely used 
after being received, as reflected in the effective coverage 
cascade for refractive error services (appendix 1 p 77). This 
issue is particularly relevant for schoolchildren in many 
settings.216 When data for effective refractive error 
coverage are gathered using a population-based survey, 
the estimate considers people not adhering to spectacle 
use at that time as having an unmet need.
Figure 19: Effective coverage cascade for cataract surgical services
CSC=cataract surgical coverage. eCSC=effective cataract surgical coverage.
All adults 50 years 
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Using coverage cascade models provides helpful 
insights into appropriate coverage indicators and helps 
to identify key system blockages. Beyond effective 
cataract and refractive error coverage, examining service 
delivery effective ness for other leading causes of vision 
impairment, such as glaucoma, diabetic retinopathy, 
and age-related macular degeneration is possibly 
more complex. We have outlined potential approaches 
for these three conditions in appendix 1 (p 78–79). 
Identifying the population in need can be challenging 
because these conditions might be asymptomatic in the 
early stages. Also, a successful outcome for each 
condition is to stabilise vision and prevent further vision 
or functional loss, which can only be confirmed after 
long follow-up between starting the service delivery and 
future observations. Therefore, an effective coverage 
indicator might be unrealistic for these conditions, 
possibly necessitating quality-adjusted service coverage 
indicators, at least in the medium-term.
Progress towards universal eye health coverage
Despite the reduction in age-standardised prevalence of 
vision impairment observed in the past 20 years, the 
estimated number of people with vision impairment has 
risen with the continuously expanding and ageing global 
population. To explore progress towards improved eye 
health within universal health coverage in more depth, 
we focused on cataract, a key tracer condition with more 
population-level data than refractive error or other 
conditions.
We looked at peer-reviewed and grey literature since 
2000 to 2020 for evidence on the delivery of cataract 
surgery in relation to the dimensions of universal health 
coverage: access, quality, financial protection, and equity 
(appendix 1 p 80).310 We also analysed all available RAAB 
datasets from the past 20 years to calculate the effective 
cataract surgical coverage, disaggregated by gender. We 
summarise the scope of reported literature for key 
cataract markers in appendix 1 (p 81).
Cataract surgical rate was the most frequently reported 
indicator with data from the past 10 years available for 
numerous regions. Cataract surgical rate data were 
available for 175 countries since 2000. Over the same 
period, the median cataract surgical rate varied 
considerably by GBD super region, from 494 in sub-
Saharan Africa to 10 136 in high-income countries 
(figure 20). The global median cataract surgical rate was 
1700 per million population per year from reports during 
the last decade (total range 95–14 188, IQR 720–3906). A 
desirable cataract surgical rate is context specific and 
depends on the unmet need, quality of service, population 
structure, population cataract incidence, and other 
factors.
There were 203 national or subnational survey reports 
of cataract surgical coverage, including 104 in the past 
decade. However, around a third of RAAB surveys done 
between 2000 and 2018 were not reported in the public 
domain, raising concerns over the selective non-reporting 
of less favourable coverage. Analysis of these additional 
datasets would contribute to a more complete 
epidemiological picture.
Cataract surgical outcome—a clinical marker of 
quality—was reported for 197 studies, which were mostly 
cross-sectional population-based surveys with variable 
time intervals between surgery and observation. We only 
considered surveys that reported presenting visual acuity 
(vision tested using spectacles if available). During the 
past 10 years most regions had two or fewer reports 
on cataract surgical outcome (appendix 1 p 81). The 
longstanding WHO benchmark for a good outcome, 
following cataract surgery, is a presenting visual acuity of 
6/18 or better. This threshold was set more than 20 years 
ago with the expectation that it can be achieved in 80% or 
more surgeries.311 Among 82 reports on presenting visual 
acuity since 2010, the median proportion of people 
achieving 6/18 or better in the operated eye after surgery 
was 60% (total range 28–82%; IQR 50–68%). The median 
proportion of people with vision of 6/60 or worse in the 
operated eye after surgery was 18% (total range 3–51%; 
IQR 13–25%). The distribution of outcomes by GBD 
super region is shown in appendix 1 (p 83). Data from 
high-income countries are reported in many ways, which 
prevents comparisons. However, population-based data 
from Australia indicate that presenting visual acuity of 
6/12 or better was achieved in around 80% of people, and 
clinic-based data from the UK indicate this number is 
closer to 90%.312,313
Many surgeons audit their surgical outcomes. 
Collecting point-of-care outcome data is important to 
drive quality improvement. However, clinical outcome 
data collection is particularly challenging in LMICs, due 
to low postoperative follow-up rates. To investigate the 
validity of early postoperative data, which is more 
practical to collect, a large prospective study314 was done 
Figure 20: Cataract surgical rate by Global Burden of Disease super region
Box and whisker plots; midlines are the median, boxes represent IQR, whiskers 
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in 40 centres across ten countries in Asia, Africa, and 
Latin America. This study found that visual acuity 
measured during the first 3 days after cataract surgery 
was highly correlated with vision measured at 40 days or 
more after surgery. Consistent with previous findings, 
the final uncorrected visual acuity reached the WHO 
benchmark of 6/18 or better in only 64% of cases. 
Outcomes improved slightly with refraction, after which 
85% had a best corrected visual acuity of 6/18 or better. 
Inadequate reporting of outcomes and frequency of poor 
results suggest that cataract surgical quality is not 
optimal and requires concerted action, with an emphasis 
on better integration with refraction services and 
strengthening of monitoring and reporting outcomes 
(appendix 1 p 84). Tools such as the Better Operative 
Outcomes Software Tool (BOOST), a mobile surgical 
outcome application, can facilitate the monitoring 
process.315
The use of effective cataract surgical coverage 
(proportion of people aged 50 years or older with 
operated cataract or operable cataract who have a good 
postoperative presenting visual acuity) has only begun 
since 2017, with a total of 28 available reports 
representing few global regions (appendix 1 p 81). To 
supplement these reports and assess progress in the 
past two decades, we have reanalysed the data from 
149 RAAB surveys from 48 countries (appendix 1 
pp 84–85). We then selected the most appropriate 
estimate available for each country. Some caution needs 
to be exercised in the interpretation of these data as 
many are subnational surveys and have been 
extrapolated to represent coverage in the whole country 
for the purposes of this analysis. Between 2000 and 
2019, the median effective cataract surgical coverage for 
48 countries was 43·4% (total range 6·5–85·7%; 
IQR 29·4–59·2%), for an outcome of 6/18 or better and 
an operable cataract threshold of worse than 6/60. Some 
inter-regional variation is present, although the data 
from some areas are scarce (figure 21).
Systematic information on financial risk and protection 
in relation to eye health is rare, with only six reports 
worldwide from the past 20 years (appendix 1 p 81). For 
many people who are least able to pay, out-of-pocket 
payment for cataract surgery and presumably other 
procedures remains common.
Equitable access to eye health services has been 
assessed by disaggregating data, most frequently by 
gender, followed by place of residence, and 
socioeconomic status (appendix 1 p 81). These variables 
need to be routinely included in population-based 
surveys and analysed, to identify and inform the design 
and delivery of services for marginalised groups. 
Disaggregation of larger datasets, particularly for 
cataract surgical coverage, has highlighted disparities 
between men and women.316–318 We have disaggregated 
the results by gender (figure 21), showing that women 
consistently have lower effective cataract surgical 
coverage rates. For example, data from the Nigerian and 
Sri Lankan National Blindness Surveys8 have been 
disaggregated by gender, marital status, and area of 
residence (urban or rural), for the prevalence of cataract 
blindness and effective cataract surgical coverage 
(appendix 1 p 85). In both countries, the effective cataract 
surgical coverage was particularly low for women who 
were widowed living in rural areas. Further work in the 
design and delivery of services is needed to ensure more 
equitable outcomes among women.
There are fewer population-based data on effective 
refractive error coverage, which have mostly been 
collected through national eye health surveys or 
subnational surveys using the Rapid Assessment of 
Refractive Error (RARE). Several of these studies are 
summarised in table 5. Only one study was from a high-
income country (Australia). The median effective 
refractive error coverage was 22% and the range was 
Figure 21: Effective cataract surgical coverage by Global Burden of Disease 
super region
(A) Cluster-adjusted, age-adjusted, and sex-adjusted estimates. (B) Cluster-
adjusted, age-adjusted, and sex-disaggregated estimates. Box and whisker plots; 
midlines are the median, boxes represent IQR, whiskers are upper and lower 
adjacent values. Outliers are plotted as individual dots. Countries within regions 
are represented by the most recent national or subnational Rapid Assessment of 
Avoidable Blindness survey and if two or more assessments occurred within 
2 years, the median of estimates was used (appendix 1 pp 84–85).
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wide at 0–94%. Despite few data, clearly, at least in 
LMICs, the effective refractive error coverage is often low 
and represents a substantial unmet need. Existing data 
gaps need to be urgently addressed to understand the 
scale of needs, to inform programme implementation, 
and track progress. An updated RAAB survey protocol 
will be released in 2021, which will support the collection 
of additional visual acuity data outlined in appendix 1 
(p 77), to enable estimation of effective refractive error 
coverage.319
Improving quality of eye care
Delivery of high quality services leading to good health 
outcomes is central to universal health coverage.320,321 
Unfortunately, high quality services are far from 
universal.320 Typically, clinical outcome measures such as 
visual acuity are used to quantify service effectiveness, 
and are tracked using population-based surveys. 
However, these provide a narrow understanding of the 
overall quality of care; a more holistic perspective is 
needed. A quality framework favoured by WHO320 
considers seven components: effectiveness, efficiency, 
people centredness, safety, timeliness, equity, and 
integration. For the purpose of this Commission, in 
alignment with the SDGs, we have added planetary 
health as a component. Using cataract as an example, we 
examine approaches to improve the quality of eye care 
services.
Annually, an estimated 25 million cataract operations 
are done globally; making it the second most common 
surgical procedure after caesarean section.322,323 However, 
from the available data on cataract surgical outcome and 
effective cataract surgical coverage, there is a major 
challenge in delivering effective and high quality 
services in many regions (figure 21). Moreover, these 
data present an overly optimistic view of the outcome 
because they define a good outcome following cataract 
surgery as 6/18 or better.311 However, 6/18 is still mild 
vision impairment. Since the WHO benchmark was set, 
cataract surgery has developed substantially with 
widespread adoption of small incision procedures and 
intraocular lens implantation. For these reasons, we 
recommend an update to the benchmark threshold of 
effectiveness for a good outcome, which should be a 
presenting visual acuity of 6/12 or better. This threshold 
would be used for reporting of surgeon-specific cataract 
surgical outcome and in the analysis of effective cataract 
surgical coverage in population-based surveys and 
would be expected to speed up efforts to improve quality 
and effectiveness.
The country with the largest number of RAAB or 
Rapid Assessment of Cataract Surgical Services surveys 
(38 between 2000 and 2015) is Vietnam. These surveys 
show rising cataract surgical coverage and effective cataract 
surgical coverage rates over the 15-year period (figure 22). 
Improvement in effective cataract surgical coverage seems 
partly attributable to increased use of intraocular lenses 
from 48% in 2000 to 98% in 2015.324 Notably, the effective 
cataract surgical coverage rates were substantially lower 
than the cataract surgical coverage rates, which indicates 
that the quality of surgical outcomes was not optimal. We 
have examined the effect of raising the effective good 
outcome threshold from the current 6/18 or better, to 
6/12 or better (figure 22). We also examined the effect 
of changing the threshold for operable cataract, the 
population denominator, from the current worse than 
6/60 to worse than 6/18 and 6/12. Both threshold changes 
lead to substantial reductions in effective cataract surgical 
coverage, which could drive action to increase coverage 
and quality of services.
There is abundant literature tracking the incremental 
technical development of cataract surgery, which usually 
Method Age group, 
years
Effective refractive error coverage (95% CI)*
Eritrea (Chan et al, 2013) Subnational; RARE 15–50 22·2% (16·7–28·5)
Nigeria (Ezelum et al, 2011) National eye health survey ≥40 3·4% (2·3– 4·4)
Tanzania (Mashayo et al, 2015) Subnational; RARE ≥15 1·7% (0–3·3)
South Africa (Naidoo et al, 2016) Subnational; RARE 15–35 51·4% (28·1–74·7)
Uganda (Nsubuga et al, 2016) Subnational; RARE 15–50 6·0% (1·7–10·2)
Mozambique (Lougham et al, 2015) Subnational; RARE 15–50 0·0%
Colombia (Casas Luque et al, 2019) Subnational; RARE ≥15 50·9%
Iran (Fotouhi et al, 2006) Subnational eye health survey ≥5 66·0%
Bangladesh (Bourne et al, 2004) National eye health survey† ≥30 25·2%
Timor-Leste (Ramke et al, 2007) Subnational; Modified RACSS‡ ≥40 15·7%
Pakistan (Shah et al, 2008) National eye health survey ≥30 15·1%
Australia (Foreman et al, 2017) National eye health survey† ≥40 93·5% (92·0–94·8) for non-Indigenous; 82·2% (78·6–85·3) for 
Indigenous Australians
References can be found in appendix 1 (p 104). RACSS=Rapid Assessment of Cataract Surgical Services. RARE=Rapid Assessment of Refractive Error. *95% CI given if reported. 
†An assumption of need, because the uncorrected visual acuity measurement was not given. ‡Used a threshold of 6/18 (not 6/12) to define refractive error.
Table 5: Population-based studies reporting effective refractive error coverage
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restores vision in the absence of other ocular 
comorbidities. Two most commonly used surgical 
techniques to treat cataract are phacoemulsification and 
manual small-incision cataract surgery. Phacoemulsifi-
cation is the standard of care in high-income countries 
and requires sophisticated equipment and more 
expensive intraocular cataract lenses and surgical 
consumables.
Manual small-incision cataract surgery uses a smaller 
incision compared with the older technique of sutured 
extracapsular cataract extraction, causes less surgically-
induced astigmatism and achieves uncorrected visual 
acuity of 6/18 or better in more patients.325,326 There has 
been a major shift from extracapsular cataract extraction 
to manual small-incision cataract surgery in many 
LMICs. Manual small-incision cataract surgery is now 
the most commonly done procedure in south Asia and 
sub-Saharan Africa.327,328 Evidence from randomised 
controlled trials329,330 suggest that people receiving 
manual small-incision cataract surgery have a small 
reduction in the chance of achieving uncorrected visual 
acuity of 6/18 or better after 6-8 weeks compared with 
phacoemulsification (pooled risk ratio 0·90, 95% CI 
0·84–0·96), probably due to more surgically-induced 
astigmatism, but are likely to achieve similar levels of 
good best corrected visual acuity (0·99, 0·98–1·01). 
Complication rates are low with both techniques. The 
cost of phacoemulsification is two to four-times the cost 
of manual small incision cataract surgery.329,330
The outcome of manual small-incision cataract surgery 
can be improved using routine ocular biometry to select 
an appropriately powered intraocular cataract lenses 
(which is not the standard in some regions),327 for 
meticulous adherence to the surgical technique, and for 
close integration of refractive and cataract services to 
prescribe spectacles. These steps are expected to eliminate 
the small outcome gap between phacoemulsification and 
manual small-incision cataract surgery. Overall, from the 
public health perspective and given the unmet need and 
limited financial and service capacity, this Commission 
cautions against recommending LMICs to transition from 
small-incision cataract surgery to phacoemulsification 
because, without a substantial increase in resources, this 
change could result in fewer people receiving treatment 
for cataract.
We reviewed published literature for interventions to 
improve the quality of cataract services (appendix 1 p 87).331 
We searched for intervention studies that addressed one 
or more of the seven dimensions of quality, plus planetary 
health. We specifically excluded intraoperative intervention 
studies—eg, those that compared alternative procedures 
or intraocular lenses—because they have been thoroughly 
reviewed elsewhere.329,332,333 We identified 143 publications, 
largely (65%) from high-income countries (appendix 1 
p 88). Most studies looked at interventions to improve 
efficiency and people centredness, with a smaller number 
examining effectiveness, safety, and equity. Appendix 1 
(p 89) summarises several interventions found to improve 
efficiency, people-centredness, and effectiveness. These 
findings highlight that many interventions can improve 
the multidimensional quality of cataract surgery services. 
However, only a few of these studies were done in LMICs. 
This evidence gap needs to be addressed to guide 
approaches and improve service quality.
A 2018 Lancet Global Health Commission321 on high-
quality health systems proposed a set of four universal 
actions for improving health care quality, which provides 
a useful framework for LMICs. The first universal action 
is to govern for quality through strong leadership 
and governance with clear policy, regulations, and 
accountability. This action is particularly relevant to eye 
health, as in many countries services are often provided 
in the private sector. The second action was to redesign 
service delivery to maximise the quality of care; there 
needs to be a thoughtful analysis of the appropriate 
Figure 22: Cataract surgical coverage in Vietnam
(A) Cluster-adjusted, age-adjusted, and gender-adjusted data from subnational 
Rapid Assessment of Avoidable Blindness surveys done in Vietnam in 2000–02 
(n=8), 2007 (n=16), and 2015 (n=14), estimated for an operable cataract 
threshold of worse than 6/60 and a good clinical outcome of 6/18 or greater. 
(B) Data from 14 subnational surveys done in Vietnam in 2015. Data are plotted 
for three thresholds of operable cataract and two different levels of vision 
outcome: 6/18 or better and 6/12 or better. Box and whisker plots; midlines are 
the median, boxes represent IQR, whiskers are upper and lower adjacent values. 
Outliers are plotted as individual dots. CSC=cataract surgical coverage. 
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location and specialised teams for service delivery to 
ensure the best possible outcome. Although there is a 
clear need to strengthen the delivery of basic eye health 
services in primary care settings, equally, specialist 
eye care services need to be appropriately staffed and 
equipped. The third action is to transform the workforce 
with intense focus on relevant competency-based 
training, strengthening health-care training institutions, 
and establishing enabling work environments. Urgent 
action is needed to develop and enable the eye health 
workforce to deliver quality care. The fourth action 
proposed is to ignite a demand for quality within the 
population by sharing information about quality 
and seeking active patient engagement to shape services 
that meet the needs of the population. This action 
is particularly relevant to ophthalmic surgery, with 
increasing publication and awareness of expected 
outcomes informing choices in some settings, with 
potential to extend to other areas.
Eye health and planetary health
Climate change is occurring, primarily mediated by 
greenhouse-gas emissions. Global health care is estimated 
to contribute to approximately 5% of all greenhouse-gas 
emissions.334 Eye care is a high volume service with a large 
number of consultations and procedures annually, and 
therefore, a substantial contributor to health-care 
emissions. With the ageing population increasingly 
requiring eye care interventions, we need to promote 
sustainable practices. We did a review to examine the 
extent and nature of the potential environmental impact 
of eye health services (appendix 1 pp 90–91). Evidence is 
scarce, with only eight reports meeting our criteria. A 
detailed carbon footprint of phacoemulsification cataract 
surgery has been estimated for individual centres in the 
UK and India.61,335 For the same procedure, the UK centre 
produced 20-times more CO2 emissions than the Indian 
centre. To improve this field, tools are being developed to 
routinely measure environmental costs associated with 
cataract surgery as a mark of quality, alongside the other 
measures of high-quality services. Every aspect of practice 
can be examined and opportunities to reduce environ-
mental impact can be identified.
Increasing access and equity in eye care
Access to eye care is not equally distributed between and 
within countries, with marginalised and socially 
disadvantaged populations experiencing more difficulty 
in accessing the required care. This persistent inequity 
must be addressed for eye care to be realised within 
universal health coverage. Indeed, unless equity is 
prioritised, inequalities will probably increase in pursuit 
of universal health coverage, as the socially advantaged 
are more able to use new or improved services.336
In many high-income countries, people can access the 
eye care they need, although often the most marginalised 
groups such as Indigenous people or other minority 
ethnic groups are unable to access eye care, such as those 
in the USA (appendix 2 p 20). Another example is 
Australia, where most non-Indigenous Australians have 
access to good quality cataract surgery (effective cataract 
surgical coverage achieving 6/12 or better, 88·5%, 95% CI 
85·2–91·2) compared with only half of Indigenous 
Australians (51·6%, 42·4–60·7).312 To explore how to 
improve access to eye care for these groups in high-
income countries, we did two separate scoping reviews 
(appendix 1 p 92).337,338 In addition, some of the key points 
for addressing eye health inequity for Indigenous 
Australians are described in appendix 2 (p 21).
In these reviews we identified 41 studies reporting 
strategies to improve access for Indigenous people, 
primarily in Australia (26 [63%]), and separately, we 
identified 67 studies reporting strategies for other minority 
ethnic groups, mainly in the USA (60 [90%]).337,338 
Strategies focused on diabetic retinopathy services were 
the most common (51% in the first review and 42% in the 
second). We mapped some of these strategies against a 
patient-centred health-care framework to show various 
ways in which access can be enabled through a pathway of 
having and perceiving a need for care; desiring, seeking, 
reaching, and using that care; and the subsequent health 
consequences (figure 23).339 The range of strategies 
outlined in figure 23 shows the complex nature of health-
care access from the service and patient perspective, and 
the breadth of possible approaches to reduce inequity. 
Several of the most effective interventions addressed three 
or more access dimensions concurrently, often from the 
patient and service perspective. Despite the strong 
emphasis on reducing inequality in these approaches, 
only a third of studies in each review reported engaging 
the target communities during the design phase.
A promising strategy in pursuit of universal health 
coverage for eye care is proportionate universalism, which 
aims to improve outcomes for all population groups and 
specifically targets disadvantaged groups to ensure that 
improvement is proportional to need at the outset, 
showing the greatest benefit in these groups.336 The benefit 
of this approach was shown in maternal and child health, 
with countries using proportionate universalism to reduce 
inequality between the poorest and richest quintiles and 
improving coverage at the aggregate level compared with 
countries using other approaches.340 There are examples 
of the need for proportionate universalism in eye health, 
such as in Nigeria and Sri Lanka, where national surveys 
revealed that unmarried rural women (mostly widows) 
had disproportionate cataract blindness.8 The social 
distribution of cataract blindness in these two countries 
(appendix 1 page 86) highlights the need to allocate 
resources and action proportionate to need, with a 
particular focus on identifying strategies to improve 
access to care for women in rural areas with low social 
support.
Unfortunately, there are no published reports of 
proportionate universalism being applied in eye care. 
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Indeed, there is little robust evidence on how to reduce 
inequity in eye health, including cataract services.341 We 
did an umbrella review of systematic reviews on gender 
and eye health. Only one of 58 included reviews described 
interventions to address gender inequality; the remaining 
reviews reported gender differences in the prevalence of 
Figure 23: Strategies to improve access to eye care for Indigenous and other minority ethnic groups
Identified from scoping reviews for Indigenous people and other non-dominant ethnic groups in high-income countries, mapped to the patient-centred access framework by Levesque et al.339 
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Acceptability Availability and accommodation Affordability Appropriateness
Ability to perceive Ability to seek Ability to reach Ability to pay Ability to engage
Supplementing existing 
diabetes eye screening 
programmes with regional 
eye health coordinators to 
support training of 
screeners and coordinate 
the programme improved 
uptake of screening services
(Moynihan, 2017) Australia
Integrating the cataract 
surgical pathway with the 
Aboriginal Medical Service at 
a primary-care level 
increased the use of cataract 
services (Penrose, 2018) 
Australia 
Storage of clinical images 
was aligned with First 
Nations Principles of 
Ownership, Control, Access 
and Possession (Kim, 2015) 
Canada
Increasing the number of 
clinic sites, rural locations, 
and eye care sessions for 
optometrists at clinics for 
Indigenous people increased 
the number of patient 
attendances and spectacles 
dispensed (Napper, 2015) 
Australia 
Nurse-led diabetes eye 
screening in communities 
reduced travel costs for 
patients  (Spurr, 2018) 
Canada
Elimination of out of pocket 
cost for optometric 
consultations and 
implementing subsidies for 
spectacles  resulted in 
increased use of the 
government spectacle 
scheme. (Layland, 2004) 
Australia
Introducing a fixed cost 
spectacle scheme reduced 
patient contribution 
required for spectacles and 
increased numbers of 
spectacles dispensed 
(Napper, 2015) Australia
Care coordinators who 
ensure patients are guided 




necessary, were well 
received and should be 
further explored
(Penrose, 2018) Australia
Strategies for Indigenous populations
Incorporating vision 
screening into a soup 
kitchen programme resulted 
in substantial detection of 
and referral for vision 
threatening diseases 
(Shahid, 2012) USA 
Community health workers 
from the same ethnic group 
facilitating patient to 
ophthalmologist 
interactions led to improved 
glycaemic control, linked to 
trust (Rovner, 2019) USA
Having audio-recorded 
instructions in patient’s own 
language was a feasible 
option for visual field testing 
in a multi-cultural context 
(Nesher, 2001) Israel
Vision screening in 
community sites (e.g. grocery 
stores, banks, churches) and 
mobile screening (with 
well-equipped van) resulted in 
substantial detection of and 
referral for vision problems 
(Al-Aswad, 2017) USA 
Geographic information 
systems help to target 
resources for diabetic 
retinopathy tele-screening 
more effectively (Jani, 2017) 
USA
Covering all examination and 
transportation costs 
appeared cost-effective in 
glaucoma detection, given 
the health benefits
(Pizzi, 2018) USA
Hiring full time nurses in 
schools to manage 
screening through to use 
of glasses increased 





whole person-based services 
are effective to reduce vision 
loss due to diabetic 
retinopathy
(Baker, 1993) USA 
Strategies for ethnic group minorities
Personalised phone calls, 
in the appropriate 
language, improved 
uptake of screening 
appointments 
(Bush, 2014) UK
Educational materials about 
childhood refractive error 
and need to see an eye care 
specialist improved 
knowledge in parents of 
children at risk
(Frazier, 2012)  USA
Intensive, personalised follow 
up, including messages such 
as “your health matters”, 
improved return rate after 
vision screening
(Anderson, 2003) USA
Tailored phone calls from 
culturally-appropriate health 
educator to build rapport and 
dispel fears improved 
completion of dilated fundus 
exam after screening 
(Walker, 2000, and 
Jones, 2011) USA
Behavioural activation (eg, 
collaborative goal setting 
to help overcome avoidant 
tendencies) was more 
effective compared with 
general supportive therapy 
to improve attendance at 
dilated fundus exam 
(Winters, 2017) USA
Removing additional 
barriers to follow-up, with 
video information, 
pre-scheduled 
appointments within short 
timeframes and voucher 
stating value of free eye 
exam, further improved 
attendance for full eye exam 
(compared with base 
program, both of which 
include support workers 
from the same ethnicity 
group, free exams,and 
reminders calls)  
(Zhao, 2018) USA
Community health workers 
leading an educational 
support group (eg, weekly 
contact, help with 
overcoming barriers) 
improved concordance with 
recommendation provided at 
screening (Vaughan, 2017) 
USA
Clear information in 
cartoons, scheduling 
reminders and a sticker 
reward system helped 
improve adherence with 
patching for children with 
amblyopia
(Tjiam, 2012- and 2013) 
Netherlands 
A teleophthalmology clinic 
increased patient 
satisfaction and 






Community elders or 
members were consulted in 
design of the diabetes eye 
screening project 
(Spurling, 2010) Australia
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eye conditions or access to cataract services (appendix 1 
pp 93–94). To reduce this evidence gap, we did a modified 
Delphi process to identify priority groups and testable 
strategies to reduce inequity that can be assessed in 
future research (appendix 1 pp 95–96). Across two rounds 
we asked 183 participants worldwide to first nominate 
and then prioritise the groups which have the most 
difficulty and represent the largest number of people 
unable to access cataract services in their region, followed 
by the most promising strategies to improve access to 
screening and surgical services for cataract. Globally, 
three groups that need to be prioritised were identified 
as: people living in rural or remote areas, those with low 
socioeconomic status, and those with low social support. 
In most regions, data are not routinely collected on these 
characteristics in relation to vision loss from cataract and 
the access to services.
South Asia was the only region in which women were 
among the top three prioritised groups, despite all 
regions having more women than men living with 
vision loss. One explanation for women not being 
prioritised might be because they are not universally 
disadvantaged, with some women able to access the 
required eye care. Married women in Nigeria and 
Sri Lanka were found to be the subgroup with the 
lowest prevalence of cataract blindness (appendix 1 
p 86).8 This disparity between different subgroups of 
women highlights the need to disaggregate by more 
than one sociodemographic factor, which provides a 
more nuanced understanding of the need distribution 
and where to target additional resources. Equity-
relevant targets are also needed. Services often aim to 
deliver 50% of services to women to be equitable. 
However, worldwide there are more women than men 
with vision loss and equity-relevant service targets 
would reflect the disproportionate number of women 
in need of care (figure 10).
The globally prioritised strategies to improve access to 
screening and surgery involved improving the availability 
of services, improving integration, and reducing out-of-
pocket costs, whereas participants from high-income 
countries prioritised efficiency, targeting at risk groups 
and cultural safety (appendix 1 pp 95–97). Some of these 
strategies have previously been described and evaluated, 
primarily those targeted to rural dwellers, people of 
low socioeconomic status, or women.10,49 A common 
reflection of this literature is that a multifaceted 
approach is needed to address the diverse nature of 
barriers faced by socially disadvantaged groups. For 
example, outreach screening combined with counselling, 
providing transport, and low out-of-pocket costs for 
surgery increased the uptake in rural Tanzania and 
Kenya, whereas cataract case finders in Madagascar were 
not successful as the people identified with operable 
cataract had no means to reach the hospital.243,342 Access 
and equity are crucial areas in which to develop better 
evidence in the coming decade.
Universal health coverage will not be realised without a 
deliberate effort to build equity into design. This needs to 
be informed by a thorough understanding of the groups 
that are being left behind and meaningful engagement 
with communities to co-design approaches that meet 
needs equitably. More representative leadership in global 
eye health is also needed, which was highlighted in our 
analysis of organisations working in this field (appendix 1 
p 98).343
Political prioritisation of global eye health
Over the past 30 years the eye health sector, including 
health ministry staff, civil society, eye health 
professionals, academics, and WHO, have worked hard 
to increase the global profile of eye health. Some good 
progress has been made—several World Health 
Assembly resolutions have been adopted,124,344–347 action 
plans implemented, and global coalitions formed.124,300,348 
Despite these improvements, international and national 
political leaders have not sufficiently prioritised eye 
health, leaving it under-resourced and poorly integrated 
into national health systems.2
To analyse factors shaping global political prioritisation 
for eye health, we applied the framework developed by 
Shiffman and Smith (panel 6; appendix 1 p 99).349 This 
framework identifies four categories that shape political 
prioritisation in global health: power of the actors 
involved, ideas they use to portray the issue, the political 
context, and characteristics of the issue. The development 
of eye health services in China since 1949 provides an 
example of the impact that evolving political prioritisation 
can have on eye health service provision (appendix 2 
p 22).
Many aspects suggest that global eye health is well 
placed to attract political support. Vision impairment is 
associated with mortality (figure 6), and eye care 
interventions are among some of the most feasible and 
cost-effective in health care. The issue is also global; 
impaired eye health and the need for eye care affect large 
numbers of people across all socioeconomic groups and 
the life course. There is broad agreement within the global 
eye health community on the policy agenda; partnerships 
have enabled the development and delivery of highly 
successful eye health programmes, such as for trachoma 
control. In addition, the International Agency for the 
Prevention of Blindness brings together a cohesive 
community of active organisations, giving the sector a 
platform and voice for collective action.
However, even when global and national political 
commitments towards eye health have been made, 
resources have not been provided at the scale and breadth 
required to meet growing demand. Several factors could 
explain this shortcoming. The case for the importance, 
severity, and ubiquity of eye health has not been made 
with sufficient force. Key opportunities have been 
missed; one notable example is that eye health is not 
referred to in the SDGs.
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WHO has provided leadership, dedicated resources, 
and technical expertise to the great benefit of eye health, 
even though the institutional priorities set by WHO have 
fluctuated. Until the encouraging formation of the 
UN Friends of Vision group of Member States, such 
institutional leadership has been largely absent in the 
rest of the UN system. The missions of UNDP, 
UN Women, UNICEF, and the International Labour 
Organization all intersect and could be enhanced by 
better eye health, but generally vision-related activities 
have not been included in their work.
Internal and external framing of eye health has been 
ambiguous. Although the sector has argued at times for 
integration of eye care as part of the mainstream health 
agenda, many high-profile successes are positioned 
outside public health systems and are viewed as vertical 
in approach. This ambiguity has reduced the need to 
compete against other health issues and eye health has 
often been omitted from health system strengthening 
and universal health coverage agendas.
The role of national and international non-
governmental organisations and donors in financing 
and delivering eye health services has sometimes had 
the unintended effect of discouraging government 
ownership and resource allocation. In some countries, 
non-governmental organi sations and donors are outside 
of government systems, limiting the responsibility and 
accountability of national actors. Some governments 
have come to wholly rely on the non-government sector 
for eye health service delivery and therefore have not 
engaged nor allocated their own resources to eye care 
within health system strengthening and universal health 
coverage.
This problem is changing. Increasingly the eye health 
sector has made a concerted effort to position vision 
within mainstream health policy, emphasising the need 
to embed eye care in national health systems and primary 
health care. Crucially, the WHO World report on vision2 
recommends that eye health should be part of every 
country’s journey towards universal health coverage.
Panel 6: Determinants of political priority in global eye health
Actor power: strength of individuals and organisations 
concerned with the issue
Policy community cohesion
There is a strong degree of coalescence among the eye health 
community on the issue. However, the sector needs to build 
partnerships outside the sector.
Leadership
The sector has produced excellent programmatic leaders but 
has few system leaders or external champions for the cause.
Guiding institutions
WHO has provided some institutional leadership on vision as a 
health issue; however, such leadership has been largely absent 
within the broader UN system.
Civil society mobilisation
Civil society organisations have mobilised international and 
national political authorities to address the issue globally; 
however, eye health has been narrowly framed as a technical 
eye care issue and involved low public engagement.
Ideas: the ways in which those involved understand and 
portray the issue
Internal frame
Eye health actors generally agree on the definitions, causes, and 
solutions to blindness and vision impairment. However, they 
have not been sufficiently united in framing the issue.
External frame
Eye health has not been portrayed in a way that resonates with 
external audiences, especially with political leaders.
Political contexts: the environments in which actors operate
Policy windows
The development of Sustainable Development Goals (SDGs) 
was a missed opportunity and eye health was not included. 
The UN Decade of Action on the SDGs and the WHO Thirteenth 
General Programme of Work with triple billion targets, including 
universal health coverage, provides new policy windows in 
which to integrate eye health.
Global governance structures
Several World Health Assembly resolutions provide high 
aspirations for improving eye health. The International Agency 
for the Prevention of Blindness coordinates international 
efforts in blindness prevention, providing an effective platform 
for collective action with over 150 member organisations 
worldwide, including non-governmental organisations and civil 
societies, corporate organisations, professional bodies, and 
research and eye care institutions.
Issue characteristics: features of the problem
Credible indicators and targets
Previous indicators and targets have been clear and ambitious 
but not realistic and not linked to a clear pathway for 
achievement, undermining their credibility. New indicators and 
targets linked to universal health coverage are under 
development.
Severity
The scale of the burden is substantial. But eye health, when 
compared with other health issues, is often regarded as a 
second-order issue by governments, because of the historic 
scarcity of evidence on measures of impact such as mortality. 
The sector has not yet managed to gain policy traction for the 
economic and development case.
Effective interventions
Effective interventions are available and among some of the 
most feasible and cost-effective of all health-care interventions.
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The COVID-19 pandemic will probably transform 
the importance of health and health systems within 
government policy in general. Although long-term 
effects will take time to be understood, conceivably, there 
will be renewed emphasis on building resilient and 
responsive health systems. Following the pandemic, eye 
health needs to be considered as an essential part of 
health and associated health service packages. However, 
the pandemic will probably lead to deterioration in the 
social determinants of eye health for many, through 
increased poverty and reduced access to services in many 
countries.
Eye health cuts across multiple SDGs. The Decade of 
Action and delivery of SDGs, called for by the 2019 
UN General Assembly, presents a new opportunity to 
position eye health equity as an integral part of the 
development agenda and to have it addressed by broader 
development institutions. This action would enable the 
case to be made at national level, to include eye care 
in economic and development plans, budgets and 
consolidate its place within health plans for universal 
health coverage. To integrate vision in the development 
agenda will require three major actions.
First, eye health needs to be clearly framed as a 
development issue, which would have substantial and 
immediate benefits for prosperity and social progress. 
This Commission shows that addressing vision 
impairment is a realistic and highly cost-effective way of 
unlocking human potential, enabling children to gain an 
education and working-age adults to get and keep a job, 
and improving equality for women and girls who are 
more likely than men to have poor vision and less likely 
to receive treatment. These steps are more likely to 
resonate with political leaders, donors, and international 
institutions.
Second, cross-sectoral partnerships need to be built, 
including economic development, education, women’s 
empower ment, business and transport, civil society, the 
technology, and private sectors. These partnerships are 
already taking place in some regions but will need to 
become much more widespread.
Third, different kinds of leadership skills and 
capabilities need to be developed. The sector has 
produced many committed and effective leaders who 
excel at designing and managing eye health programmes. 
However, achieving progress across the development 
agenda will require leaving current approaches behind. 
A more innovative and adaptive approach that engages 
broad networks of diverse stakeholders is required. 
Leaders will need to be able to connect the whole system 
together.
Call to action
We call on the global community to consider the 
recommendations outlined in the Key messages panel for 
urgent action. Vision is an enabling tool for sustainable 
development, accelerating delivery of the SDGs. We have 
presented the benefits of vision for everyone and 
supported these by evidence. Vision as an integral 
component of health has been insufficiently represented 
in the targets of the SDGs but the Decade of Action, called 
for by the 2019 UN General Assembly, presents an 
opportunity to reintegrate eye health into developmental 
and economic plans. To achieve this transition, the sector 
must build the right bridges, engage in new partnerships, 
and train new leaders skilled in systems change, which 
will be a global challenge for the next decade.
Investing in universal eye health is a realistic, 
cost-effective way of unlocking human potential by 
improving health and wellbeing, education, work, and 
the economy; it is essential to achieving the SDGs.
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